
<html lang="en"     class="pb-page"  data-request-id="44b8d5ed-e352-49ff-ac2b-eebbb08705b2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-14;article:article:10.1021/acs.jmedchem.7b00385;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists" /></meta><meta name="dc.Creator" content="Joseph  Carpenter" /></meta><meta name="dc.Creator" content="Ying  Wang" /></meta><meta name="dc.Creator" content="Gang  Wu" /></meta><meta name="dc.Creator" content="Jianxin  Feng" /></meta><meta name="dc.Creator" content="Xiang-Yang  Ye" /></meta><meta name="dc.Creator" content="Christian L.  Morales" /></meta><meta name="dc.Creator" content="Matthias  Broekema" /></meta><meta name="dc.Creator" content="Karen A.  Rossi" /></meta><meta name="dc.Creator" content="Keith J.  Miller" /></meta><meta name="dc.Creator" content="Brian J.  Murphy" /></meta><meta name="dc.Creator" content="Ginger  Wu" /></meta><meta name="dc.Creator" content="Sarah E.  Malmstrom" /></meta><meta name="dc.Creator" content="Anthony V.  Azzara" /></meta><meta name="dc.Creator" content="Philip M.  Sher" /></meta><meta name="dc.Creator" content="John M.  Fevig" /></meta><meta name="dc.Creator" content="Andrew  Alt" /></meta><meta name="dc.Creator" content="Robert L.  Bertekap, Jr." /></meta><meta name="dc.Creator" content="Mary Jane  Cullen" /></meta><meta name="dc.Creator" content="Timothy M.  Harper" /></meta><meta name="dc.Creator" content="Kimberly  Foster" /></meta><meta name="dc.Creator" content="Emily  Luk" /></meta><meta name="dc.Creator" content="Qian  Xiang" /></meta><meta name="dc.Creator" content="Mary F.  Grubb" /></meta><meta name="dc.Creator" content="Jeffrey A.  Robl" /></meta><meta name="dc.Creator" content="Dean A.  Wacker" /></meta><meta name="dc.Description" content="Agonism of the 5-HT2C receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT2A and 5-HT2B ..." /></meta><meta name="Description" content="Agonism of the 5-HT2C receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT2A and 5-HT2B ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 7, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00385" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00385" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00385" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00385" /></link>
        
    
    

<title>Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00385" /></meta><meta property="og:title" content="Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0017.jpeg" /></meta><meta property="og:description" content="Agonism of the 5-HT2C receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT2A and 5-HT2B receptors is critical as their activation has been shown to lead to undesirable side effects and major safety concerns. In this communication, we report the development of a new screening paradigm that utilizes an active site mutant D134A (D3.32) 5-HT2C receptor to identify atypical agonist structures. We additionally report the discovery and optimization of a novel class of nonbasic heterocyclic amide agonists of 5-HT2C. SAR investigations around the screening hits provided a diverse set of potent agonists at 5-HT2C with high selectivity over the related 5-HT2A and 5-HT2B receptor subtypes. Further optimization through replacement of the amide with a variety of five- and six-membered heterocycles led to the identification of 6-(1-ethyl-3-(quinolin-8-yl)-1H-pyrazol-5-yl)pyridazin-3-amine (69). Oral administration of 69 to rats reduced food intake in an ad libitum feeding model, which could be completely reversed by a selective 5-HT2C antagonist." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00385"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00385">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00385&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00385&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00385&amp;href=/doi/10.1021/acs.jmedchem.7b00385" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6166-6190</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00380" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00435" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT<sub>2C</sub> Receptor Agonists</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Carpenter">Joseph Carpenter</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-0885-1590" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Wang">Ying Wang</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Wu">Gang Wu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianxin++Feng">Jianxin Feng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiang-Yang++Ye">Xiang-Yang Ye</a></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-3739-0930" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christian+L.++Morales">Christian L. Morales</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Broekema">Matthias Broekema</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen+A.++Rossi">Karen A. Rossi</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Keith+J.++Miller">Keith J. Miller</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+J.++Murphy">Brian J. Murphy</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ginger++Wu">Ginger Wu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+E.++Malmstrom">Sarah E. Malmstrom</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+V.++Azzara">Anthony V. Azzara</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+M.++Sher">Philip M. Sher</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+M.++Fevig">John M. Fevig</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Alt">Andrew Alt</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+L.++Bertekap%2C++Jr.">Robert L. Bertekap, Jr.</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Jane++Cullen">Mary Jane Cullen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+M.++Harper">Timothy M. Harper</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kimberly++Foster">Kimberly Foster</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily++Luk">Emily Luk</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qian++Xiang">Qian Xiang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+F.++Grubb">Mary F. Grubb</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+A.++Robl">Jeffrey A. Robl</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean+A.++Wacker">Dean A. Wacker</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Departments of Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div><div class="corresp-info"><strong>*</strong>J.C.: e-mail, <a href="/cdn-cgi/l/email-protection#cba1a4b8aebba3e5a8aab9bbaea5bfaeb98b898698e5a8a4a6"><span class="__cf_email__" data-cfemail="acc6c3dfc9dcc482cfcddedcc9c2d8c9deeceee1ff82cfc3c1">[email protected]</span></a>; phone, (609) 466-5025.</div><div class="corresp-info"><strong>*</strong>Y.W.: e-mail, <a href="/cdn-cgi/l/email-protection#ed9484838ac39a8c838aad8f809ec38e8280"><span class="__cf_email__" data-cfemail="fb8292959cd58c9a959cbb999688d5989496">[email protected]</span></a>; phone, (609) 466-5092.</div><div class="corresp-info"><strong>*</strong>D.A.W.: e-mail, <a href="/cdn-cgi/l/email-protection#8befeeeae5a5fceae8e0eef9cbe9e6f8a5e8e4e6"><span class="__cf_email__" data-cfemail="701415111e5e0711131b150230121d035e131f1d">[email protected]</span></a>; phone, (609) 466-5087.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00385&amp;href=/doi/10.1021%2Facs.jmedchem.7b00385" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6166–6190</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 21, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 March 2017</li><li><span class="item_label"><b>Published</b> online</span>7 July 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 July 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00385" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00385</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6166%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJoseph%2BCarpenter%252C%2BYing%2BWang%252C%2BGang%2BWu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D14%26contentID%3Dacs.jmedchem.7b00385%26title%3DUtilization%2Bof%2Ban%2BActive%2BSite%2BMutant%2BReceptor%2Bfor%2Bthe%2BIdentification%2Bof%2BPotent%2Band%2BSelective%2BAtypical%2B5-HT2C%2BReceptor%2BAgonists%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6190%26publicationDate%3DJuly%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00385"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1774</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00385" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Carpenter&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Jianxin&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Xiang-Yang&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;L. Morales&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Broekema&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;A. Rossi&quot;},{&quot;first_name&quot;:&quot;Keith&quot;,&quot;last_name&quot;:&quot;J. Miller&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;J. Murphy&quot;},{&quot;first_name&quot;:&quot;Ginger&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;E. Malmstrom&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;V. Azzara&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;M. Sher&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;M. Fevig&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Alt&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;L. Bertekap&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Jane Cullen&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;M. Harper&quot;},{&quot;first_name&quot;:&quot;Kimberly&quot;,&quot;last_name&quot;:&quot;Foster&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;Luk&quot;},{&quot;first_name&quot;:&quot;Qian&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;F. Grubb&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;A. Robl&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;A. Wacker&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;6166-6190&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00385&quot;},&quot;abstract&quot;:&quot;Agonism of the 5-HT2C receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT2A and 5-HT2B receptors is critical as their activation has been shown to lead to undesirable side effects and major safety concerns. In this communication, we report the development of a new screening paradigm that utilizes an active site mutant D134A (D3.32) 5-HT2C receptor to identify atypical agonist structures. We additionally report the discovery and optimization of a novel class of nonbasic heterocyclic amide agonists of 5-HT2C. SAR investigations around the screening hits provided a diverse set of potent agonists at 5-HT2C with high selectivity over the related 5-HT2A and 5-HT2B receptor subtypes. Further optimization through replacement of the amide with a variety of five- and six-membered heterocycles led to the identification of 6-(1-ethyl-3-(quinolin-8-yl)-1H-pyrazol-5-yl)pyridazin-3-amine (69). Oral administration of&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00385&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00385" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00385&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00385" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00385&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00385" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00385&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00385&amp;href=/doi/10.1021/acs.jmedchem.7b00385" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00385" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00385" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00385%26sid%3Dliteratum%253Aachs%26pmid%3D28635286%26genre%3Darticle%26aulast%3DCarpenter%26date%3D2017%26atitle%3DUtilization%2Bof%2Ban%2BActive%2BSite%2BMutant%2BReceptor%2Bfor%2Bthe%2BIdentification%2Bof%2BPotent%2Band%2BSelective%2BAtypical%2B5-HT2C%2BReceptor%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D14%26spage%3D6166%26epage%3D6190%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290658" title="Amides">Amides</a>,</li><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/jmcmar.2017.60.issue-14/20170727/jmcmar.2017.60.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Agonism of the 5-HT<sub>2C</sub> receptor represents one of the most well-studied and clinically proven mechanisms for pharmacological weight reduction. Selectivity over the closely related 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors is critical as their activation has been shown to lead to undesirable side effects and major safety concerns. In this communication, we report the development of a new screening paradigm that utilizes an active site mutant D134A (D3.32) 5-HT<sub>2C</sub> receptor to identify atypical agonist structures. We additionally report the discovery and optimization of a novel class of nonbasic heterocyclic amide agonists of 5-HT<sub>2C</sub>. SAR investigations around the screening hits provided a diverse set of potent agonists at 5-HT<sub>2C</sub> with high selectivity over the related 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptor subtypes. Further optimization through replacement of the amide with a variety of five- and six-membered heterocycles led to the identification of 6-(1-ethyl-3-(quinolin-8-yl)-1<i>H</i>-pyrazol-5-yl)pyridazin-3-amine (<b>69</b>). Oral administration of <b>69</b> to rats reduced food intake in an ad libitum feeding model, which could be completely reversed by a selective 5-HT<sub>2C</sub> antagonist.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The ever-increasing prevalence of obesity represents a great burden on global human health. As a major risk factor for type II diabetes, coronary heart disease, heart failure and stroke, obesity and its comorbidities account for a growing number of worldwide deaths each year.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> In 2014, it was estimated that 13% of the world’s adult population were considered obese, and 42 million children under the age of 5 were obese in 2013.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Conceptually, the prevention and treatment of obesity can be accomplished through diet and exercise, but unfortunately, many people are unable to attain significant and lasting reductions in body weight through these methods alone. Drug-based therapy may provide an opportunity for these patients to achieve clinically beneficial weight loss and concomitant reductions in incidence of associated comorbidities.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">The neurotransmitter serotonin (5-hydroxytryptamine or 5-HT, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) is known to play a critical role in the regulation of numerous neurological functions including mood, sexual desire and function, appetite, sleep, memory, learning, and temperature regulation.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a> There are 14 serotonin receptor subtypes, all of which are G-protein-coupled receptors (GPCR) with the exception of the ligand-gated ion channel 5-HT<sub>3</sub>. Serotonin’s effects on appetite and feeding have been shown to be largely controlled through the expression and activation of the 5-HT<sub>2C</sub> receptor.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Lorcaserin (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) elicits its response through activation of the 5-HT<sub>2C</sub> receptor, which remains among the most well-studied and proven mechanisms for pharmacological weight reductions.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> The 2012 FDA approval of lorcaserin was an important milestone for the treatment of obesity, as it represents the first regulatory approval of a weight loss drug in over a decade.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. 5-HT<sub>2C</sub> agonist structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite lorcaserin’s approval, the search for highly selective 5-HT<sub>2C</sub> agonists remains an attractive area of research, as agonism of the closely related 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors can lead to hallucinations and potentially fatal fibrotic cardiac valvulopathy, respectively.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14 ref15 ref16">(11-16)</a> The discovery and development of novel agonist structures may enable greater efficacy with a differentiated safety and tolerability profile through better selectivity versus the 2A and 2B receptor subtypes. A major hindrance to developing selective agonists is the highly conserved nature of the serotonin binding site across all receptor subtypes. Aromatic amino acids (Phe, Tyr, Trp) form what has been coined the aromatic box, which interact with the indole portion of serotonin while a conserved Asp residue serves to anchor the agonist through formation of a tight salt-bridge with serotonin’s basic nitrogen.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> It should not be surprising then that typical 5-HT<sub>2C</sub> agonists (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) consist of a hydrophobic aryl or heteroaryl ring system tethered to a basic nitrogen that is capable of mimicking the interactions observed with serotonin.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22 ref23 ref24">(18-24)</a> These common structural features are typically considered indispensable for active site binding and receptor activation and likely contribute to poor receptor subtype selectivity. In addition to the adverse events such as valvular hypertrophy and CNS-based events mentioned previously, the amphiphilic nature of these common structures has also been implicated in various off-target toxicities such as ion channel inhibition and phospholipidosis.<a onclick="showRef(event, 'ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28">(25-28)</a></div><div class="NLM_p last">Allosteric modulation of GPCRs is emerging as a promising new strategy for the identification of novel chemical entities for the treatment of a variety of central nervous system disorders.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In 2003, Dinh and co-workers reported on the discovery of a positive allosteric modulator (PAM) of 5-HT<sub>2C</sub> which enhanced both the binding and functional potency of serotonin in several mammalian cell lines with no analogous effect on the related 2A and 2B receptors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In principle, a positive allosteric modulator of 5-HT<sub>2C</sub> could act to enhance the in vivo activity of endogenous serotonin which is known to be elevated in the fed state and could lead to enhanced satiety, an overall reduction of food intake, and concomitant weight reduction. Moreover, because allosteric compounds would not bind to the serotonin site, they would likely have a structure quite divergent from that of classical 5-HT<sub>2C</sub> agonists. In turn, we reasoned that these atypical structures could provide an opportunity to not only obtain high selectivity over closely related serotonin subtypes but also avoid common aforementioned toxicities associated with the typical 5-HT<sub>2C</sub> pharmacophore.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Lead Identification</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72474" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72474" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Given the possibilities presented by an allosteric modulator, we embarked on a journey to identify novel positive allosteric modulators of 5-HT<sub>2C</sub>. In order to realize this outcome, we screened the BMS compound library in PAM mode using serotonin as the agonist. Unfortunately, no positive allosteric modulators were found, but we did identify nearly 50 000 compounds that exhibited 5-HT<sub>2C</sub> agonism. Although our original goal of identifying a positive allosteric modulator was not achieved, we were intrigued by the number of atypical structures that did not conform to the classic 5-HT<sub>2C</sub> agonist pharmacophore. From this set of screening hits, we considered the possibility of identifying a completely unique series of compounds that could allow for a deviation from the known selectivity and toxicity concerns that plague the field. After eliminating all of the known 5-HT<sub>2C</sub> agonists and any additional compounds with high structural similarity to known 5-HT<sub>2C</sub> agonists (i.e., compounds that contained an aromatic ring with a 2–3 atom tether to a basic amine moiety), we were left with approximately 18 000 compounds that did not fit the typical basic amine containing pharmacophore. From this set, 68 unique high-potency compounds with differentiated chemical structures were chosen for purification and retesting. To our disappointment, none of the compounds retained any 5-HT<sub>2C</sub> potency following purification, which was likely attributed to removal of contaminants in the deck sample. Four representative examples of screening hits are given in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. As indicated in red, these compounds possess embedded substructures that are well-known 5-HT<sub>2C</sub> agonists that could be remnants of synthetic impurities or liberated during deterioration of the parent molecule upon long-term storage in DMSO. Although these results were discouraging, we still wondered if within the remaining screening hits there were compounds where the 5-HT<sub>2C</sub> potency was attributed to the parent molecule and not a possible impurity or degradant.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Screening hits with embedded 5-HT<sub>2C</sub> agonist substructures indicated in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Purification and retesting of 18 000 compounds was not feasible, so an alternative approach to evaluating these hits was needed. We reasoned that this selection process could be accomplished by site-selective mutagenesis of the 5-HT<sub>2C</sub> receptor active site. Our hypothesis was that while the residues that form the aromatic box are necessary for the receptor’s agonist activity, the active site aspartic acid (Asp 134, D3.32) was only important for amine binding and could be mutated without impacting receptor function. This mutant receptor should not respond to compounds whose activity was driven by amine binding eliminating any samples contaminated with classical 5-HT<sub>2C</sub> agonist impurities. This approach was not without significant risk as mutation of Asp 134 could lead to a misfolded protein or a functionally inactive receptor, even if the protein was able to adopt the proper tertiary structure. The desired D134A mutant was prepared and found to have no functional activity in the presence of serotonin or several additional known 5-HT<sub>2C</sub> agonists. However, upon screening against our compound library, several hits were obtained that were agonists at both the wild-type and mutant receptor, but they were not active in a parental cell line that lacks the 5-HT<sub>2C</sub> receptor. The screening hits were also tested for PAM activity in the presence of serotonin and were found to have no impact on serotonin’s binding or functional response.</div><div class="NLM_p">Among the high throughput screening hits identified, two thiazole-based leads <b>1</b> and <b>2</b> were found to give promising 5-HT<sub>2C</sub> agonism in both the wild-type and D134A mutant receptors while being completely devoid of functional activity at the 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Furthermore, these leads could be divided into three simple fragments (aryl ring, heterocyclic core, and carboxamide) that should allow for rapid SAR evaluation of each segment. These features, together with their low molecular weight and polar surface area, represented an attractive starting point for the optimization of a novel chemical series for brain-penetrant 5-HT<sub>2C</sub> agonists.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Novel thiazole-based leads from HTS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial investigations focused on amide SAR of <b>1</b>, as we were wary of the hydrophobic aryl ring system coupled with a basic amine functionality present in <b>2</b> which was reminiscent of the traditional 5-HT<sub>2C</sub> agonist pharmacophore we hoped to avoid due to potential off-target toxicity. For thiazole compound <b>1</b>, over 100 amide variations were prepared (alkyl, heteroalkyl, aryl, heteroaryl) resulting in mostly inactive compounds with only a few close analogs showing similar levels of potency or receptor activation (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, <b>3</b>–<b>6</b>). Similarly, attempts to modify the dichlorophenyl moiety with differentially substituted mono- and bicyclic aryl and heteroaryls led to compounds with diminished 5-HT<sub>2C</sub> potency (<b>7</b>–<b>13</b>). We next turned our efforts to the evaluation of the thiazole core (<b>14</b>–<b>17</b>). Morpholine amides of several isomeric and methyl substituted thiazoles were prepared, and although most of the core replacements resulted in significant reductions in potency, this exercise led to identification of compound <b>17</b> with promising 5-HT<sub>2C</sub> potency of 28 nM and full intrinsic activity. Unfortunately, as we had seen with modifications to <b>1</b>, we were again met with disappointment as the improved 5-HT<sub>2C</sub> potency of <b>17</b> did not translate broadly to more potent derivatives upon further modification (data not shown). Variation of the amide revealed narrow SAR, and given an in vitro human half-life of less than 2 min, this thiazole isomer series was not progressed.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Modifications of Lead Thiazole <b>1</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0007.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values were calculated from dose–response curves. Functional screenings were carried out in HEK293E cells expressing the human 5-HT<sub>2C</sub> receptor. EC<sub>50</sub> determination experiments were performed at least in triplicate, and the values are presented as mean ± SD unless indicated otherwise or by inclusion of two values. Positive control was mCPP which gave 5-HT<sub>2C</sub>, EC<sub>50</sub> = 15 ± 4 nM. All compounds were functionally inactive (EC<sub>50</sub> > 10 μM) at 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Intrinsic activity (IA) for all compounds as compared to serotonin at 3 μM (defined as IA = 1).</p></div></div><div></div></div><div class="NLM_p">After our unsuccessful attempt to identify a tractable lead from <b>1</b> we shifted our efforts to modification of screening hit <b>2</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). We were pleased to find that the morpholine amide analog <b>18</b> retained the 5-HT<sub>2C</sub> potency of <b>2</b> without the basic amine functionality we had hoped to avoid. In an attempt to gain potency, we inserted the thiazole core from <b>17</b> to give <b>19</b>, but despite the apparent similarities of leads <b>1</b> and <b>2</b>, the SAR was found to diverge and this substitution resulted in a loss of potency. This variance was also exemplified by <b>13</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), as incorporation of the 1-naphthyl core from screening hit <b>2</b> into <b>1</b> resulted in a nearly 8-fold loss of potency. Removal of the 4-methyl substituent (<b>20</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) or swapping the location of nitrogen and sulfur (<b>21</b>) was also detrimental to 5-HT<sub>2C</sub> potency, and thus <b>18</b> was chosen for further optimization.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Modification of Thiazole Lead <b>2</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values were calculated from dose–response curves. Functional screenings were carried out in HEK293E cells expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptor. EC<sub>50</sub> determination experiments were performed at least in triplicate, and the values are presented as mean ± SD unless indicated otherwise or by inclusion of two values. Positive control was mCPP which gave 5-HT<sub>2C</sub>, EC<sub>50</sub> = 15 ± 4 nM. All compounds were functionally inactive (EC<sub>50</sub> > 10 μM) at 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Intrinsic activity (IA) for all compounds as compared to serotonin at 3 μM (defined as IA = 1).</p></div></div><div></div></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A general synthetic approach to analogs of thiazole lead <b>2</b> is outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> as exemplified by three key compounds <b>31</b>, <b>41</b>, and <b>47</b>. For thiazole <b>31</b>, synthesis commenced with condensation of naphthylene-1-thiocarboxamide (<b>A</b>) with ethyl 2-chloro-3-oxobutanoate (<b>B</b>) to give the thiazole ester intermediate <b>C</b>. The carboxylic acid, obtained via saponification, underwent facile amide coupling with piperidin-4-ylmethanol to give thiazole amide <b>31</b> in the three-step process depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> line i. Pyrrole <b>41</b> (line ii) was prepared through an initial Suzuki coupling between naphthalene-1-boronic acid (<b>D</b>) and commercially available or readily synthesized ethyl 5-bromo-2-methyl-1<i>H</i>-pyrrole-3-carboxylate (<b>E</b>), followed by saponification of <b>F</b> and amide coupling to yield the final product. For the synthesis of pyrazole <b>47</b> (line iii) we employed a condensation of ethyl 4-(naphthalen-1-yl)-2,4-dioxobutanoate (<b>G</b>) with hydrazine and subsequent alkylation with iodomethane to give the <i>N</i>-methyl pyrazole ester intermediate (<b>H</b>). As with previous examples, final compound <b>47</b> was readily obtained by hydrolysis and amide coupling.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Key Compounds <b>31</b>, <b>41</b>, <b>47</b>, and <b>69</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EtOH, 80 °C, sealed tube. (b) LiOH, THF/H<sub>2</sub>O/MeOH, rt. (c) Piperidin-4-ylmethanol, T<sub>3</sub>P, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, rt. (d) NBS, DMF, rt. (e) PdCl<sub>2</sub>(dppf)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 90–100 °C, sealed tube. (f) Hydrazine, AcOH, 90 °C. (g) CH<sub>3</sub>I, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, rt. (h) LDA, isopropyl pinacol borate, – 78 °C to rt, THF. (i) PdCl<sub>2</sub>(dtbpf)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C, sealed tube. (j) H<sub>2</sub>, Pd/C, MeOH, rt. (k) <i><sup>t</sup></i>BuONO, Cu(I)Br, LiBr, acetonitrile, 50 °C. (l) TFA, rt.</p></p></figure><div class="NLM_p last">As described in line iv, commercially available 1-ethyl-3-nitro-1<i>H</i>-pyrazole (<b>I</b>) was converted to the corresponding pinacol boronic ester prior to Suzuki coupling with bis-Boc protected 6-chloropyridazin-3-amine (<b>J</b>). During optimization of this coupling, we found that the more reactive 1,1′-bis(di-<i>tert</i>-butylphosphino)ferrocene (dtbpf) ligand was vastly superior to the more commonly used 1,1′-bis(diphenylphosphino)ferrocene (dppf) ligand at forging the biaryl union. Reduction of the nitro group and conversion of the resultant aminopyrazole (<b>K</b>) to the corresponding bromopyrazole under Sandmeyer conditions set up a penultimate Suzuki coupling with quinoline-8-boronic acid (<b>L</b>). Deprotection of the Boc protecting groups was facilitated with TFA to give compound <b>69</b>.</div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Lead Optimization</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To our satisfaction, we discovered that further SAR investigation of <b>18</b> gave rise to a diverse set of compounds that exhibited appreciable 5-HT<sub>2C</sub> potency while being completely devoid of functional activity at 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Although the primary carboxamide <b>22</b> was inactive, we found that with the appropriate amide substitution we were able to retain and even improve the full-agonist activity and potency of <b>18</b>. For example, simple acyclic and cyclic aliphatic amides <b>23</b> and <b>24</b> were functionally active with an EC<sub>50</sub> as low as 24 nM in the case of piperidine amide <b>24</b>. Further amide SAR revealed that tertiary and cyclic amides were preferred, as secondary amides typically lacked potency or gave only partial 5-HT<sub>2C</sub> agonism (<b>25</b> vs <b>26</b>). Results were also sensitive to steric bulk as exemplified by the complete loss of potency for <b>28</b> vs <b>27</b>. Although we were pleased with the potency attainable in this series, most compounds tested suffered from poor metabolic stability when incubated with human and rat liver microsomes. In an effort to improve metabolic stability, heteroatoms were introduced into the amide chain with mixed results (<b>25</b>–<b>32</b>). Hydroxylation of the amide side chains (<b>27</b>, <b>29</b>–<b>31</b>) not only improved microsomal stability but also retained or increased 5-HT<sub>2C</sub> potency, with the hydroxymethylpiperidine amide <b>31</b> being optimal. We were somewhat surprised to find the decrease in potency for piperizine amide <b>32</b> given the presence of a basic secondary amine and structural similarity to traditional 5-HT<sub>2C</sub> agonists. Importantly, this may suggest that <b>32</b> acts through an alternative mode of binding and receptor activation than that of serotonin. Nitrogen-containing heterocycles <b>33</b>–<b>36</b> were synthesized with the intent of further improving microsomal stability, and although several were well-tolerated, they did not improve stability or provide a clear advantage relative to the nonheterocycles in terms of potency.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Amide SAR: 5-HT<sub>2C</sub> EC<sub>50</sub> and IA and Microsomal Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0010.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values were calculated from dose–response curves. Functional screenings were carried out in HEK293E cells expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptor. EC<sub>50</sub> determination experiments were performed at least in triplicate, and the values are presented as mean ± SD unless indicated otherwise or by inclusion of two values. Positive control was mCPP which gave 5-HT<sub>2C</sub>, EC<sub>50</sub> = 15 ± 4 nM. All compounds were functionally inactive (EC<sub>50</sub> > 10 μM) at 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Intrinsic activity (IA) for all compounds as compared to serotonin at 3 μM (defined as IA = 1).</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Compounds were incubated with human or rat liver microsomes at 5 mM. Values represent % parent remaining after 10 min. ND = not determined.</p></div></div><div></div></div><div class="NLM_p">At this juncture, we chose to evaluate five-membered heterocyclic replacements for the thiazole core with the hope of identifying a molecule that would retain 5-HT<sub>2C</sub> potency and selectivity while further improving metabolic stability. Holding the naphthyl ring system and hydroxymethylpiperidine amide of <b>31</b> constant, we systematically modified the core heterocycle structure (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Our anticipation, based on previous observations with different thiazole isomers, was that changing the effective ring size and geometry by moving or replacing the sulfur atom would be detrimental to 5-HT<sub>2C</sub> activity, but again the SAR was mostly unpredictable. Cores containing one heteroatom were generally tolerated, but as observed with thiazoles, the potency could vary dramatically between isomeric structures. Both thiophene isomers <b>37</b> and <b>38</b> retained 5-HT<sub>2C</sub> potency (20 nM and 83 nM, respectively) but gave no improvement in terms of microsomal stability. However, furan <b>39</b> was >250-fold less potent than isomer <b>31</b>. Pyrrole <b>41</b> (12 nM) was the most potent single nitrogen-containing heterocycle with isomers <b>40</b> and <b>42</b> losing 3- to 30-fold potency at 5-HT<sub>2C</sub>. Of the cores containing multiple heteroatoms, oxazoles, imidazoles, triazoles, and tetrazoles (<b>43</b>–<b>46</b>, <b>49</b>, <b>50</b>) were not ideal giving approximately 16- to 700-fold loss in potency relative to thiazole <b>31</b>. Pyrazoles <b>47</b> and <b>48</b> on the other hand were potent (6 and 16 nM), and as a result of this exercise, we had several potent, selective 5-HT<sub>2C</sub> agonists within this series that we chose to advance for further in vitro and in vivo profiling.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Core Replacement of Thiazole <b>31</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0011.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0012.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values were calculated from dose–response curves. Functional screenings were carried out in HEK293E cells expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptor. EC<sub>50</sub> determination experiments were performed at least in triplicate, and the values are presented as mean ± SD unless indicated otherwise or by inclusion of two values. Positive control was mCPP which gave 5-HT<sub>2C</sub>, EC<sub>50</sub> = 15 ± 4 nM; 5-HT<sub>2B</sub>, EC<sub>50</sub> = 287 ± 94 nM; 5-HT<sub>2A</sub>, EC<sub>50</sub> = 290 ± 110 nM.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Intrinsic activity for all compounds as compared to serotonin at 3 μM (defined as 1).</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Compounds were incubated with human or rat liver microsomes at 5 mM. Values represent % parent remaining after 10 min.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">EC<sub>50</sub> value represents the average of multiple test occasions, several of which indicated no functional 5-HT<sub>2A</sub> activity.</p></div></div><div></div></div><div class="NLM_p">Given the promising metabolic stability in human liver microsomes and the higher overall plasma and brain exposures observed for compound <b>47</b> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>), the pyrazole core represented an attractive lead for additional SAR investigations. With the intent of further increasing lipophilicity via changes to the polar amide moiety, we prepared a set of heterocyclic amide isosteres. Various five- or six-membered heteroaryl amide replacements were investigated (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). <i>N</i>-Methylimidazole <b>51</b> (73 nM) was a promising initial result, and we found that by changing the core pyrazole alkyl substituent to ethyl to give <b>52</b>, we gained approximately 2-fold potency at 5-HT<sub>2C</sub> (32 nM). Unfortunately these compounds suffered from poor microsomal metabolic stability. Introduction of the isomeric imidazole <b>53</b> or pyrazole <b>54</b> resulted in a substantial loss of functional activity and potency (4120 nM, 3500 nM, respectively), which was only partially restored in the case of triazole <b>55</b> or tetrazole <b>56</b> (400 nM, 450 nM, respectively). With respect to six-membered heterocyclic amide replacements, pyridine <b>57</b> and pyrimidine <b>58</b> lacked sufficient 5-HT<sub>2C</sub> potency for advancement, whereas pyridazines <b>59</b> and <b>60</b> exhibited good potency, intrinsic activity, and selectivity for 5-HT<sub>2C</sub>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Amide Isostere SAR: 5-HT<sub>2C</sub> EC<sub>50</sub> and IA and Microsomal Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0013.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0014.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values were calculated from dose–response curves. Functional screenings were carried out in HEK293E cells expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptor. EC<sub>50</sub> determination experiments were performed at least in triplicate, and the values are presented as mean ± SD unless indicated otherwise or by inclusion of two values. Positive control was mCPP which gave 5-HT<sub>2C</sub>, EC<sub>50</sub> = 15 ± 4 nM; 5-HT<sub>2B</sub>, EC<sub>50</sub> = 287 ± 94 nM; 5-HT<sub>2A</sub>, EC<sub>50</sub> = 290 ± 110 nM.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Intrinsic activity for all compounds as compared to serotonin at 3 μM (defined as 1).</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">Compounds were incubated with human or rat liver microsomes at 5 mM. Values represent % parent remaining after 10 min. ND = not determined.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">EC<sub>50</sub> value represents the average of multiple test occasions, several of which indicated no functional 5-HT<sub>2A</sub> activity.</p></div></div><div></div></div><div class="NLM_p">Having established that the pyridazine ring was optimal for 5-HT<sub>2C</sub> potency and activity, detailed metabolite profiling of <b>60</b> revealed the naphthalene ring to be particularly susceptible to oxidative metabolism, and thus further SAR exploration focused on its stabilization via incorporation of a nitrogen atom into the ring system (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). To this end, we prepared a series of compounds with a single nitrogen atom in each position around the naphthalene ring with the intent of blocking the major site of oxidative degradation. While analogs <b>61</b>–<b>63</b> exhibited approximately 20- to 30-fold diminished 5-HT<sub>2C</sub> potency and analogs <b>64</b> and <b>65</b> were >100-fold less potent, we were pleased to find that isoquinoline <b>66</b> at 28 nM was comparable to <b>60</b>. Moreover, quinoline <b>67</b> gave a marked improvement in 5-HT<sub>2C</sub> potency (2 nM) but remained highly prone to oxidative metabolism. We again turned to metabolite identification to determine what region of <b>67</b> was subject to oxidative degradation and found that the liability had now shifted to the pyridazine. Introduction of an amino substituent at the 3-position on the pyridazine was found to partially mitigate its metabolism and retain or even improve 5-HT<sub>2C</sub> potency for compounds <b>68</b> and <b>69</b> relative to the unsubstituted analogs (7 nM, 79% remaining, 5 nM, 61% remaining respectively).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Amide Isostere SAR: 5-HT<sub>2C</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2A</sub> EC<sub>50</sub> and IA and Microsomal Stability</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0015.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0016.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> values were calculated from dose–response curves. Functional screenings were carried out in HEK293E cells expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptor. EC<sub>50</sub> determination experiments were performed at least in triplicate, and the values are presented as mean ± SD unless indicated otherwise or by inclusion of two values. Positive control was mCPP which gave 5-HT<sub>2C</sub>, EC<sub>50</sub> = 15 ± 4 nM; 5-HT<sub>2B</sub>, EC<sub>50</sub> = 287 ± 94 nM; 5-HT<sub>2A</sub>, EC<sub>50</sub> = 290 ± 110 nM.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Intrinsic activity for all compounds as compared to serotonin at 3 μM (defined as 1).</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">Compounds were incubated with human or rat liver microsomes at 5 mM. Values represent % parent remaining after 10 min. ND = not determined.</p></div><div class="footnote" id="t6fn4"><sup>Table d</sup><p class="last">EC<sub>50</sub> value represents the average of multiple test occasions, several of which indicated no functional 5-HT<sub>2A</sub> activity.</p></div><div class="footnote" id="t6fn5"><sup>Table e</sup><p class="last">EC<sub>50</sub> value represents results from a single experiment.</p></div></div><div></div></div></div><div id="sec1_4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Pharmacokinetics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00624" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00624" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>31</b>, <b>41</b>, <b>47</b>, and <b>69</b> were selected for further in vitro profiling and rat pharmacokinetic studies, the data for which are given in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. These studies were designed to assess the permeability of each compound along with relative exposure of the compounds in the brain versus the plasma. In general, the compounds had excellent pH independent permeability as measured by a parallel artificial membrane permeability assay (PAMPA), in addition to Caco-2 ratios that suggested good permeability with a low probability of transporter mediated efflux. In a preliminary experiment, compound <b>31</b> was administered orally (po) to rats at a dose of 30 mg/kg and the brain and plasma concentrations were determined 7 h after administration. Given the low in vitro rat microsomal stability of <b>31</b> (<i>T</i><sub>1/2</sub> = 6 min), we were not surprised to observe low exposures (736 nM plasma, 35 nM brain, <i>b</i>/<i>p</i> = 0.05) with a short half-life. In an attempt to circumvent degradation of the compound through oxidative first-pass metabolism, compound <b>31</b> was subsequently administered intravenously (iv) at 1 mg/kg and its brain and plasma concentrations were determined at 1 h after dose. Despite the modified dosing protocol, low plasma and brain concentrations were again observed for <b>31</b> (569 nM, 76 nM, respectively, <i>b</i>/<i>p</i> = 0.15). Taken together, the low brain to plasma concentrations were surprising considering the high PAMPA permeability and lack of Caco-2 efflux. In an attempt to understand possible reasons for low brain exposure, several follow-up studies were conducted utilizing P-glycoprotein and breast cancer resistance protein (Pgp, BCRP) transporter knockout mice and specially engineered cellular systems that overexpress these membrane transporters. These experiments ultimately revealed that compound <b>31</b> was a substrate of rodent Pgp and BCRP transporters but exhibited no significant in vitro affinity for human Pgp or BCRP transporters.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro and in Vivo Profiling of Selected 5-HT<sub>2C</sub> Agonists</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">exposure (nM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PAMPA (nm/s), pH 5.5/7.4</th><th class="colsep0 rowsep0" align="center">Caco-2 (nm/s), efflux ratio (BA/AB)</th><th class="colsep0 rowsep0" align="center">protein binding (% bound), human/rat</th><th class="colsep0 rowsep0" align="center">microsomal <i>T</i><sub>1/2</sub> (min), human/rat</th><th class="colsep0 rowsep0" align="center">plasma</th><th class="colsep0 rowsep0" align="center">brain</th><th class="colsep0 rowsep0" align="center"><i>B</i>/<i>P</i> <a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">607/739</td><td class="colsep0 rowsep0" align="left">0.5 (175/329)</td><td class="colsep0 rowsep0" align="left">99.5/99.6</td><td class="colsep0 rowsep0" align="left">21/6</td><td class="colsep0 rowsep0" align="left">736<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">35<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">624/492</td><td class="colsep0 rowsep0" align="left">1.3 (219/172)</td><td class="colsep0 rowsep0" align="left">98.3/92.5</td><td class="colsep0 rowsep0" align="left">41/11</td><td class="colsep0 rowsep0" align="left">1137<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">202<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">588/613</td><td class="colsep0 rowsep0" align="left">0.5 (168/323)</td><td class="colsep0 rowsep0" align="left">97.7/92.4</td><td class="colsep0 rowsep0" align="left">36/8</td><td class="colsep0 rowsep0" align="left">2476<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">721<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">727/889</td><td class="colsep0 rowsep0" align="left">0.7 (528/777)</td><td class="colsep0 rowsep0" align="left">93.8/92.1</td><td class="colsep0 rowsep0" align="left">16/25</td><td class="colsep0 rowsep0" align="left">7543<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">3920<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">0.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">The value represents the average of three male animals. Plasma and brain concentrations were determined after the indicated time. The brain sample was diluted (1:2 (vol/weight)) with water before homogenization. The dilution factor is 3.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">The compound was dosed orally at 30 mg/kg. Dosing vehicle: 0.15% docusate sodium; 2% polyvinyl pyrrolidinone-K; 97.85% water.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Plasma and brain concentration was determined at 7 h.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Plasma and brain concentration was determined at 1 h.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">Plasma and brain concentration was determined at 2 h.</p></div><div class="footnote" id="t7fn6"><sup>f</sup><p class="last">Plasma and brain concentration was determined at 3 h.</p></div></div></div><div class="NLM_p">Given our lack of high throughput rodent Pgp and BCRP assays and with no clear advantage to iv administration, we chose to move forward with oral administration of the remaining compounds as the means to determine if high rodent brain exposure would be feasible within our current series of heterocyclic 5-HT<sub>2C</sub> agonists. Compounds <b>41</b> and <b>47</b> were subsequently administered to rats according to the original oral dosing regimen (30 mg/kg po), and as with compound <b>31</b>, we observed reasonable plasma concentrations for compounds <b>41</b> and <b>47</b>, but relative brain penetration was again low (<i>b</i>/<i>p</i> = 0.3, 0.2 respectively). On the other hand, when compound <b>69</b> was administered orally at 30 mg/kg, it exhibited higher plasma and brain exposures (7.5 μM, 3.9 μM, respectively) with an increased brain to plasma ratio (0.9) relative to compounds <b>31</b>, <b>41</b>, and <b>47</b>.</div><div class="NLM_p">On the basis of its potency and overall pharmacokinetic properties, compound <b>69</b> was chosen for evaluation in a rodent efficacy model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). In an acute feeding model, ∼225 g male Sprague Dawley rats were orally administered <b>69</b> 1 h prior to free access to food and water.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In this study, <b>69</b> showed a dose-dependent reduction in food pellet consumption. Specifically, the 3 and 10 mg/kg dose groups exhibited reduced food intake for the first 4 h and the 30 mg/kg group showed reduced food intake over the entire sampling period. The effect observed at the 30 mg/kg dose was equivalent to the cannabinoid type 1 (CB1) receptor blocker, rimonabant, which was used as a positive control. Moreover, there was no effect on locomotor activity, as assessed by light beam breaks, and no reduction in water intake. In order to determine if the observed food intake reduction was driven by 5-HT<sub>2C</sub> agonism, a subsequent study was conducted with <b>69</b> either alone or in combination with <b>70</b> (SB-243213, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>), a selective 5-HT<sub>2C</sub> antagonist.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Indeed the feeding effects of <b>69</b> were completely reversed by coadministration of <b>70</b>, suggesting a 5-HT<sub>2C</sub> mechanism-based reduction in food intake (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The modest reduction of feeding observed at late time points with the <b>70</b> alone and <b>70</b> + <b>69</b> may be due to the anxiolytic properties of <b>70</b>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rat ad libitum feeding model with 5-HT<sub>2C</sub> agonist <b>69</b>. The values represent the average of six male animals. Cumulative food intake was analyzed via repeated-measure between-group analysis of variance using StatView software (Scientific Computing, Cary, NC). Time points with overall significance were further analyzed with Bonferroni post hoc tests to determine between-group significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Reversal in the rat ad libitum feeding model with 5-HT<sub>2C</sub> antagonist <b>70</b>. The values represent the average of six male animals. Cumulative food intake was analyzed via repeated-measure between-group analysis of variance using StatView software (Scientific Computing, Cary, NC). Time points with overall significance were further analyzed with Bonferroni post hoc tests to determine between-group significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24284" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24284" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new screening protocol utilizing an active site mutant receptor was developed for the identification of novel 5-HT<sub>2C</sub> receptor agonists. This protocol successfully enabled the discovery of a series of heterocycles that exhibited good potency at 5-HT<sub>2C</sub>. Further, with few exceptions, these compounds were found to have excellent subtype functional selectivity against the closely related 5-HT<sub>2B</sub> and 5-HT<sub>2A</sub> receptors. These results, combined with promising in vitro and in vivo profiles, make the compounds described attractive candidates for further investigation. Moreover, these compounds represent a significant structural divergence from what has typically been considered a requisite for agonism of the 5-HT<sub>2C</sub> receptor, namely, exclusion of the basic amine that is proposed to interact with the active site Asp 134 residue. This unique structural series may additionally lead to clinical candidates with improved efficacy, tolerability, and toxicity profiles compared to presently known 5-HT<sub>2C</sub> agonists.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16721" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16721" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div class="NLM_p last">All nonaqueous reactions were carried out under an argon or nitrogen atmosphere at room temperature, unless otherwise noted. All reagents and solvents were purchased from commercial sources and were used without further purification or distillation, unless otherwise stated. Organic solutions were concentrated under reduced pressure on a Büchi rotary evaporator using a water bath. Chromatographic purification of products was accomplished using Teledyne Isco ICN 60 32–64 mesh SiO<sub>2</sub> prepacked columns. Thin-layer chromatography (TLC) was performed on Silicycle 0.25 mm SiO<sub>2</sub> F-254 plates. Visualization of the developed chromatogram was performed by fluorescence quenching or by anisaldehyde, ceric ammonium molybdate, or potassium permanganate stain. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 500 (500 and 125 MHz) unless otherwise noted. Chemical shifts (δ) are reported from tetramethylsilane with the solvent resonance as the internal standard (CDCl<sub>3</sub>, δ 7.26; C<sub>6</sub>D<sub>6</sub>, δ 7.15; CD<sub>3</sub>OD, δ 4.78, 3.31; DMSO-<i>d</i><sub>6</sub>, δ 2.50; CD<sub>3</sub>CN, δ 1.94). Data are reported as follows: chemical shift (δ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, h = heptet, br = broad, m = multiplet), integration, coupling constants (Hz), and assignment. Unless noted otherwise, the reported <sup>1</sup>H NMR signals were assigned using standard NMR techniques or by a direct comparison to the <sup>1</sup>H NMR spectra of corresponding starting materials. Analytical high-pressure liquid chromatography (HPLC) and LCMS analyses were conducted using Shimadzu LC-10AS pumps and a SPD-10AV UV–vis detector set at 220 nm with the MS detection performed with a Micromass Platform LC spectrometer. All compounds were found to be ≥95% pure by HPLC analysis unless otherwise noted.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure for Amide Coupling: General Method A</h3><div class="NLM_p last">Triethylamine (3 equiv) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P) (2 equiv) were added to a stirring suspension of the appropriate carboxylic acid (1 equiv) in an appropriate solvent (0.1 M) at room temperature. After 5 min, the desired amine (1.5 equiv) was added and the mixture was stirred at room temperature until LCMS analysis indicated completion. The crude reaction mixture was then loaded directly onto an Isco SiO<sub>2</sub> cartridge for purification. Alternatively, the products could be purified via preparative HPLC. The desired fractions were combined and concentrated to give the designated amide products.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure for Suzuki Coupling: General Method B</h3><div class="NLM_p last">A degassed mixture of the appropriate heteroaryl halides (2 equiv), 1-ethyl-3-(naphthalen-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1 equiv), tetrakis(triphenylphosphine)palladium(0) (0.15 equiv), and K<sub>3</sub>PO<sub>4</sub> (3 equiv) in <i>N</i>-methyl-2-pyrrolidinone (0.3M) was heated to 95–100 °C until LCMS analysis indicated completion. The reaction mixture was cooled to room temperature and then purified by preparative HPLC (Phenomenex Luna 21.2 mm × 100 mm column; mobile phase A = 10:90 methanol/water with 0.1% trifluoroacetic acid; mobile phase B = 90:10 methanol/water with 0.1% trifluoroacetic acid; or Waters XBridge C18, 19 mm × 100 mm column; mobile phase A = 5:95 acetonitrile/water with 10 mM ammonium acetate; mobile phase B = 95:5 acetonitrile/water with 10-mM ammonium acetate). Alternatively, the crude reaction mixtures could be purified by Isco SiO<sub>2</sub> flash chromatography. The desired fractions were combined and concentrated to give the designated products.</div></div><div id="sec3_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (2-(2,3-Dichlorophenyl)thiazol-4-yl)(morpholino)methanone (<b>1</b>)</h3><div class="NLM_p"><i>Step 1.</i> Lithium hydroxide monohydrate (0.5 g, 12 mmol) was added to a stirring solution of ethyl 2-bromothiazole-4-carboxylate (0.6 g, 2.4 mmol) in tetrahydrofuran (23 mL), water (4.6 mL), and methanol (2.3 mL). After 1.5 h the reaction mixture was diluted with ethyl acetate and acidified to ∼pH 2 with 1.0 N HCl. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent removed in vacuo to give 2-bromothiazole-4-carboxylic acid (0.5 g, 2.4 mmol, 100% yield) as a pale-yellow solid. The product was used without further purification. MS (ESI) <i>m</i>/<i>z</i>, 207.7 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.29 (br s, 1H), 8.45 (s, 1H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of 2-bromothiazole-4-carboxylic acid (330 mg, 1.6 mmol) and morpholine (140 mg, 1.6 mmol) in dichloromethane (6 mL) was added Hunig’s base (0.8 mL, 4.8 mmol) followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P), 50% solution in ethyl acetate (1.5 mL, 2.9 mmol). The resulting solution was stirred under argon at room temperature for 2 h until complete by HPLC analysis. The reaction was loaded onto a SiO<sub>2</sub> flash column via a solid cartridge and was purified by Isco flash chromatography (0–75% ethyl acetate/hexanes) to afford (2-bromothiazol-4-yl)(morpholino)methanone (380 mg, 1.4 mmol, 87% yield) as an off-white solid. MS (ESI) <i>m</i>/<i>z</i>, 279.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.87 (s, 1H), 3.85 (br s, 2H), 3.67 (br s, 6H).</div><div class="NLM_p last"><i>Step 3.</i> To a solution of (2-bromothiazol-4-yl)(morpholino)methanone (50 mg, 0.18 mmol) and (2,3-dichlorophenyl)boronic acid (41 mg, 0.22 mmol) in tetrahydrofuran (4 mL) and water (1 mL) was added K<sub>2</sub>CO<sub>3</sub> (62 mg, 0.45 mmol). The mixture was degassed with a stream of argon for several minutes. Pd(dppf)Cl<sub>2</sub> (7.4 mg, 9.0 μmol) was then added, and the reaction mixture was heated with stirring to 80 °C in a sealed vial. After 2 h, the reaction vessel was removed from heat and stirred overnight. The reaction mixture was diluted with ethyl acetate, washed with saturated aqueous NaHCO<sub>3</sub>, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford an oil. The material was taken up in minimal dichloromethane and purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes, 15 min linear gradient, Isco 12 g column). The desired fractions were combined and concentrated to give <b>1</b> (25 mg, 0.07 mmol, 38% yield) as a pale-yellow solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 343.0, found <i>m</i>/<i>z</i> 343.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.07 (s, 1H), 7.94 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.51 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 7.26 (t, <i>J</i> = 7.8 Hz, 1H), 3.98 (br s, 2H), 3.81–3.64 (m, 6H).</div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (4-Methyl-2-(naphthalen-1-yl)thiazol-5-yl)(4-methylpiperazin-1-yl)methanone, TFA (<b>2</b>)</h3><div class="NLM_p"><i>Step 1.</i> Ethyl 2-chloro-3-oxobutanoate (2.7 mL, 19 mmol) was added to a solution of naphthalene-1-carbothioamide (3.5 g, 19 mmol) in ethanol (19 mL). The reaction vessel was sealed and heated to 80 °C for 19 h and then cooled to room temperature. The excess solvent was removed in vacuo and the residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–20% ethyl acetate/hex, Isco 120 g column) to give ethyl 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylate (4.6 g, 15 mmol, 82% yield) as a waxy white solid. MS (ESI) <i>m</i>/<i>z</i>: 298.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, <i>J</i> = 8.53 Hz, 1H), 7.98 (d, <i>J</i> = 8.28 Hz, 1H), 7.89–7.95 (m, 1H), 7.85 (dd, <i>J</i> = 1.13, 7.15 Hz, 1H), 7.49–7.66 (m, 3H), 4.40 (q, <i>J</i> = 7.19 Hz, 2H), 2.89 (s, 3H), 1.42 (t, <i>J</i> = 7.15 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (1.3 g, 31 mmol) was added to a rapidly stirring suspension of ethyl 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylate (4.6 g, 16 mmol) in tetrahydrofuran (118 mL), water (24 mL), and methanol (12 mL). The reaction mixture was stirred at room temperature for 14 h and was then diluted with ethyl acetate and acidified to pH 3 with 10% aqueous citric acid. The organic phase was washed with brine, and the combined aqueous layers were further extracted with ethyl acetate (2 × 100 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid. The product was used subsequently without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.43 (br s, 1H), 8.81 (d, <i>J</i> = 8.28 Hz, 1H), 8.14 (d, <i>J</i> = 8.28 Hz, 1H), 8.02–8.08 (m, 1H), 7.96 (dd, <i>J</i> = 1.25, 7.28 Hz, 1H), 7.58–7.73 (m, 3H), 2.78 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and 1-methylpiperazine to give <b>2</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>22</sub>N<sub>3</sub>OS) requires <i>m</i>/<i>z</i> 352.1, found <i>m</i>/<i>z</i> 352.1; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91–8.81 (m, <i>J</i> = 7.8, 1.3 Hz, 1H), 8.14 (d, <i>J</i> = 8.3 Hz, 1H), 8.10–8.04 (m, 1H), 7.93 (dd, <i>J</i> = 7.3, 1.0 Hz, 1H), 7.72–7.60 (m, 3H), 4.30 (br s, 2H), 3.18 (br s, 2H), 2.85 (br s, 2H), 2.55 (s, 3H), 1.53–1.41 (m, 2H), 1.00–0.92 (m, 2H); spectrum is partially obscured by DMSO and H<sub>2</sub>O peaks.</div></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> (2-(2,3-Dichlorophenyl)thiazol-4-yl)(piperidin-1-yl)methanone (<b>3</b>)</h3><div class="NLM_p"><i>Step 1.</i> 2,3-Dichlorobenzothioamide (5.0 g, 24 mmol) and 3-bromo-2-oxopropanoic acid (4.2 g, 26 mmol) were dissolved in acetonitrile (120 mL) and heated to 80 °C for 1 h. After being cooled to room temperature, the excess solvent was removed in vacuo and the solid was triturated with diethyl ether until the washings were colorless. The resultant solid was dried in vacuo to give 2-(2,3-dichlorophenyl)thiazole-4-carboxylic acid (6.2 g, 23 mmol, 94% yield) as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 8.11 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.83 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.55 (t, <i>J</i> = 7.9 Hz, 1H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method A with 2-(2,3-dichlorophenyl)thiazole-4-carboxylic acid and piperidine to give <b>3</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>15</sub>C<sub>l2</sub>N<sub>2</sub>OS) requires <i>m</i>/<i>z</i> 341.0, found <i>m</i>/<i>z</i> 341.4; <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.07 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 8.05 (s, 1H), 7.65–7.62 (m, 1H), 7.42–7.37 (m, 1H), 3.83–3.68 (m, 4H), 1.84–1.60 (m, 6H).</div></div><div id="sec3_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (2-(2,3-Dichlorophenyl)thiazol-4-yl)(1,4-oxazepan-4-yl)methanone (<b>4</b>)</h3><div class="NLM_p last">Prepared according to general method A with 2-(2,3-dichlorophenyl)thiazole-4-carboxylic acid and 1,4-oxazepane to give <b>4</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>15</sub>C<sub>l2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 357.0, found <i>m</i>/<i>z</i> 357.4; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.17 (d, <i>J</i> = 7.9 Hz, 1H), 8.02 (ddd, <i>J</i> = 18.8, 7.9, 1.5 Hz, 1H), 7.63 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.40 (t, <i>J</i> = 7.9 Hz, 1H), 4.08–3.98 (m, 2H), 3.96–3.82 (m, 6H), 2.14–2.00 (m, 2H).</div></div><div id="sec3_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (2-(2,3-Dichlorophenyl)thiazol-4-yl)(4-hydroxypiperidin-1-yl)methanone (<b>5</b>)</h3><div class="NLM_p last">Prepared according to general method A with 2-(2,3-dichlorophenyl)thiazole-4-carboxylic acid and piperidin-4-ol to give <b>5</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>15</sub>C<sub>l2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 357.0, found <i>m</i>/<i>z</i> 357.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.00 (d, <i>J</i> = 1.7 Hz, 1H), 7.98 (s, 1H), 7.50 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.26 (t, <i>J</i> = 8.0 Hz, 1H), 4.24–4.15 (m, 2H), 3.99–3.92 (m, 1H), 3.53–3.43 (m, 1H), 3.39–3.32 (m, 1H), 2.00–1.87 (m, 2H), 1.64–1.56 (m, 2H); OH proton is not observed.</div></div><div id="sec3_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl(2-(2,3-dichlorophenyl)thiazol-4-yl)methanone (<b>6</b>)</h3><div class="NLM_p last">Prepared according to general method A with 2-(2,3-dichlorophenyl)thiazole-4-carboxylic acid and 2-oxa-5-azabicyclo[2.2.1]heptane, HCl to give <b>6</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 355.0, found <i>m</i>/<i>z</i> 355.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.34 (d, <i>J</i> = 8.5 Hz, 1H), 8.09–7.95 (m, 1H), 7.60 (ddd, <i>J</i> = 8.0, 6.3, 1.5 Hz, 1H), 7.36 (td, <i>J</i> = 7.9, 5.3 Hz, 3H), 4.73 (d, <i>J</i> = 5.3 Hz, 1H), 4.11 (br s, 2H), 4.07 (d, <i>J</i> = 7.0 Hz, 1H), 4.00–3.89 (m, 1H), 3.71 (d, <i>J</i> = 2.5 Hz, 1H).</div></div><div id="sec3_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (2-(2-Chlorophenyl)thiazol-4-yl)(morpholino)methanone (<b>7</b>)</h3><div class="NLM_p"><i>Step 1.</i> 2-Chlorobenzothioamide (1.5 g, 8.7 mmol) and 3-bromo-2-oxopropanoic acid (1.5 g, 8.7 mmol) were dissolved in dioxane (29 mL) and heated with stirring to 90 °C for 2 h in a sealed reaction vial. The reaction mixture was transferred to a round-bottom flask and concentrated in vacuo. The resultant solid was triturated with diethyl ether until the washings were colorless. The remaining solid was dried in vacuo to give 2-(2-chlorophenyl)thiazole-4-carboxylic acid as a tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.15 (br s, 1H), 8.64 (s, 1H), 8.24–8.14 (m, 1H), 7.72–7.63 (m, 1H), 7.59–7.47 (m, 2H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method A with 2-(2-chlorophenyl)thiazole-4-carboxylic acid and morpholine to give <b>7</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>14</sub>ClN<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 309.0, found <i>m</i>/<i>z</i> 309.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.08–8.04 (m, 1H), 8.04 (s, 1H), 7.48–7.43 (m, 1H), 7.34–7.29 (m, 2H), 4.01 (br s, 2H), 3.81–3.66 (m, 6H).</div></div><div id="sec3_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (2-(2-Chloro-3-fluorophenyl)thiazol-4-yl)(morpholino)methanone (<b>8</b>)</h3><div class="NLM_p"><i>Step 1.</i> A mixture of (2-chloro-3-fluorophenyl)boronic acid (86 mg, 0.50 mmol), methyl 2-bromothiazole-4-carboxylate (100 mg, 0.45 mmol), and K<sub>2</sub>CO<sub>3</sub> (75 mg, 0.54 mmol) in toluene (3.4 mL) and methanol (1.1 mL) was degassed under argon for 20 min, and then PdCl<sub>2</sub>(dppf) (20 mg, 0.03 mmol) was added and the reaction flask was sealed and heated with stirring to 100 °C. After 5 h the crude reaction mixture was loaded onto an Isco SiO<sub>2</sub> cartridge for purification by Isco flash chromatography (0–100% ethyl acetate/hexanes, Isco 4 g column) to give methyl 2-(2-chloro-3-fluorophenyl)thiazole-4-carboxylate (70 mg, 0.26 mmol, 57% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.53 (s, 1H), 8.15 (dd, J = 8.0, 1.3 Hz, 1H), 7.44–7.35 (m, 2H), 3.97 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (54.1 mg, 1.3 mmol) was added to a rapidly stirring solution of methyl 2-(2-chloro-3-fluorophenyl)thiazole-4-carboxylate (70 mg, 0.26 mmol) in tetrahydrofuran (2.5 mL), water (0.4 mL), and methanol (0.2 mL). After stirring at room temperature for 1 h, the reaction mixture was diluted with ethyl acetate/water and acidified to pH 2 with 1 N aqueous HCl. The organic layer was separated, washed with brine, and the combined aqueous layers were further extracted with ethyl acetate. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 2-(2-chloro-3-fluorophenyl)thiazole-4-carboxylic acid (67 mg, 0.26 mmol, 100% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.76 (br s, 1H), 8.54 (s, 1H), 8.11 (d, J = 7.5 Hz, 1H), 7.69–7.55 (m, 2H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 2-(2-chloro-3-fluorophenyl)thiazole-4-carboxylic acid and morpholine to give <b>8</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>13</sub>ClFN<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 327.0, found <i>m</i>/<i>z</i> 327.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.12–8.03 (m, 2H), 7.38 (td, <i>J</i> = 8.0, 5.3 Hz, 1H), 7.33–7.28 (m, 1H), 3.80 (d, <i>J</i> = 4.5 Hz, 8H).</div></div><div id="sec3_3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (2-(3-Chloro-2-fluorophenyl)thiazol-4-yl)(morpholino)methanone (<b>9</b>)</h3><div class="NLM_p"><i>Step 1.</i> 3-Chloro-2-fluorobenzamide (0.2 g, 1.2 mmol) and phosphorus(V) sulfide (0.10 g, 0.23 mmol) were dissolved in dioxane and heated with stirring to 90 °C for 2 h. At this point, complete conversion to the thioamide was determined by LCMS. 3-Bromo-2-oxopropanoic acid (0.20 g, 1.2 mmol) was then added, and the reaction mixture was heated with stirring to 90 °C for an additional 2 h. After being cooled to room temperature, the excess solvent was removed and the residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes, Isco 12 g column) to give 2-(3-chloro-2-fluorophenyl)thiazole-4-carboxylic acid as a light-pink solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.68 (s, 1H), 8.25–8.14 (m, 1H), 7.83–7.73 (m, 1H), 7.44 (t, <i>J</i> = 8.0 Hz, 1H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method A with 2-(3-chloro-2-fluorophenyl)thiazole-4-carboxylic acid and morpholine to give <b>9</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>13</sub>ClFN<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 327.0, found <i>m</i>/<i>z</i> 327.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14 (s, 1H), 7.58–7.47 (m, 1H), 7.24 (m, 2H), 4.08 (br s, 2H), 3.83 (br s, 6H).</div></div><div id="sec3_3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (2-(2,4-Dichlorophenyl)thiazol-4-yl)(morpholino)methanone (<b>10</b>)</h3><div class="NLM_p"><i>Step 1.</i> Lithium hydroxide monohydrate (0.50 g, 12 mmol) was added to a stirring solution of ethyl 2-bromothiazole-4-carboxylate (0.56 g, 2.4 mmol) in tetrahydrofuran (23 mL), water (4.6 mL), and methanol (2.3 mL). After 1.5 h the reaction mixture was diluted with ethyl acetate and acidified to pH 2 with 1.0 N aqueous HCl. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 2-bromothiazole-4-carboxylic acid (0.50 g, 2.4 mmol, 100% yield) as a pale-yellow solid. The product was used without further purification. MS (ESI) <i>m</i>/<i>z</i>, 207.7 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.29 (br s, 1H), 8.45 (s, 1H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of 2-bromothiazole-4-carboxylic acid (330 mg, 1.6 mmol) and morpholine (140 mg, 1.6 mmol) in dichloromethane (6 mL) was added Hunig’s base (0.83 mL, 4.8 mmol) followed by 1-propanephosphonic acid cyclic anhydride (T3P), 50% solution in ethyl acetate (1.5 mL, 2.9 mmol). The resulting solution was stirred under argon at room temperature for 2 h until complete conversion was determined by LCMS analysis. The crude reaction mixture was loaded onto a SiO<sub>2</sub> flash column via a solid cartridge purified on SiO<sub>2</sub> via Isco flash chromatography (0–75% ethyl acetate/hexanes) to afford (2-bromothiazol-4-yl)(morpholino)methanone (380 mg, 1.4 mmol, 87% yield) as an off-white solid. MS (ESI) <i>m</i>/<i>z</i>, 279.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.87 (s, 1H), 3.85 (br s, 2H), 3.67 (br s, 6H).</div><div class="NLM_p last"><i>Step 3.</i> A mixture of (2-bromothiazol-4-yl)(morpholino)methanone (40 mg, 0.14 mmol), (2,4-dichlorophenyl)boronic acid (33 mg, 0.17 mmol), Pd(dppf)Cl<sub>2</sub> (5.9 mg, 7.2 μmol), and K<sub>2</sub>CO<sub>3</sub> (50 mg, 0.36 mmol) in tetrahydrofuran (1.0 mL) and water (1.0 mL) was degassed by bubbling argon through the mixture, and then the reaction vessel was sealed and heated with stirring at 80 °C overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–50% ethyl acetate/hexanes). The product was further purified by preparatory HPLC (Shimadzu VP-ODS 20 mm × 50 mm; 30–100% solvent B in solvent A over 5 min; A = 10:90 methano/ water with 0.1% trifluoroacetic acid, B = 90:10 methanol/water with 0.1% trifluoroacetic acid, 20 mL/min). The product containing fraction was extracted with ethyl acetate, washed with water and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford <b>10</b> (15 mg, 0.04 mmol, 30% yield) as a white solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 343.0, found <i>m</i>/<i>z</i> 343.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13 (s, 1H), 8.11 (s, 1H), 7.55 (d, <i>J</i> = 2.2 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 4.05 (br s, 2H), 3.90–3.71 (m, 6H).</div></div><div id="sec3_3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (2-(2,3-Dimethylphenyl)thiazol-4-yl)(morpholino)methanone (<b>11</b>)</h3><div class="NLM_p last">A mixture of (2-bromothiazol-4-yl)(morpholino)methanone (40 mg, 0.14 mmol), (2,3-dimethylphenyl)boronic acid (26 mg, 0.17 mmol), Pd(dppf)Cl<sub>2</sub> (5.9 mg, 7.2 μmol), and K<sub>2</sub>CO<sub>3</sub> (50 mg, 0.36 mmol) in tetrahydrofuran (1.0 mL) and water (1.0 mL) was degassed by bubbling argon through the mixture, and then the reaction vessel was sealed and heated with stirring at 80 °C overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic was dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–50% ethyl acetate/hexanes) to afford <b>11</b> (31 mg, 0.10 mmol, 70% yield) as a colorless film. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 303.1, found <i>m</i>/<i>z</i> 303.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.07 (s, 1H), 7.42 (d, <i>J</i> = 7.7 Hz, 1H), 7.30–7.26 (m, 1H), 7.22–7.16 (m, 1H), 4.09 (br s, 2H), 3.82 (br s, 4H), 3.74 (br s, 2H), 2.42 (s, 3H), 2.38 (s, 3H).</div></div><div id="sec3_3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Morpholino(2-(pyridin-3-yl)thiazol-4-yl)methanone (<b>12</b>)</h3><div class="NLM_p last">Prepared according to general method A with 2-(pyridin-3-yl)thiazole-4-carboxylic acid and morpholine to give <b>12</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>13</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 276.1, found <i>m</i>/<i>z</i> 276.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.22–9.16 (m, 1H), 8.71 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 8.22 (dt, <i>J</i> = 8.0, 2.0 Hz, 1H), 8.05 (s, 1H), 7.43 (ddd, <i>J</i> = 8.0, 4.8, 0.8 Hz, 1H), 4.08 (br s, 2H), 3.83 (br s, 6H).</div></div><div id="sec3_3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Morpholino(2-(naphthalen-1-yl)thiazol-4-yl)methanone (<b>13</b>)</h3><div class="NLM_p"><i>Step 1.</i> Naphthalene-1-carbothioamide (0.25 g, 1.3 mmol) and 3-bromo-2-oxopropanoic acid (0.22 g, 1.3 mmol) were dissolved in dioxane (6.7 mL). The reaction mixture was then heated with stirring in a sealed vial at 100 °C for 20 h. The solvent was then removed in vacuo, and the residue was triturated with diethyl ether until the washings were clear. The resultant solid was dried in vacuo to give 2-(naphthalen-1-yl)thiazole-4-carboxylic acid (0.25 g, 0.98 mmol, 73% yield) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 256.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.18 (br s, 1H), 8.84 (d, <i>J</i> = 8.3 Hz, 1H), 8.64 (s, 1H), 8.13 (d, <i>J</i> = 8.3 Hz, 1H), 8.06 (d, <i>J</i> = 7.5 Hz, 1H), 7.96 (d, <i>J</i> = 7.0 Hz, 1H), 7.73–7.59 (m, 3H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method A with 2-(naphthalen-1-yl)thiazole-4-carboxylic acid and morpholine to give <b>13</b> as a gum. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 325.1, found <i>m</i>/<i>z</i> 325.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.80–8.73 (m, 1H), 8.13 (s, 1H), 7.99 (d, <i>J</i> = 8.3 Hz, 1H), 7.96–7.91 (m, 1H), 7.85 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.64–7.51 (m, 3H), 4.14 (br s, 2H), 3.91–3.73 (m, 6H).</div></div><div id="sec3_3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (2-(2,3-Dichlorophenyl)-4-methylthiazol-5-yl)(morpholino)methanone (<b>14</b>)</h3><div class="NLM_p"><i>Step 1.</i> A solution of 2,3-dichlorobenzothioamide (0.1 g, 0.48 mmol) and methyl 2-chloro-3-oxobutanoate (0.06 mL, 0.48 mmol) in dioxane (2.4 mL) was heated with stirring at 100 °C in a sealed vial. After 36 h the reaction mixture was cooled to room temperature and the solvent was removed in vacuo giving methyl 2-(2,3-dichlorophenyl)-4-methylthiazole-5-carboxylate (0.14 g, 0.46 mmol, 95% yield) as a yellow solid that was used subsequently without further purification. MS (ESI) <i>m</i>/<i>z</i>: 301.9 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.23 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.59 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.34 (t, <i>J</i> = 8.0 Hz, 1H), 3.93 (s, 3H), 2.82 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (39 mg, 0.93 mmol) was added to a rapidly stirring solution of methyl 2-(2,3-dichlorophenyl)-4-methylthiazole-5-carboxylate (140 mg, 0.46 mmol) in tetrahydrofuran (4.4 mL), water (0.89 mL) and methanol (0.44 mL). After stirring at room temperature for 2 h, the reaction mixture was diluted with ethyl acetate and water and then acidified to ∼pH 1 with 1 N aqueous HCl. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed in vacuo to give 2-(2,3-dichlorophenyl)-4-methylthiazole-5-carboxylic acid (13 mg, 0.46 mmol, 99% yield) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 288.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.52 (br s, 1H), 8.20 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.84 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.54 (t, <i>J</i> = 7.9 Hz, 1H), 2.71 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 2-(2,3-dichlorophenyl)-4-methylthiazole-5-carboxylic acid (26 mg, 0.09 mmol) and morpholine (8.6 μL, 0.10 mmol) to give <b>14</b> (27 mg, 0.07 mmol, 81% yield) as a white solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 357.0, found <i>m</i>/<i>z</i> 357.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.14 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.57 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.38–7.29 (m, 1H), 3.85–3.56 (m, 8H), 2.54 (s, 3H).</div></div><div id="sec3_3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (2-(2,3-Dichlorophenyl)thiazol-5-yl)(morpholino)methanone (<b>15</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a rapidly stirring solution of ethyl 2-(2,3-dichlorophenyl)thiazole-5-carboxylate (48 mg, 0.16 mmol) in tetrahydrofuran (2 mL) methanol (1 mL) and water (1 mL) was added lithium hydroxide monohydrate (5.7 mg, 0.24 mmol). The reaction mixture was stirred at room temperature until complete conversion was determined by LCMS analysis. The reaction mixture was then diluted with ethyl acetate and washed successively with 0.1 M HCl, water, brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo to afford 2-(2,3-dichlorophenyl)thiazole-5-carboxylic acid (41 mg, 0.15 mmol, 94% yield) as an off-white solid. The product was used without further purification. MS (ESI) <i>m</i>/<i>z</i>, 276.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method A with 2-(2,3-dichlorophenyl)thiazole-5-carboxylic acid (41 mg, 0.15 mmol) and morpholine (13 mg, 0.15 mmol) to afford <b>15</b> (36 mg, 0.10 mmol, 69% yield) as an off-white solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 343.0, found <i>m</i>/<i>z</i> 343.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.16 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 8.07 (s, 1H), 7.59 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 3.84–3.74 (m, 8H).</div></div><div id="sec3_3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (2-(2,3-Dichlorophenyl)-5-methylthiazol-4-yl)(morpholino)methanone (<b>16</b>)</h3><div class="NLM_p"><i>Step 1.</i> 2,3-Dichlorobenzothioamide (0.1 g, 0.48 mmol) was added to a solution of methyl 3-bromo-2-oxobutanoate (0.10 g, 0.53 mmol) in ethanol (1.0 mL). The reaction vessel was sealed and heated with stirring at 80 °C for 18 h. The excess solvent was removed in vacuo and the residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–40% ethyl acetate/hex, Isco 24 g column) to give a mixture of methyl 2-(2,3-dichlorophenyl)-5-methylthiazole-4-carboxylate and ethyl 2-(2,3-dichlorophenyl)-5-methylthiazole-4-carboxylate. The mixture was carried on to the next step.</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (16 mg, 0.39 mmol) was added to a rapidly stirring solution of the mixture from step 1 (120 mg, 0.39 mmol) in tetrahydrofuran (3.8 mL), water (0.87 mL), and methanol (0.38 mL). After stirring at room temperature for 12 h, the solvent was removed in vacuo and the solid was dried in vacuo to give 2-(2,3-dichlorophenyl)-5-methylthiazole-4-carboxylic acid, lithium salt (120 mg, 0.40 mmol, 100% yield) as a white solid. The product was used in the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.05 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.69 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.51–7.41 (m, 1H), 2.74 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 2-(2,3-dichlorophenyl)-5-methylthiazole-4-carboxylic acid, lithium salt (20 mg, 0.07 mmol) and morpholine (7.0 μL, 0.08 mmol) to give <b>16</b> (20 mg, 0.06 mmol, 81% yield) as a white solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>15</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 357.0, found <i>m</i>/<i>z</i> 357.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.00 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.55 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.31 (t, <i>J</i> = 7.9 Hz, 1H), 3.83 (br s, 4H), 3.75–3.68 (m, 4H), 2.68 (s, 3H).</div></div><div id="sec3_3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (4-(2,3-Dichlorophenyl)thiazol-2-yl)(morpholino)methanone (<b>17</b>)</h3><div class="NLM_p"><i>Step 1.</i> Lithium hydroxide monohydrate (9.0 μL, 0.33 mmol) was added to a rapidly stirring solution of ethyl 4-(2,3-dichlorophenyl)thiazole-2-carboxylate (82 mg, 0.27 mmol) in tetrahydrofuran (2.6 mL), water (0.5 mL), and methanol (0.3 mL). After stirring at room temperature for 2 h the reaction mixture was diluted with ethyl acetate and water and then acidified to pH 1 with 1 N aqueous HCl. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed in vacuo to give 4-(2,3-dichlorophenyl)thiazole-2-carboxylic acid (75 mg, 0.27 mmol, 100% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.42 (s, 1H), 7.75 (ddd, <i>J</i> = 13.4, 8.0, 1.5 Hz, 2H), 7.49 (t, <i>J</i> = 7.9 Hz, 1H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method A with 4-(2,3-dichlorophenyl)thiazole-2-carboxylic acid (20 mg, 0.07 mmol) and morpholine (6.7 mg, 0.08 mmol) to give <b>17</b> (22 mg, 0.06 mmol, 89% yield) as a gum. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>14</sub>H<sub>13</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 343.0, found <i>m</i>/<i>z</i> 343.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (s, 1H), 7.66 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.52 (dd, <i>J</i> = 8.0, 1.8 Hz, 1H), 7.30 (t, <i>J</i> = 7.9 Hz, 1H), 4.57–4.49 (m, <i>J</i> = 3.8 Hz, 2H), 3.89–3.76 (m, 6H).</div></div><div id="sec3_3_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-((4-Methyl-2-(1-naphthyl)-1,3-thiazol-5-yl)carbonyl)morpholine (<b>18</b>)</h3><div class="NLM_p"><i>Step 1.</i> Ethyl 2-chloro-3-oxobutanoate (2.7 mL, 19 mmol) was added to a solution of naphthalene-1-carbothioamide (3.5 g, 19 mmol) in ethanol (19 mL). The reaction vessel was sealed and heated with stirring at 80 °C for 19 h and then cooled to room temperature. The excess solvent was removed in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–20% ethyl acetate/hex, Isco 120 g column) to give ethyl 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylate (4.6 g, 15 mmol, 82% yield) as a waxy white solid. MS (ESI) <i>m</i>/<i>z</i>, 298.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, <i>J</i> = 8.53 Hz, 1H), 7.98 (d, <i>J</i> = 8.28 Hz, 1H), 7.89–7.95 (m, 1H), 7.85 (dd, <i>J</i> = 1.13, 7.15 Hz, 1H), 7.49–7.66 (m, 3H), 4.40 (q, <i>J</i> = 7.19 Hz, 2H), 2.89 (s, 3H), 1.42 (t, <i>J</i> = 7.15 Hz, 3H).</div><div class="NLM_p">Lithium hydroxide monohydrate (1.3 g, 31 mmol) was added to a rapidly stirring suspension of ethyl 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylate (4.6 g, 15 mmol) in tetrahydrofuran (120 mL), water (24 mL), and methanol (12 mL). The reaction mixture was stirred at room temperature for 14 h and was then diluted with ethyl acetate and acidified to pH 3 with 10% aqueous citric acid. The organic phase was washed with brine, and the combined aqueous layers were further extracted with ethyl acetate (2 × 100 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The product was used in subsequent steps without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.43 (br s, 1H), 8.81 (d, <i>J</i> = 8.28 Hz, 1H), 8.14 (d, <i>J</i> = 8.28 Hz, 1H), 8.02–8.08 (m, 1H), 7.96 (dd, <i>J</i> = 1.25, 7.28 Hz, 1H), 7.58–7.73 (m, 3H), 2.78 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and morpholine to give <b>18</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 339.1, found <i>m</i>/<i>z</i> 339.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.76 (dd, J = 8.4, 0.9 Hz, 1H), 7.97 (d, J = 8.3 Hz, 1H), 7.95–7.89 (m, 1H), 7.81 (dd, J = 7.3, 1.3 Hz, 1H), 7.66–7.49 (m, 3H), 3.83–3.69 (m, 8H), 2.62 (s, 3H).</div></div><div id="sec3_3_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Morpholino(4-(naphthalen-1-yl)thiazol-2-yl)methanone (<b>19</b>)</h3><div class="NLM_p"><i>Step 1.</i> Bromine (0.07 mL, 1.3 mmol) was added to a solution of 1-(naphthalen-1-yl)ethanone (0.22 g, 1.3 mmol) in acetic acid (6.6 mL). The reaction mixture was stirred at room temperature for 24 h and was then concentrated in vacuo. The residue was loaded directly onto an Isco SiO<sub>2</sub> cartridge for purification via Isco flash chromatography (0–20% ethyl acetate/hexanes, 15 min linear gradient, Isco 24 g column). The desired fractions were combined and concentrated to give 2-bromo-1-(naphthalen-1-yl)ethanone (0.29 g, 1.2 mmol, 88% yield) as a colorless oil.</div><div class="NLM_p"><i>Step 2.</i> Ethyl 2-amino-2-thioxoacetate (0.19 g, 1.4 mmol) was added to a solution of 2-bromo-1-(naphthalen-1-yl)ethanone (0.29 g, 1.2 mmol) in ethanol (5.8 mL). The reaction mixture was heated with stirring at 80 °C in a sealed vial for 16 h, and then the solvent was removed in vacuo. The residue was then loaded directly onto an Isco SiO<sub>2</sub> cartridge for purification via Isco flash chromatography (0–20% ethyl acetate/hexanes, 15 min linear gradient, Isco 4 g column). The desired fractions were combined and concentrated to give ethyl 4-(naphthalen-1-yl)thiazole-2-carboxylate (0.26 g, 0.94 mmol, 80% yield) as a waxy white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.19–8.12 (m, 1H), 7.95–7.89 (m, 2H), 7.74 (s, 1H), 7.71 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 7.57–7.49 (m, 3H), 4.54 (q, <i>J</i> = 7.0 Hz, 2H), 1.48 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p"><i>Step 3.</i> Lithium hydroxide monohydrate (0.20 g, 4.7 mmol) was added to a rapidly stirring solution of ethyl 4-(naphthalen-1-yl)thiazole-2-carboxylate (0.26 g, 0.94 mmol) in tetrahydrofuran (9.0 mL), water (1.8 mL), and methanol (0. Nine mL). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with ethyl acetate and water and then acidified to pH 1 with 1.0 N aqueous HCl. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed in vacuo to give a brown oil. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–40% ethyl acetate/hexanes, Isco 40 g column) to give only the decarboxylated product 4-(naphthalen-1-yl)thiazole after concentration. There were additional fractions that contained the correct product by LCMS, but they also gave the decarboxylated product upon concentration. Because of this decomposition pathway, crude Isco fractions of 4-(naphthalen-1-yl)thiazole-2-carboxylic acid in ethyl acetate/hexanes were taken as a solution into the next step, and thus no further characterization was possible.</div><div class="NLM_p last"><i>Step 4.</i> Triethylamine (33 μL, 0.24 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P) (120 μL, 0.20 mmol) were added to the Isco fractions from step 3 containing 4-(naphthalen-1-yl)thiazole-2-carboxylic acid and morpholine (8.2 μL, 0.09 mmol) in dichloromethane (1.1 mL). The reaction mixture was stirred at room temperature for 3 h and was then loaded directly onto a SiO<sub>2</sub> cartridge for purification via Isco flash chromatography (0–100% ethyl acetate/hexanes, 15 min linear gradient, Isco 4 g column). The product was further purified by preparative HPLC (Sunfire 5 μm C18 30 mm × 100 mm column, 15 min gradient from 10% to 100% B in A, A = 10:90 methanol/water with 0.1% trifluoroacetic acid, B = 90:10 methanol/water with 0.1% trifluoroacetic acid). The desired fraction was concentrated to give <b>19</b> (15 mg, 0.04 mmol, 56% yield) as a sticky solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 325.1, found <i>m</i>/<i>z</i> 325.2; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.21–8.15 (m, 1H), 7.97–7.91 (m, 2H), 7.71–7.65 (m, 2H), 7.59–7.48 (m, 3H), 4.58 (br s, 2H), 3.86 (d, <i>J</i> = 6.3 Hz, 4H), 3.76 (br s, 2H).</div></div><div id="sec3_3_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Morpholino(2-(naphthalen-1-yl)thiazol-5-yl)methanone (<b>20</b>)</h3><div class="NLM_p"><i>Step 1.</i> A solution of naphthalene-1-carbothioamide (0.1 g, 0.53 mmol) and ethyl 2-chloro-3-oxopropanoate (1.8 mL, 0.53 mmol) in dioxane (2.7 mL) was heated with stirring at 100 °C in a sealed vial. After 36 h the reaction mixture was cooled to room temperature and the solvent was removed in vacuo. Ethyl 2-(naphthalen-1-yl)thiazole-5-carboxylate (0.15 g, 0.53 mmol, 99% yield) was obtained as a yellow solid and was used without purification.</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (0.12 g, 2.8 mmol) was added to a stirring solution of ethyl 2-(naphthalen-1-yl)thiazole-5-carboxylate (0.15 g, 0.53 mmol) in tetrahydrofuran (5.4 mL), water (1.1 mL), and methanol (0.54 mL). After stirring at room temperature for 3 h the reaction mixture was diluted with ethyl acetate and water and acidified to pH 1 with 1 N aqueous HCl. The organic layer was washed with brine and the combined aqueous layers were further extracted with ethyl acetate. The organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed in vacuo to give a red solid that was carried directly to the next step.</div><div class="NLM_p last"><i>Step 3.</i> Triethylamine (33 μL, 0.24 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (T3P) (120 μL, 0.20 mmol) were added to a solution of the solid from step 2 containing 2-(naphthalen-1-yl)thiazole-5-carboxylic acid (20 mg, 0.08 mmol) and morpholine (8.5 mg, 0.10 mmol) in dichloromethane (1.1 mL) at room temperature. The reaction mixture was stirred for 4 h and was then loaded directly onto an Isco SiO<sub>2</sub> cartridge for purification via Isco flash chromatography (0–100% ethyl acetate/hexanes, 15 min linear gradient, Isco 4 g column). The residue required further purification by preparatory HPLC (Sunfire 5 μm C18 30 mm × 100 mm column, 15 min gradient from 10% to 100% B in A, A = 10:90 methanol/water with 0.1% trifluoroacetic acid, B = 90:10 methanol/water with 0.1% trifluoroacetic acid). The product containing fractions were combined and concentrated to give <b>20</b> (12 mg, 0.04 mmol, 46% yield) as a gum. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 325.1, found <i>m</i>/<i>z</i> 325.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.73 (dd, <i>J</i> = 8.3, 1.0 Hz, 1H), 8.17 (s, 1H), 8.01 (d, <i>J</i> = 8.3 Hz, 1H), 7.96–7.92 (m, 1H), 7.85 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 7.66–7.51 (m, 3H), 3.90–3.78 (m, 8H).</div></div><div id="sec3_3_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (5-Methyl-2-(naphthalen-1-yl)thiazol-4-yl)(morpholino)methanone (<b>21</b>)</h3><div class="NLM_p"><i>Step 1.</i> Naphthalene-1-carbothioamide (0.1 g, 0.53 mmol) was added to a solution of methyl 3-bromo-2-oxobutanoate (0.12 g, 0.59 mmol) in ethanol (1.1 mL). The reaction vessel was sealed and heated with stirring at 80 °C for 18 h. The solvents were removed in vacuo and the residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–40% ethyl acetate/hexanes, Isco 24 g column) to give a mixture of methyl 5-methyl-2-(naphthalen-1-yl)thiazole-4-carboxylate and ethyl 5-methyl-2-(naphthalen-1-yl)thiazole-4-carboxylate as a yellow oil.</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (17 mg, 0.41 mmol) was added to a rapidly stirring solution of the mixture from step 1 (120 mg, 0.41 mmol) in tetrahydrofuran (4.0 mL), water (0.8 mL), and methanol (0.4 mL). After stirring at room temperature for 12 h the solvent was removed in vacuo and the solid was dried to give 5-methyl-2-(naphthalen-1-yl)thiazole-4-carboxylic acid, lithium salt (114 mg, 0.41 mmol, 100% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.76–8.67 (m, 1H), 8.07–7.99 (m, 2H), 7.81 (dd, <i>J</i> = 7.3, 1.0 Hz, 1H), 7.65–7.56 (m, 3H), 2.75 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 5-methyl-2-(naphthalen-1-yl)thiazole-4-carboxylic acid, lithium salt and morpholine to give <b>21</b> as a white solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 339.1, found <i>m</i>/<i>z</i> 339.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.84–8.76 (m, 1H), 7.99–7.88 (m, 2H), 7.79 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.63–7.48 (m, 3H), 3.94–3.67 (m, 8H), 2.71 (s, 3H).</div></div><div id="sec3_3_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 4-Methyl-2-(naphthalen-1-yl)thiazole-5-carboxamide (<b>22</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and ammonium chloride to give <b>22</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>15</sub>H<sub>13</sub>N<sub>2</sub>OS) requires <i>m</i>/<i>z</i> 269.1, found <i>m</i>/<i>z</i> 269.0; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.76 (d, <i>J</i> = 8.53 Hz, 1H), 7.99 (d, <i>J</i> = 8.28 Hz, 1H), 7.93 (d, <i>J</i> = 7.28 Hz, 1H), 7.84 (dd, <i>J</i> = 1.13, 7.15 Hz, 1H), 7.48–7.67 (m, 3H), 5.69 (br s, 2H), 2.88 (s, 3H).</div></div><div id="sec3_3_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>,<i>N</i>,4-Trimethyl-2-(naphthalen-1-yl)thiazole-5-carboxamide (<b>23</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and dimethylamine to give <b>23</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>17</sub>N<sub>2</sub>OS) requires <i>m</i>/<i>z</i> 297.1, found <i>m</i>/<i>z</i> 297.0; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.20 (d, <i>J</i> = 7.9 Hz, 1H), 6.63 (d, <i>J</i> = 7.9 Hz, 1H), 6.59–6.54 (m, 1H), 6.42 (d, <i>J</i> = 6.4 Hz, 1H), 6.22 (s, 2H), 6.24–6.15 (m, 2H), 1.81 (s, 6H), 1.19 (s, 3H).</div></div><div id="sec3_3_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 1-((4-Methyl-2-(1-naphthyl)-1,3-thiazol-5-yl)carbonyl)piperidine (<b>24</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and piperidine to give <b>24</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>21</sub>N<sub>2</sub>OS) requires <i>m</i>/<i>z</i> 337.1, found 337.0; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.57 (d, <i>J</i> = 7.93 Hz, 1H), 7.99 (d, <i>J</i> = 8.42 Hz, 1H), 7.89–7.94 (m, 1H), 7.75–7.80 (m, 1H), 7.50–7.58 (m, 3H), 3.51–3.81 (m, 4H), 2.54 (s, 3H), 1.74 (d, <i>J</i> = 4.46 Hz, 2H), 1.67 (br s, 4H).</div></div><div id="sec3_3_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-(2-Methoxyethyl)-<i>N</i>,4-dimethyl-2-(naphthalen-1-yl)thiazole-5-carboxamide (<b>25</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and 2-methoxy-<i>N</i>-methylethanamine to give <b>25</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 341.1, found 341.0; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (d, <i>J</i> = 8.4 Hz, 1H), 8.11 (d, <i>J</i> = 8.4 Hz, 1H), 8.05 (d, <i>J</i> = 7.4 Hz, 1H), 7.91 (d, <i>J</i> = 7.4 Hz, 1H), 7.71–7.59 (m, 3H), 3.73–3.46 (m, 4H), 3.05 (br s, 3H), 2.47 (s, 4H) additional peaks lost under H<sub>2</sub>O peak.</div></div><div id="sec3_3_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(2-Methoxyethyl)-4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxamide (<b>26</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and 2-methoxyethanamine to give <b>26</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 327.1, found 327.0; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.16 (d, <i>J</i> = 7.4 Hz, 1H), 6.61 (d, <i>J</i> = 7.9 Hz, 1H), 6.57–6.52 (m, 1H), 6.40 (d, <i>J</i> = 6.4 Hz, 1H), 6.20–6.13 (m, 1H), 2.94 (s, 2H), 2.20 (s, 4H), 2.02 (s, 3H), 1.38 (s, 3H).</div></div><div id="sec3_3_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-(2-Hydroxyethyl)-<i>N</i>,4-dimethyl-2-(naphthalen-1-yl)thiazole-5-carboxamide (<b>27</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and 2-(methylamino)ethanol to give <b>27</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 327.1, found 327.0; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.85 (d, <i>J</i> = 7.9 Hz, 1H), 8.11 (d, <i>J</i> = 7.9 Hz, 1H), 8.07–8.01 (m, 1H), 7.91 (d, <i>J</i> = 6.9 Hz, 1H), 7.74–7.54 (m, 3H), 4.86 (t, <i>J</i> = 5.2 Hz, 1H), 3.70–3.50 (m, 3H), 3.05 (br s, 3H), 2.47 (s, 3H).</div></div><div id="sec3_3_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(2-Hydroxyethyl)-<i>N</i>-isopropyl-4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxamide (<b>28</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and 2-(isopropylamino)ethanol to give <b>28</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 355.1, found 355.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.66 (br s, 1H), 8.73 (d, <i>J</i> = 8.53 Hz, 1H), 7.88–8.06 (m, 2H), 7.79–7.87 (m, 1H), 7.44–7.68 (m, 3H), 4.93 (t, <i>J</i> = 5.40 Hz, 1H), 4.75 (t, <i>J</i> = 5.40 Hz, 1H), 4.07 (br s, 1H), 3.41 (br s, 2H), 2.90 (s, 1H), 2.87 (s, 2H), 1.47 (d, <i>J</i> = 6.53 Hz, 6H).</div></div><div id="sec3_3_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (4-Hydroxypiperidin-1-yl)(4-methyl-2-(naphthalen-1-yl)thiazol-5-yl)methanone (<b>29</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and piperidin-4-ol to give <b>29</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>21</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 353.1, found 353.2; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.94–7.88 (m, 1H), 7.82 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.65–7.49 (m, 3H), 4.06 (tt, <i>J</i> = 7.8, 3.7 Hz, 2H), 3.46 (t, <i>J</i> = 9.3 Hz, 2H), 2.61 (s, 3H), 2.04–1.93 (m, 2H), 1.72–1.59 (m, 4H).</div></div><div id="sec3_3_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (4-Hydroxyazepan-1-yl)(4-methyl-2-(naphthalen-1-yl)thiazol-5-yl)methanone (<b>30</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and azepan-4-ol to give <b>30</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 367.1, found 367.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, <i>J</i> = 8.53 Hz, 1H), 7.96 (d, <i>J</i> = 8.28 Hz, 1H), 7.92 (dd, <i>J</i> = 1.00, 8.28 Hz, 1H), 7.81 (dd, <i>J</i> = 1.13, 7.15 Hz, 1H), 7.50–7.64 (m, 3H), 4.03 (br s, 1H), 3.52–3.87 (m, 4H), 2.60 (s, 3H), 1.96–2.21 (m, 2H), 1.72–1.99 (m, 4H), 1.45 (br s, 1H).</div></div><div id="sec3_3_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (4-(Hydroxymethyl)piperidin-1-yl)(4-methyl-2-(naphthalen-1-yl)thiazol-5-yl)methanone (<b>31</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and piperidin-4-ylmethanol to give <b>31</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S) requires <i>m</i>/<i>z</i> 367.1, found 367.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.96 (d, <i>J</i> = 8.3 Hz, 1H), 7.94–7.87 (m, 1H), 7.81 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 7.65–7.48 (m, 4H), 3.58 (t, <i>J</i> = 5.6 Hz, 2H), 3.02 (br s, 2H), 2.59 (s, 3H), 1.95–1.75 (m, 4H), 1.38–1.22 (m, 3H).</div></div><div id="sec3_3_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (4-Methyl-2-(naphthalen-1-yl)thiazol-5-yl)(piperazin-1-yl)methanone, HCl (<b>32</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and <i>tert</i>-butyl piperazine-1-carboxylate to give <b>32</b> after HCl mediated deprotection. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>20</sub>N<sub>3</sub>OS) requires <i>m</i>/<i>z</i> 338.1, found 338.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.11 (br s, 1H), 8.48 (d, <i>J</i> = 8.5 Hz, 1H), 8.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.99–7.92 (m, 1H), 7.80 (d, <i>J</i> = 7.0 Hz, 1H), 7.69–7.50 (m, 3H), 4.09 (br s, 4H), 3.42 (br s, 4H), 2.66 (s, 3H).</div></div><div id="sec3_3_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>,4-Dimethyl-<i>N</i>-((1-methyl-1<i>H</i>-pyrazol-4-yl)methyl)-2-(1-naphthyl)-1,3-thiazole-5-carboxamide (<b>33</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and <i>N</i>-methyl-1-(1-methyl-1<i>H</i>-pyrazol-3-yl)methanamine to give<b>33</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>OS) requires <i>m</i>/<i>z</i> 377.1, found 377.1; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.84 (d, <i>J</i> = 8.42 Hz, 1H), 8.11 (d, <i>J</i> = 8.42 Hz, 1H), 8.05 (d, <i>J</i> = 7.43 Hz, 1H), 7.92 (d, <i>J</i> = 6.94 Hz, 1H), 7.70 (br s, 1H), 7.59–7.68 (m, 3H), 7.40 (br s, 1H), 4.48 (s, 2H), 3.82 (s, 3H), 2.97 (s, 3H), 2.46 (s, 3H).</div></div><div id="sec3_3_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (6,7-Dihydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-5(4<i>H</i>)-yl)(4-methyl-2-(naphthalen-1-yl)thiazol-5-yl)methanone (<b>34</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and 4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridine to give <b>34</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>OS) requires <i>m</i>/<i>z</i> 375.1, found 375.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.72 (d, <i>J</i> = 8.3 Hz, 1H), 8.51 (s, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.93–7.87 (m, 1H), 7.80 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 7.66–7.47 (m, 3H), 4.83 (br s, 2H), 3.96 (t, <i>J</i> = 4.6 Hz, 2H), 2.90 (br s, 2H), 2.60 (s, 3H).</div></div><div id="sec3_3_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>,4-Dimethyl-2-(1-naphthyl)-<i>N</i>-(2-(3-pyridinyl)ethyl)-1,3-thiazole-5-carboxamide (<b>35</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and <i>N</i>-methyl-2-(pyridin-3-yl)ethan-1-amine to give <b>35</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>23</sub>H<sub>22</sub>N<sub>3</sub>OS) requires <i>m</i>/<i>z</i> 388.1, found 388.1; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.53 (d, <i>J</i> = 8.42 Hz, 1H), 8.41 (d, <i>J</i> = 3.47 Hz, 1H), 7.98 (d, <i>J</i> = 8.42 Hz, 1H), 7.90–7.94 (m, 1H), 7.74 (d, <i>J</i> = 6.44 Hz, 1H), 7.51–7.57 (m, 3H), 7.36 (br s, 1H), 4.28 (s, 1H), 3.83 (br s, 2H), 3.14 (br s, 3H), 3.04 (br s, 2H), 2.43 (s, 3H).</div></div><div id="sec3_3_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>,4-Dimethyl-2-(1-naphthyl)-<i>N</i>-(3-pyridinylmethyl)-1,3-thiazole-5-carboxamide (<b>36</b>)</h3><div class="NLM_p last">Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)thiazole-5-carboxylic acid and <i>N</i>-methyl-1-(pyridin-3-yl)methanamine to give <b>36</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>OS) requires <i>m</i>/<i>z</i> 374.1, found 374.1; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.57 (d, <i>J</i> = 8.42 Hz, 2H), 8.51 (dd, <i>J</i> = 1.49, 4.95 Hz, 1H), 7.99 (d, <i>J</i> = 8.42 Hz, 1H), 7.90–7.94 (m, 1H), 7.82 (br s, 1H), 7.77 (d, <i>J</i> = 6.94 Hz, 1H), 7.50–7.57 (m, 3H), 7.44 (dd, <i>J</i> = 4.95, 7.43 Hz, 1H), 4.80 (s, 2H), 3.12 (s, 3H), 2.56 (s, 3H).</div></div><div id="sec3_3_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (4-(Hydroxymethyl)piperidin-1-yl)(3-methyl-5-(naphthalen-1-yl)thiophen-2-yl)methanone (<b>37</b>)</h3><div class="NLM_p"><i>Step 1.</i> A mixture of 1-bromonaphthalene (180 mg, 0.86 mmol), (5-formyl-4-methylthiophen-2-yl)boronic acid (140 mg, 0.82 mmol), PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (20 mg, 0.02 mmol), and K<sub>2</sub>CO<sub>3</sub> (280 mg, 2.06 mmol) in tetrahydrofuran (3 mL) and water (1.5 mL) was degassed by bubbling argon through the mixture. The reaction flask was sealed and then heated with stirring at 75 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–10% ethyl acetate/hexanes) to afford 3-methyl-5-(naphthalen-1-yl)thiophene-2-carbaldehyde (40 mg, 0.16 mmol, 19% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 10.11 (s, 1H), 8.23–8.16 (m, 1H), 7.96–7.89 (m, 2H), 7.61–7.48 (m, 4H), 7.14 (s, 1H), 2.67 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> A solution of sodium chlorite (32 mg, 0.28 mmol) in water (0.3 mL) was added dropwise to a solution of 3-methyl-5-(naphthalen-1-yl)thiophene-2-carbaldehyde (40 mg, 0.16 mmol) and sodium dihydrogen phosphate (28 mg, 0.24 mmol) in DMSO (1 mL). The resulting suspension was allowed to stir under argon at room temperature overnight. The reaction mixture was diluted with water, acidified to pH 3 with 1 N aqueous HCl, extracted twice with ethyl acetate, and concentrated to an oil which became a light yellow solid upon standing. The solid was then triturated with hexane to afford 3-methyl-5-(naphthalen-1-yl)thiophene-2-carboxylic acid (46 mg, 0.15 mmol, 94% yield) after drying in vacou. The product was used in subsequent steps without further purification.</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 3-methyl-5-(naphthalen-1-yl)thiophene-2-carboxylic acid and piperidin-4-ylmethanol to give <b>37</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>24</sub>NO<sub>2</sub>S) requires <i>m</i>/<i>z</i> 366.1, found 366.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.29–8.23 (m, 1H), 7.93–7.85 (m, 2H), 7.59–7.46 (m, 4H), 7.00 (s, 1H), 4.42 (br s, 2H), 3.57 (d, <i>J</i> = 5.8 Hz, 2H), 3.06–2.94 (m, 2H), 2.35 (s, 3H), 1.90–1.83 (m, 2H), 1.43 (dt, <i>J</i> = 14.2, 7.2 Hz, 1H), 1.36–1.29 (m, 2H).</div></div><div id="sec3_3_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (4-(Hydroxymethyl)piperidin-1-yl)(2-methyl-5-(naphthalen-1-yl)thiophen-3-yl)methanone (<b>38</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a solution of 5-bromo-2-methylthiophene-3-carboxylic acid (100 mg, 0.45 mmol) and piperidin-4-ylmethanol (55 mg, 0.48 mmol) in dichloromethane (2.0 mL) was added Hunig’s base (0.24 mL, 1.4 mmol) followed by 1-propanephosphonic acid cyclic anhydride (T3P), 50% solution in ethyl acetate (0.42 mL, 0.81 mmol). The resulting solution was stirred under argon at room temperature for 30 min. The reaction mixture was loaded onto an Isco SiO<sub>2</sub> column for purification via Isco flash chromatography (0–40% ethyl acetate/hexanes) to afford (5-bromo-2-methylthiophen-3-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone (110 mg, 0.35 mmol, 76% yield). MS (ESI) <i>m</i>/<i>z</i>, 320.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.80 (s, 1H), 4.64 (d, <i>J</i> = 11.3 Hz, 1H), 3.68 (d, <i>J</i> = 6.6 Hz, 1H), 3.48–3.37 (m, 2H), 2.98 (d, <i>J</i> = 11.3 Hz, 1H), 2.77–2.60 (m, 2H), 2.35 (s, 3H), 1.80 (d, <i>J</i> = 10.7 Hz, 1H), 1.39–1.30 (m, 1H), 1.25–1.13 (m, 1H), 1.07 (d, <i>J</i> = 9.4 Hz, 1H).</div><div class="NLM_p last"><i>Step 2.</i> A mixture of naphthalen-1-ylboronic acid (25.0 mg, 0.14 mmol), (5-bromo-2-methylthiophen-3-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone (44 mg, 0.14 mmol), PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (3.4 mg, 4.2 μmol), and K<sub>2</sub>CO<sub>3</sub> (49 mg, 0.35 mmol) in tetrahydrofuran (1 mL) and water (0.5 mL) was degassed by bubbling argon through the mixture for several minutes. The reaction flask was sealed and then heated with stirring at 80 °C for 2 h until LCMS analysis indicated complete conversion. The reaction mixture was diluted with 0.1 M aqueous HCl and extracted twice with ethyl acetate. The organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated to dryness in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes) to afford <b>38</b> (35 mg, 0.09 mmol, 66% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>24</sub>NO<sub>2</sub>S) requires <i>m</i>/<i>z</i> 366.1, found 366.2; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.28–8.22 (m, 1H), 7.92–7.87 (m, 1H), 7.85 (d, <i>J</i> = 8.3 Hz, 1H), 7.56–7.43 (m, 4H), 7.02 (s, 1H), 4.77 (br s, 1H), 3.92 (br s, 1H), 3.52 (br s, 2H), 3.07 (br s, 1H), 2.78 (br s, 1H), 2.54 (s, 3H), 1.93–1.72 (m, 4H), 1.34–1.30 (m, 1H).</div></div><div id="sec3_3_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> (4-(Hydroxymethyl)piperidin-1-yl)(3-methyl-5-(naphthalen-1-yl)furan-2-yl)methanone (<b>39</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a degassed solution of methyl 5-bromo-3-methylfuran-2-carboxylate (230 mg, 1.0 mmol), naphthalen-1-ylboronic acid (270 mg, 1.6 mmol), and K<sub>2</sub>CO<sub>3</sub> (440 mg, 3.2 mmol) in dioxane (9 mL) and water (3 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (73 mg, 0.06 mmol). The reaction mixture was stirred at 100 °C overnight. The reaction mixture was then cooled to room temperature, diluted with water, and extracted 3 times with dichloromethane. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified on SiO<sub>2</sub> via Isco flash chromatography (0–35% ethyl acetate/hexanes) to give methyl 3-methyl-5-(naphthalen-1-yl)furan-2-carboxylate (190 mg, 0.72 mmol, 69% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.44–8.38 (m, 1H), 7.94–7.87 (m, 2H), 7.82 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 7.61–7.50 (m, 3H), 6.71 (s, 1H), 3.95 (s, 3H), 2.49 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of methyl 3-methyl-5-(naphthalen-1-yl)furan-2-carboxylate (190 mg, 0.71 mmol) in tetrahydrofuran (5 mL) was added a 1 M aqueous solution of lithium hydroxide (2.1 mL, 2.1 mmol). The reaction mixture was stirred at room temperature until LCMS analysis indicated complete conversion. The reaction mixture was then washed with 1 N aqueous HCl and extracted with ethyl acetate. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to obtain 3-methyl-5-(naphthalen-1-yl)furan-2-carboxylic acid (170 mg, 0.67 mmol, 94% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.47–8.41 (m, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.85 (dd, <i>J</i> = 7.2, 1.1 Hz, 1H), 7.63–7.58 (m, 1H), 7.57–7.52 (m, 2H), 6.76 (s, 1H), 2.53 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 3-methyl-5-(naphthalen-1-yl)furan-2-carboxylic acid and piperidin-4-ylmethanol to give <b>39</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>24</sub>NO<sub>3</sub>) requires <i>m</i>/<i>z</i> 350.2, found 350.0; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.43–8.36 (m, 1H), 7.94–7.85 (m, 2H), 7.73 (dd, <i>J</i> = 7.3, 1.2 Hz, 1H), 7.60–7.49 (m, 3H), 6.68 (s, 1H), 4.58 (br s, 2H), 3.55 (d, <i>J</i> = 5.8 Hz, 2H), 2.39 (s, 3H), 1.91–1.78 (m, 3H), 1.52 (br s, 3H), 1.42–1.28 (m, 2H).</div></div><div id="sec3_3_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> (4-(Hydroxymethyl)piperidin-1-yl)(1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-pyrrol-2-yl)methanone (<b>40</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a degassed solution of methyl 4-bromo-1-methyl-1<i>H</i>-pyrrole-2-carboxylate (0.62 g, 2.8 mmol), naphthalen-1-ylboronic acid (0.61 g, 3.5 mmol), and K<sub>2</sub>CO<sub>3</sub> (0.98 g, 7.1 mmol) in dioxane (11 mL) and water (3.5 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (0.16 g, 0.14 mmol). The reaction mixture was heated with stirring at 100 °C. After 18 h, LCMS analysis indicated complete conversion and the reaction mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes) to give methyl 1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-pyrrole-2-carboxylate. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.33–8.20 (m, 1H), 7.96–7.87 (m, 1H), 7.85–7.77 (dt, <i>J</i> = 8.0, 1.1 Hz, 1H), 7.57–7.41 (m, 4H), 7.26–7.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.10–7.01 (d, <i>J</i> = 2.2 Hz, 1H), 4.13–4.03 (s, 3H), 3.99–3.83 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a suspension of methyl 1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-pyrrole-2-carboxylate (0.62 g, 2.3 mmol) in methanol (23 mL) was added 1 N aqueous lithium hydroxide (7.7 mL, 7.7 mmol). The mixture was heated with stirring at 50 °C while the reaction progress was monitored periodically by LCMS. Once complete, the reaction mixture was cooled to room temperature, diluted with water (20 mL), and acidified with 1 N aqueous HCl giving a white precipitate. The solid was collected via suction filtration and dried to afford 1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-pyrrole-2-carboxylic acid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.25 (d, <i>J</i> = 5.8 Hz, 1H), 7.90 (d, <i>J</i> = 5.2 Hz, 1H), 7.81 (d, <i>J</i> = 7.4 Hz, 1H), 7.58–7.43 (m, 4H), 7.38 (br s, 1H), 7.10 (br s, 1H), 4.07 (br s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> To a suspension of 1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-pyrrole-2-carboxylic acid (13 mg, 0.05 mmol), piperidin-4-ylmethanol (8.8 mg, 0.08 mmol), HOBT (12.0 mg, 0.08 mmol), and EDC (20 mg, 0.10 mmol) in DMF (510 μL) was added Hunig’s base (36 μL, 0.20 mmol) slowly. The resulting mixture was stirred at room temperature overnight giving complete conversion based on HPLC analysis. The excess solvent was removed in vacuo and the residue was purified via preparative HPLC (Sunfire 5 μm C18 30 mm × 100 mm column, 10 min gradient from 10% to 100% B in A, A = 10:90 methanol/water with 0.1% trifluoroacetic acid, B = 90:10 methanol/water with 0.1% trifluoroacetic acid). The fractions containing desired product were passed through a NaHCO<sub>3</sub>-polymer supported cartridge to remove TFA. The solvents were then removed in vacuo to give <b>40</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 349.2, found 348.9; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.28 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.91–7.85 (m, 1H), 7.78 (d, <i>J</i> = 7.7 Hz, 1H), 7.53–7.40 (m, 4H), 6.94 (d, <i>J</i> = 1.9 Hz, 1H), 6.59 (d, <i>J</i> = 1.9 Hz, 1H), 4.64 (d, <i>J</i> = 12.7 Hz, 2H), 3.89 (s, 3H), 3.56 (d, <i>J</i> = 5.8 Hz, 2H), 2.98 (br s, 2H), 1.90–1.77 (m, 3H), 1.37–1.22 (m, 2H).</div></div><div id="sec3_3_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> (4-(Hydroxymethyl)piperidin-1-yl)(2-methyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrrol-3-yl)methanone (<b>41</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a round-bottom flask containing ethyl 2-methyl-1<i>H</i>-pyrrole-3-carboxylate (0.5 g, 3.3 mmol) in DMF (13 mL) was added <i>N</i>-bromosuccinimide (0.61 g, 3.4 mmol). The reaction mixture was stirred at room temperature for 40 min. Water (40 mL) was added resulting in precipitate formation. The solid was isolated by suction filtration to give ethyl 5-bromo-2-methyl-1<i>H</i>-pyrrole-3-carboxylate. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (br s, 1H), 6.31 (s, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 2.37 (s, 3H), 1.23 (t, <i>J</i> = 7.1 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a degassed solution of ethyl 5-bromo-2-methyl-1<i>H</i>-pyrrole-3-carboxylate (0.75 g, 3.2 mmol), naphthalen-1-ylboronic acid (0.70 g, 4.0 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.1 g, 8.1 mmol) in dioxane (34 mL) and water (11 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (0.19 g, 0.16 mmol). The reaction mixture was heated with stirring at 100 °C until LCMS analysis indicated complete conversion. Most of the solvent was removed, and the residue was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–60% ethyl acetate/hexanes). The product containing fractions were combined and concentrated to afford ethyl 2-methyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylate. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (br s, 1H), 8.29–8.23 (m, 1H), 7.94–7.87 (m, 1H), 7.86–7.78 (m, 1H), 7.56–7.51 (m, 2H), 7.51–7.47 (m, 2H), 6.84 (d, <i>J</i> = 2.9 Hz, 1H), 4.34 (q, <i>J</i> = 7.0 Hz, 2H), 2.66 (s, 3H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p"><i>Step 3.</i> To a suspension of ethyl 2-methyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylate (0.66 g, 2.4 mmol) in methanol (24 mL) was added 1 N aqueous lithium hydroxide (7.8 mL, 7.8 mmol). The mixture was heated to 50 °C, while the reaction was monitored periodically by LCMS. After 17 h there was remaining starting material so additional methanol (10 mL) and 1 N aqueous lithium hydroxide (5 mL) were added and heating was increased to 70 °C. After 48 h LCMS indicated complete consumption of starting material and formation of desired product. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 × 10 mL). The organic layers were discarded, and the aqueous layer was acidified with 1 N aqueous HCl, giving precipitate formation. The suspension was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated, and then lyophilized to afford 2-methyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylic acid which was used without further purification.</div><div class="NLM_p last"><i>Step 4.</i> To a solution of 2-methyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylic acid (100 mg, 0.40 mmol), piperidin-4-ylmethanol (92 mg, 0.80 mmol), HOBT (91 mg, 0.60 mmol), and EDC (150 mg, 0.80 mmol) in dichloromethane (4 mL) was added Hunig’s base (0.28 mL, 1.6 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was washed with sat. NaHCO<sub>3</sub> and extracted with dichloromethane. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The crude product was dissolved in acetonitrile, filtered, and purified by preparative HPLC (Sunfire 5 μm C18 30 mm × 100 mm column, 10 min gradient from 10% to 100% B in A, A = 10:90 methanol/water with 0.1% trifluoroacetic acid, B = 90:10 methanol/water with 0.1% trifluoroacetic acid) to give <b>41</b> (97 mg, 0.26 mmol, 66% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 349.2, found 349.0; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.33 (br s, 1H), 8.30–8.25 (m, 1H), 7.93–7.85 (m, 1H), 7.84–7.78 (m, 1H), 7.55–7.49 (m, 2H), 7.49–7.45 (m, 2H), 6.42 (d, <i>J</i> = 2.8 Hz, 1H), 4.54 (br s, 2H), 3.54 (d, <i>J</i> = 5.8 Hz, 2H), 2.92 (br s, 2H), 2.47 (s, 3H), 1.85–1.74 (m, 3H), 1.36–1.17 (m, 2H).</div></div><div id="sec3_3_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> (4-(Hydroxymethyl)piperidin-1-yl)(4-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrrol-3-yl)methanone (<b>42</b>)</h3><div class="NLM_p"><i>Step 1.</i> To ethyl 4-methyl-1<i>H</i>-pyrrole-3-carboxylate (0.5 g, 3.3 mmol), naphthalen-1-ylboronic acid (0.59 g, 3.4 mmol), and pyridine (0.53 mL, 6.5 mmol) in DMF (16 mL) were added copper(II) acetate (0.60 g, 3.3 mmol) and 1 g of crushed 4 Å molecular sieves. The resulting deep blue mixture was stirred at 70 °C in a sealed vial overnight. At this point, additional boronic acid (0.5 g) was added and heating was continued for an additional 18 h giving partial conversion to desired product. The dark-blue reaction mixture was diluted with ethyl acetate and filtered through a pad of Celite. The filtrate was washed with a 1:1 mixture of saturated aqueous NH<sub>4</sub>Cl–NaHCO<sub>3</sub> and brine. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes) to afford ethyl 4-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylate as a yellow oil.</div><div class="NLM_p"><i>Step 2.</i> To a solution of ethyl 4-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylate (44 mg, 0.16 mmol) in tetrahydrofuran (1.6 mL) was added 1 N aqueous lithium hydroxide (470 μL, 0.47 mmol). The reaction mixture was stirred at room temperature overnight giving no conversion to desired product. The reaction mixture was then heated to 50 °C and monitored by LCMS, but little conversion was observed. Additional 1 N aqueous lithium hydroxide (470 μL) and methanol (1.5 mL) were added, and heating was increased to 60 °C overnight giving complete conversion. The reaction mixture was washed with 1 N aqueous HCl and extracted with ethyl acetate. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to obtain 4-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylic acid (36 mg, 0.14 mmol, 90% yield). The product was used subsequently without further purification or characterization.</div><div class="NLM_p last"><i>Step 3.</i> To a suspension of 4-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrrole-3-carboxylic acid (12 mg, 0.05 mmol), piperidin-4-ylmethanol (8.0 mg, 0.07 mmol), HOBT (11 mg, 0.07 mmol), and EDC (18 mg, 0.09 mmol) in DMF (540 μL) was added Hunig’s base (32 μL, 0.19 mmol) slowly. The resulting mixture was stirred at room temperature overnight. The reaction mixture was quenched with saturated aqueous NH<sub>4</sub>Cl (4 mL) and extracted with ethyl acetate (3 × 4 mL). The combined organic layers were washed with H<sub>2</sub>O, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC (Sunfire 5 μm C18 30 mm × 100 mm column, 10 min gradient from 10% to 100% B in A, A = 10:90 acetonitrile/water with 0.1% trifluoroacetic acid, B = 90:10 acetonitrile/water with 0.1% trifluoroacetic acid) to give <b>42</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 349.2, found 349.2; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.95–7.91 (m, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.3, 0.8 Hz, 1H), 7.58–7.53 (m, 1H), 7.53–7.49 (m, 2H), 7.46–7.41 (m, 1H), 7.03 (d, <i>J</i> = 2.2 Hz, 1H), 6.76 (dd, <i>J</i> = 2.2, 1.1 Hz, 1H), 4.53 (br s, 2H), 3.55 (t, <i>J</i> = 5.5 Hz, 2H), 2.95 (br s, 2H), 2.25 (d, <i>J</i> = 0.8 Hz, 3H), 1.88–1.74 (m, 3H), 1.35 (t, <i>J</i> = 5.4 Hz, 1H), 1.32–1.19 (m, 2H).</div></div><div id="sec3_3_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> (4-(Hydroxymethyl)piperidin-1-yl)(4-methyl-2-(naphthalen-1-yl)oxazol-5-yl)methanone (<b>43</b>)</h3><div class="NLM_p"><i>Step 1.</i> Ethyl 2-chloro-3-oxobutanoate (0.53 mL, 3.6 mmol) was added to a solution of 1-naphthamide (0.25 g, 1.5 mmol) in ethanol (1.5 mL). The reaction vessel was sealed and heated to 110 °C for 24 h. Additional ethyl 2-chloro-3-oxobutanoate (0.53 mL, 3.6 mmol) was added, but it was found to only increase the number of impurities being formed so the reaction was cooled to room temperature and the excess solvent was removed in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–30% ethyl acetate/hexanes, Isco 40 g column) to give ethyl 4-methyl-2-(naphthalen-1-yl)oxazole-5-carboxylate (0.15 g, 0.53 mmol, 36% yield) as a waxy white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.28 (d, <i>J</i> = 8.5 Hz, 1H), 8.35 (d, <i>J</i> = 7.3 Hz, 1H), 8.02 (d, <i>J</i> = 8.3 Hz, 1H), 7.93 (d, <i>J</i> = 7.8 Hz, 1H), 7.68 (t, <i>J</i> = 7.7 Hz, 1H), 7.62–7.54 (m, 2H), 4.46 (q, <i>J</i> = 7.3 Hz, 2H), 2.64 (s, 3H), 1.45 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (0.11 g, 2.7 mmol) was added to a solution of ethyl 4-methyl-2-(naphthalen-1-yl)oxazole-5-carboxylate (0.15 g, 0.53 mmol) in tetrahydrofuran (4.1 mL), water (0.82 mL) and methanol (0.41 mL). After 16 h the reaction was diluted with water and ethyl acetate and acidified to pH 1 with 1.0 N HCl. The organic layer was washed with brine, and the combined aqueous layers were further extracted with ethyl acetate. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed in vacuo giving 4-methyl-2-(naphthalen-1-yl)oxazole-5-carboxylic acid (0.13 g, 0.50 mmol, 95% yield) as a white solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.56 (br s, 1H), 9.21 (d, <i>J</i> = 8.5 Hz, 1H), 8.27 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 8.19 (d, <i>J</i> = 8.3 Hz, 1H), 8.07 (d, <i>J</i> = 8.0 Hz, 1H), 7.77–7.61 (m, 3H), 2.54 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 4-methyl-2-(naphthalen-1-yl)oxazole-5-carboxylic acid and piperidin-4-ylmethanol to give <b>43</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub>) requires <i>m</i>/<i>z</i> 351.2, found 351.2; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.25 (d, <i>J</i> = 8.8 Hz, 1H), 8.19 (dd, <i>J</i> = 7.4, 1.1 Hz, 1H), 8.00 (d, <i>J</i> = 8.3 Hz, 1H), 7.93 (d, <i>J</i> = 8.3 Hz, 1H), 7.67 (ddd, <i>J</i> = 8.5, 7.0, 1.5 Hz, 1H), 7.61–7.53 (m, 2H), 4.54 (br s, 2H), 3.59 (t, <i>J</i> = 5.5 Hz, 2H), 3.05 (br s, 2H), 2.56 (s, 3H), 1.97–1.81 (m, 3H), 1.47–1.31 (m, 3H).</div></div><div id="sec3_3_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> (4-(Hydroxymethyl)piperidin-1-yl)(5-methyl-2-(naphthalen-1-yl)oxazol-4-yl)methanone (<b>44</b>)</h3><div class="NLM_p"><i>Step 1.</i> 1-Naphthamide (0.2 g, 1.2 mmol) was added to a solution of methyl 3-bromo-2-oxobutanoate (0.30 g, 1.4 mmol) in dioxane (5.8 mL). The reaction vial was sealed and slowly heated to 90 °C. After 1 h, LCMS analysis indicated formation of the desired product. The reaction was cooled to room temperature, and the solvent was removed in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–40% ethyl acetate/hexanes, Isco 24 g column) to give methyl 5-methyl-2-(naphthalen-1-yl)oxazole-4-carboxylate (0.08 g, 0.3 mmol, 24% yield) as a thick oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.19 (d, <i>J</i> = 7.78 Hz, 1H), 8.21 (dd, <i>J</i> = 1.26, 7.28 Hz, 1H), 7.99 (d, <i>J</i> = 8.03 Hz, 1H), 7.91 (d, <i>J</i> = 8.03 Hz, 1H), 7.67 (ddd, <i>J</i> = 1.51, 6.96, 8.60 Hz, 1H), 7.51–7.60 (m, 2H), 3.99 (s, 3H), 2.79 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> Lithium hydroxide monohydrate (59 mg, 1.4 mmol) was added to a rapidly stirring mixture of methyl 5-methyl-2-(naphthalen-1-yl)oxazole-4-carboxylate (75 mg, 0.28 mmol) in tetrahydrofuran (2.2 mL), methanol (0.22 mL), and water (0.43 mL). After 3 h LCMS analysis indicated the reaction had reached completion. The reaction mixture was diluted with ethyl acetate and acidified to pH 1 with 1 N HCl. The organic layer was washed with brine, and the aqueous layers were extracted further with ethyl acetate. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and the solvent was removed in vacuo to give 5-methyl-2-(naphthalen-1-yl)oxazole-4-carboxylic acid (58 mg, 0.23 mmol, 81% yield) as a light brown solid. The product was used without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.06 (s, 1H), 9.26 (d, <i>J</i> = 8.53 Hz, 1H), 8.20 (d, <i>J</i> = 7.28 Hz, 1H), 8.14 (d, <i>J</i> = 8.03 Hz, 1H), 8.06 (d, <i>J</i> = 7.78 Hz, 1H), 7.61–7.77 (m, 3H), 2.72 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 5-methyl-2-(naphthalen-1-yl)oxazole-4-carboxylic acid and piperidin-4-ylmethanol to give <b>44</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub>) requires <i>m</i>/<i>z</i> 351.2, found 351.3; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.28 (d, <i>J</i> = 9.03 Hz, 1H), 8.20 (dd, <i>J</i> = 1.25, 7.53 Hz, 1H), 7.97 (d, <i>J</i> = 8.28 Hz, 1H), 7.92 (d, <i>J</i> = 8.78 Hz, 1H), 7.61–7.69 (m, 1H), 7.50–7.60 (m, 2H), 4.63–5.09 (m, 2H), 3.59 (d, <i>J</i> = 6.02 Hz, 2H), 3.21 (br s, 1H), 2.83 (d, <i>J</i> = 16.56 Hz, 1H), 2.69 (s, 3H), 1.80–1.99 (m, 3H), 1.30–1.43 (m, 2H).</div></div><div id="sec3_3_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> (4-(Hydroxymethyl)piperidin-1-yl)(1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-imidazol-2-yl)methanone (<b>45</b>)</h3><div class="NLM_p"><i>Step 1.</i><i>N</i>-Bromosuccinimide (1.4 g, 7.8 mmol) was added to a stirring solution of ethyl 1-methyl-1<i>H</i>-imidazole-2-carboxylate (1.0 g, 6.5 mmol) in anhydrous tetrahydrofuran (17 mL) at approximately −5 °C (ice–salt bath). The reaction mixture was kept at that temperature for 2 h and then allowed to achieve room temperature for 16 h. The solvent was evaporated in vacuo to afford an oil/solid mixture. LCMS analysis indicated a mixture of desired product with some isomeric bromination product and bis-brominated product. The crude reaction mixture was purified on SiO<sub>2</sub> via Isco flash chromatography (10–40% ethyl acetate/hexanes) to afford ethyl 4-bromo-1-methyl-1<i>H</i>-imidazole-2-carboxylate (400 mg, 1.7 mmol, 26% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.99 (s, 1H), 4.38 (q, <i>J</i> = 7.2 Hz, 2H), 3.97 (s, 3H), 1.38 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a degassed solution of ethyl 4-bromo-1-methyl-1<i>H</i>-imidazole-2-carboxylate (0.40 g, 1.7 mmol), naphthalen-1-ylboronic acid (0.36 g, 2.1 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.59 g, 4.2 mmol) in dioxane (18 mL) and water (5.9 mL) was added Pd(Ph<sub>3</sub>P)<sub>4</sub> (0.10 g, 0.09 mmol). The reaction mixture was stirred at 90 °C while being monitored by LCMS. Once the reaction was complete, lithiium hydroxide monohydrate (3.5 eq 14 mg) was added and the reaction mixture was heated in a 50 °C oil bath for 5 h until LCMS indicated complete hydrolysis. The reaction mixture was cooled to room temperature, acidified with 1 N aqueous HCl and extracted with ethyl acetate (3 × 5 mL). The organic layers were found by LCMS to contain mostly impurities and only a trace amount of desired product. The aqueous layer was found to contain the desired product and was concentrated in vacuo. The residue was purified by HPLC (Sunfire 5 μm C18 30 mm × 100 mm column, 10 min gradient from 10% to 100% B in A, A = 10:90 acetonitrile/water with 0.1% trifluoroacetic acid, B = 90:10 acetonitrile/water with 0.1% trifluoroacetic acid) to give 1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-imidazole-2-carboxylic acid (125 mg, 0.50 mmol, 29% yield) as a light yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.00–7.94 (m, 1H), 7.94–7.88 (m, 2H), 7.60 (d, <i>J</i> = 6.9 Hz, 2H), 7.56–7.46 (m, 4H), 7.26 (s, 1H), 4.16 (s, 3H).</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 1-methyl-4-(naphthalen-1-yl)-1<i>H</i>-imidazole-2-carboxylic acid and piperidin-4-ylmethanol to give <b>45</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 350.2, found 350.0; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.52 (dd, <i>J</i> = 6.2, 3.4 Hz, 1H), 7.92–7.86 (m, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 7.2 Hz, 1H), 7.54–7.46 (m, 3H), 7.25 (s, 1H), 4.96 (d, <i>J</i> = 11.3 Hz, 1H), 4.77 (d, <i>J</i> = 13.2 Hz, 1H), 3.99 (s, 3H), 3.56 (d, <i>J</i> = 5.8 Hz, 2H), 3.28 (t, <i>J</i> = 12.8 Hz, 1H), 2.86 (td, <i>J</i> = 12.9, 2.3 Hz, 1H), 1.96–1.80 (m, 3H), 1.52–1.41 (m, 2H), 1.41–1.30 (m, 1H).</div></div><div id="sec3_3_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> (1,4-Dimethyl-2-(naphthalen-1-yl)-1<i>H</i>-imidazol-5-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone (<b>46</b>)</h3><div class="NLM_p"><i>Step 1.</i> Rigorously degassed dioxane (3.0 mL) was added to a vial containing PdCl<sub>2</sub>(dppf) (110 mg, 0.15 mmol), Cs<sub>2</sub>CO<sub>3</sub> (0.65 g, 2.0 mmol), ethyl 2-bromo-4-methyl-1<i>H</i>-imidazole-5-carboxylate (230 mg, 1.0 mmol), and naphthalen-1-ylboronic acid (210 mg, 1.2 mmol). The reaction vial was sealed and heated to 90 °C overnight. The reaction mixture was cooled to room temperature and passed through a 0.45 μm nylon filter. The excess solvents were removed in vacuo and the residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–30% ethyl acetate/hexanes, Isco 40 g column) to give ethyl 4-methyl-2-(naphthalen-1-yl)-1<i>H</i>-imidazole-5-carboxylate (190 mg, 0.67 mmol, 67% yield) as a gum. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.61 (d, <i>J</i> = 8.1 Hz, 1H), 8.06–7.84 (m, 2H), 7.75 (dd, <i>J</i> = 7.0, 0.9 Hz, 1H), 7.65–7.41 (m, 4H), 4.38 (q, <i>J</i> = 7.1 Hz, 2H), 2.65 (s, 3H), 1.42 (t, <i>J</i> = 7.0 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> Ethyl 2-(3,4-dihydroquinoxalin-1(2<i>H</i>)-yl)-4-methylthiazole-5-carboxylate (28 mg, 0.1 mmol) and K<sub>2</sub>CO<sub>3</sub> (28 mg, 0.20 mmol) were added to a stirring solution of iodomethane (28 mg, 0.20 mmol) in acetone (5 mL) at room temperature under argon. The reaction mixture was stirred at room temperature overnight. The desired product was evident by LCMS analysis, but there was a major side product with <i>m</i>/<i>z</i> of the desired product + 14. The excess solvent was removed, and the crude product was used directly in the next step.</div><div class="NLM_p"><i>Step 3.</i> To a solution of ethyl 1,4-dimethyl-2-(naphthalen-1-yl)-1<i>H</i>-imidazole-5-carboxylate (29 mg, 0.10 mmol) in 2 mL of tetrahydrofuran/methanol (1:1) was added aqueous 5 N NaOH (0.06 mL, 0.30 mmol). The reaction mixture was heated with stirring at 50 °C overnight giving complete conversion by LCMS analysis. To the reaction mixture was then added 2.0 mL of 0.1 N aqueous HCl resulting in precipitate formation. The solid was collected by suction filtration, washed with water, and dried in vacuo to yield 1,4-dimethyl-2-(naphthalen-1-yl)-1<i>H</i>-imidazole-5-carboxylic acid as a tan solid. The crude product was used directly in the next step without further purification.</div><div class="NLM_p last"><i>Step 4.</i> Prepared according to general method A with 1,4-dimethyl-2-(naphthalen-1-yl)-1<i>H</i>-imidazole-5-carboxylic acid and piperidin-4-ylmethanol to give <b>46</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 364.2, found 364.2; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.98–9.12 (m, 1H), 8.93 (d, <i>J</i> = 7.43 Hz, 1H), 8.24 (d, <i>J</i> = 8.25 Hz, 1H), 7.89 (d, <i>J</i> = 7.98 Hz, 1H), 7.67 (t, <i>J</i> = 7.29 Hz, 1H), 7.50 (dd, <i>J</i> = 3.99, 7.01 Hz, 1H), 3.56 (br s, 2H), 2.87 (d, <i>J</i> = 7.43 Hz, 5H), 1.82 (br s, 3H), 1.40 (t, <i>J</i> = 7.57 Hz, 4H), 1.29 (d, <i>J</i> = 10.45 Hz, 2H).</div></div><div id="sec3_3_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (4-(Hydroxymethyl)piperidin-1-yl)(1-methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)methanone (<b>47</b>)</h3><div class="NLM_p"><i>Step 1.</i> A mixture of ethyl 4-(naphthalen-1-yl)-2,4-dioxobutanoate (7.0 g, 26 mmol) and hydrazine (0.85 mL, 27 mmol) in acetic acid (65 mL) was heated at 90 °C for 4 h. The reaction mixture was then cooled to room temperature and concentrated under reduced pressure to remove excess acetic acid. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–50% ethyl acetate/hexanes, Isco 120 g column) to give ethyl 3-(naphthalen-1-yl)-1<i>H</i>-pyrazole-5-carboxylate (6.0 g, 22 mmol, 86% yield) as a pale-yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.22 (d, <i>J</i> = 4.7 Hz, 1H), 7.95–7.89 (m, 2H), 7.62 (dd, <i>J</i> = 7.0, 1.0 Hz, 1H), 7.57–7.49 (m, 3H), 7.14 (s, 1H), 4.45 (q, <i>J</i> = 7.2 Hz, 2H), 1.44 (t, <i>J</i> = 7.2 Hz, 3H), 1.02 (d, <i>J</i> = 6.6 Hz, 1H).</div><div class="NLM_p"><i>Step 2.</i> To a stirred suspension of ethyl 3-(naphthalen-1-yl)-1<i>H</i>-pyrazole-5-carboxylate (5.9 g, 22 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (9.4 g, 29 mmol) in acetonitrile (170 mL) was slowly added iodomethane (1.5 mL, 24 mmol). The reaction mixture was stirred at room temperature for 2 h. LCMS of the reaction mixture indicated the formation of two regioisomers of methylated products. The solvent was evaporated to dryness, and the residue was suspended in ethyl acetate and washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–30% ethyl acetate/hexanes, Isco 220 g column). Fractions of the first eluting, less polar peak were collected and concentrated under reduced pressure to give the desired isomer ethyl 1-methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole-5-carboxylate (3.1 g, 11 mmol, 49% yield) as a colorless oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.47–8.42 (m, 1H), 7.92–7.89 (m, 1H), 7.88 (d, <i>J</i> = 8.3 Hz, 1H), 7.68 (dd, <i>J</i> = 7.0, 1.2 Hz, 1H), 7.57–7.48 (m, 3H), 7.16 (s, 1H), 4.42 (q, <i>J</i> = 7.2 Hz, 2H), 4.33 (s, 3H), 1.43 (t, <i>J</i> = 7.2 Hz, 3H). Fractions of the second eluting, more polar peak were collected and concentrated under reduced pressure to give ethyl 1-methyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrazole-3-carboxylate (2.6 g, 9.2 mmol, 41% yield) as a light-yellow oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.99 (d, <i>J</i> = 8.3 Hz, 1H), 7.96–7.92 (m, 1H), 7.59–7.48 (m, 4H), 7.46 (dd, <i>J</i> = 7.0, 1.2 Hz, 1H), 6.95 (s, 1H), 4.47 (q, <i>J</i> = 7.2 Hz, 2H), 3.72 (s, 3H), 1.45 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p"><i>Step 3.</i> To a solution of ethyl 1-methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole-5-carboxylate (0.24 g, 0.87 mmol) in tetrahydrofuran (1.1 mL) and water (1.1 mL) was added lithium hydroxide monohydrate (0.07 g, 2.9 mmol). The reaction mixture was stirred at room temperature while being monitored by LCMS. After 2 days the reaction mixture was cooled to 0 °C and neutralized with 1 N aqueous HCl. The mixture was extracted with ethyl acetate (2 × 2 mL), and then the combined organic layers were washed with H<sub>2</sub>O (2 × 5 mL), brine (5 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The solid was dried in vacuo and the crude product was used in the next reaction without further purification.</div><div class="NLM_p last"><i>Step 4.</i> Prepared according to general method A with 1-methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole-5-carboxylic acid and piperidin-4-ylmethanol to give <b>47</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 350.2, found 350.0; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.50–8.43 (m, 1H), 7.91–7.88 (m, 1H), 7.87 (d, <i>J</i> = 8.3 Hz, 1H), 7.67 (dd, <i>J</i> = 7.0, 1.2 Hz, 1H), 7.55–7.48 (m, 3H), 6.60 (s, 1H), 4.78 (br s, 1H), 4.09 (s, 3H), 3.56 (d, <i>J</i> = 3.6 Hz, 2H), 3.15 (br s, 1H), 2.84 (br s, 1H), 1.97–1.75 (m, 3H), 1.61 (br s, 2H), 1.41–1.18 (m, 2H).</div></div><div id="sec3_3_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> (4-(Hydroxymethyl)piperidin-1-yl)(3-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrazol-4-yl)methanone (<b>48</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a solution of ethyl 3-methyl-1<i>H</i>-pyrazole-4-carboxylate (1.6 g, 10 mmol) and naphthalen-1-ylboronic acid (1.8 g, 11 mmol) in DMF (30 mL) were added copper(II) acetate (1.8 g, 10 mmol), pyridine (1.6 mL, 20 mmol), and 2.5 g of crushed 4 Å molecular sieves. The resulting deep blue mixture was stirred in a loosely capped flask under air at room temperature until LCMS analysis indicated complete conversion (approximately 2 days). The dark blue reaction mixture was diluted with ethyl acetate and saturated aqueous NH<sub>4</sub>Cl and then stirred vigorously in a round-bottom flask. The layers were then separated and the organic layer was washed with saturated aqueous NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered through a pad of SiO<sub>2</sub>, and concentrated in vacuo to afford a purple oil. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–60% ethyl acetate/hexanes, Isco 80 g column). Product containing fractions were combined and concentrated to afford ethyl 3-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrazole-4-carboxylate (1.7 g, 6.1 mmol, 61% yield) as a yellow solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.23 (s, 1H), 7.99–7.91 (m, 2H), 7.86–7.77 (m, 1H), 7.61–7.50 (m, 4H), 4.36 (q, <i>J</i> = 7.2 Hz, 2H), 2.63 (s, 3H), 1.39 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of ethyl 3-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrazole-4-carboxylate (1.4 g, 5.1 mmol) in methanol (25 mL) was added 1 N aqueous NaOH (20 mL, 20 mmol). The reaction mixture was stirred at 55 °C while being monitored by LCMS. The reaction was complete within 3 h. The heat was turned off, and stirring was continued at room temperature overnight. The reaction mixture was acidified with 12 N HCl and extracted with ethyl acetate. The organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to afford 3-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrazole-4-carboxylic acid (1.3 g, 4.9 mmol, 95% yield) as a tan solid. The product was used without further purification.</div><div class="NLM_p last"><i>Step 3.</i> Prepared according to general method A with 3-methyl-1-(naphthalen-1-yl)-1<i>H</i>-pyrazole-4-carboxylic acid and piperidin-4-ylmethanol to give <b>48</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 350.2, found 350.2; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.97–7.91 (m, 2H), 7.89–7.84 (m, 1H), 7.83 (s, 1H), 7.59–7.51 (m, 4H), 3.55 (br s, 2H), 2.98 (br s, 2H), 2.49 (s, 3H), 1.90–1.77 (m, 3H), 1.49 (br s, 1H), 1.36–1.22 (m, 2H).</div></div><div id="sec3_3_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> (4-(Hydroxymethyl)piperidin-1-yl)(5-methyl-2-(naphthalen-1-yl)-2<i>H</i>-1,2,3-triazol-4-yl)methanone (<b>49</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a 0 °C solution of naphthalen-1-amine (1.4 g, 10 mmol) in ethanol (4 mL) and water (4 mL) was added concentrated HCl (2.2 mL, 74 mmol) followed by sodium nitrite (0.69 g, 10 mmol) dissolved in water (1.5 mL). The reaction mixture was stirred at −5 °C for 10 min. This mixture was then slowly added to a mixture of ethyl 3-oxobutanoate (1.3 g, 10 mmol), sodium acetate (4.1 g, 50 mmol), 1 M aqueous sodium carbonate (10 mL, 10 mmol), and ethanol (20 mL) at 0 °C. The resulting mixture was stirred for 2 h and then diluted with water and extracted with ethyl acetate (2 × 100 mL). The combined organic extracts were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give the crude product, which was used in the next step without purification.</div><div class="NLM_p"><i>Step 2.</i> To the crude (<i>E</i>)-ethyl 2-(2-(naphthalen-1-yl)hydrazono)-3-oxobutanoate (2.8 g, 10 mmol) from the previous step in ethanol (40 mL) were added copper(II) chloride (3.0 g, 22 mmol) and ammonium acetate (7.7 g, 100 mmol). The reaction mixture was heated to reflux for 4 h and then cooled to room temperature and poured into a mixture of ice and concentrated HCl. Some solid was observed, which was collected by filtration. The filtrate was extracted with ethyl acetate, and the collected organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness. The residue was combined with the solids collected via filtration and further purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes, 80 g column) to yield ethyl 5-methyl-2-(naphthalen-1-yl)-2<i>H</i>-1,2,3-triazole-4-carboxylate (2.3 g, 8.2 mmol, 82% yield) as tan solid.</div><div class="NLM_p"><i>Step 3.</i> To a solution of ethyl 5-methyl-2-(naphthalen-1-yl)-2<i>H</i>-1,2,3-triazole-4-carboxylate (2.0 g, 7.1 mmol) in tetrahydrofuran (40 mL) was added 2 M NaOH (11 mL, 21 mmol). The reaction mixture was stirred at room temperature overnight under argon to give complete conversion. 2 N HCl was added until pH 4. The solid product that had formed was collected by suction filtration and further washed with water (3 × 2 mL). The product was dried overnight and used directly in the next step.</div><div class="NLM_p last"><i>Step 4.</i> Prepared according to general method A with 5-methyl-2-(naphthalen-1-yl)-2<i>H</i>-1,2,3-triazole-4-carboxylic acid and piperidin-4-ylmethanol to give <b>49</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 351.2, found 351.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.24–8.15 (m, 1H), 8.01–7.89 (m, 2H), 7.77 (dd, <i>J</i> = 7.5, 1.1 Hz, 1H), 7.61–7.50 (m, 3H), 4.81 (d, <i>J</i> = 13.1 Hz, 1H), 4.54 (d, <i>J</i> = 13.4 Hz, 1H), 3.52 (dd, <i>J</i> = 5.8, 4.3 Hz, 2H), 3.23–3.11 (m, 1H), 2.82 (td, <i>J</i> = 12.8, 2.4 Hz, 1H), 2.61 (s, 3H), 1.96–1.75 (m, 3H), 1.66 (br s, 1H), 1.33 (d, <i>J</i> = 12.1 Hz, 2H).</div></div><div id="sec3_3_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> (4-(Hydroxymethyl)piperidin-1-yl)(2-(naphthalen-1-yl)-2<i>H</i>-tetrazol-5-yl)methanone (<b>50</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a −5 °C solution of naphthalen-1-amine (1.8 g, 12 mmol) in ethanol (8 mL) and water (8 mL) was added concentrated HCl (4.5 mL, 150 mmol) followed by sodium nitrite (0.86 g, 12 mmol) dissolved in 1.5 mL of water. The reaction mixture was stirred at −5 °C for 10 min. This solution was used in step 2.</div><div class="NLM_p"><i>Step 2.</i> To ethyl 2-oxoacetate (3.5 g, 17 mmol) and benzenesulfonohydrazide (2.0 g, 12 mmol) in a 100 mL round-bottom flask was added ethanol (30 mL) at room temperature. After 1 h, the ethanol was evaporated and the residue was taken up in pyridine (20 mL) and cooled to −5 °C. To this mixture was then added the cooled solution from step 1, and the reaction mixture was allowed to achieve room temperature. After stirring at room temperature overnight, LCMS analysis indicated formation of desired product. Volatile solvents were removed in vacuo, and the residue was partitioned between ethyl acetate (25 mL) and brine (25 mL). The organic layer was collected, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was used directly in the next step.</div><div class="NLM_p"><i>Step 3.</i> The crude product from step 2 was taken up in 2 N NaOH (0.5 mL, 1.0 mmol) and stirred at 50 °C overnight giving complete hydrolysis based on LCMS analysis. The reaction mixture was diluted with 5 mL of 1 N NaOH and extracted with ethyl acetate (5 mL). To the aqueous layer was added 6 mL of 1 N HCl, giving precipitate formation. The solid was collected by suction filtration, washed with water (2 × 2 mL), and dried overnight to give 2-(naphthalen-1-yl)-2<i>H</i>-tetrazole-5-carboxylic acid (0.2 g, 0.9 mmol, 46% yield) as a dark solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.13 (d, <i>J</i> = 8.36 Hz, 1H), 7.96–8.05 (m, 2H), 7.92 (d, <i>J</i> = 6.82 Hz, 1H), 7.53–7.74 (m, 3H).</div><div class="NLM_p last"><i>Step 4.</i> Prepared according to general method A with 2-(naphthalen-1-yl)-2<i>H</i>-tetrazole-5-carboxylic acid and piperidin-4-ylmethanol to give <b>50</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>) requires <i>m</i>/<i>z</i> 338.2, found 338.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.10 (d, <i>J</i> = 8.14 Hz, 1H), 8.02–8.07 (m, 1H), 8.00 (dd, <i>J</i> = 3.63, 5.83 Hz, 1H), 7.90 (dd, J = 1.10, 7.48 Hz, 1H), 7.54–7.73 (m, 2H), 4.89 (tdd, J = 2.34, 4.40, 13.15 Hz, 1H), 4.38 (td, J = 2.01, 13.59 Hz, 1H), 3.58 (dd, J = 3.96, 5.94 Hz, 2H), 3.20–3.34 (m, 1H), 2.92 (dt, J = 2.97, 12.93 Hz, 1H), 2.08 (s, 3H), 1.82–1.99 (m, 3H).</div></div><div id="sec3_3_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 1-Methyl-5-(1-methyl-1<i>H</i>-imidazol-2-yl)-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole Formic Acid Salt (<b>51</b>)</h3><div class="NLM_p"><i>Step 1.</i> A mixture of naphthalen-1-ylboronic acid (1.7 g, 9.6 mmol), 3-bromo-1-methyl-1<i>H</i>-pyrazole (1.0 g, 6.0 mmol), tetrakis(triphenylphosphine)palladium(0) (0.49 g, 0.42 mmol), and K<sub>3</sub>PO<sub>4</sub> (3.8 g, 18 mmol) in <i>N</i>-methyl-2-pyrrolidinone (10 mL) was heated with stirring at 90 °C under an argon atmosphere for 4 days. The reaction mixture was cooled to room temperature, diluted with water, and then extracted with diethyl ether (3 × 50 mL). The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–50% ethyl acetate/hexanes) to give 1-methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole (1.023 g, 78% yield) as a pale yellow oil. MS (ESI) <i>m</i>/<i>z</i>, 209.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.53 (ddt, <i>J</i> = 1.2, 3.4, 6.4 Hz, 1H), 7.96–7.82 (m, 2H), 7.70 (dd, <i>J</i> = 1.3, 7.1 Hz, 1H), 7.58–7.47 (m, 4H), 6.58 (d, <i>J</i> = 2.2 Hz, 1H), 4.06 (s, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of 1-methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole (280 mg, 1.3 mmol) in tetrahydrofuran (4.3 mL) at −78 °C was added <i>n</i>-butyllithium (2.0 M solution in pentane, 0.84 mL, 1.7 mmol) dropwise. The mixture was stirred at −78 °C for 2 h and at −40 °C for 1 h. The reaction mixture was recooled to −78 °C followed by addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.32 mL, 1.5 mmol) dropwise. After stirring at −78 °C for 20 min, the reaction mixture was warmed to room temperature and stirred for 45 min. The mixture was then cooled to 0 °C and quenched with water. Acetic acid was then added dropwise to the cold mixture until the pH of the aqueous layer was ∼6–7. The resulting mixture was extracted three times with ethyl acetate. The combined organic extracts were washed with brine/water (1:1), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 1-methyl-3-(naphthalen-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (490 mg with 75% purity, 86% yield) as a yellow oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.58–8.48 (m, 1H), 7.96–7.82 (m, 2H), 7.74–7.66 (m, 1H), 7.58–7.45 (m, 3H), 7.06 (s, 1H), 4.24 (s, 3H), 1.41 (s, 12H).</div><div class="NLM_p last"><i>Step 3.</i> A mixture of 2-iodo-1-methyl-1<i>H</i>-imidazole (32 mg, 0.16 mmol), 1-methyl-3-(naphthalen-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (23 mg, 0.05 mmol), tetrakis(triphenylphosphine)palladium(0) (8.5 mg, 7.4 μmol), and K<sub>3</sub>PO<sub>4</sub> (31 mg, 0.15 mmol) in <i>N</i>-methyl-2-pyrrolidinone (160 μL) was purged with argon and then heated with stirring at 100 °C for 21 h. The reaction mixture was cooled to room temperature and then purified by preparative HPLC (Waters XBridge C18, 19 mm × 200 mm column; mobile phase A = 5:95 acetonitrile/water with 0.1% formic acid; mobile phase B = 95:5 acetonitrile/water with 0.1% formic acid). Fractions containing the desired product were combined and dried via centrifugal evaporation to give <b>51</b> (5.7 mg, 32% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>17</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 289.1, found 289.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.82–8.65 (m, 1H), 8.05–7.92 (m, 2H), 7.80 (d, <i>J</i> = 7.0 Hz, 1H), 7.65–7.53 (m, 3H), 7.41 (s, 1H), 7.15 (s, 1H), 7.10 (s, 1H), 4.14 (s, 3H), 3.83 (s, 3H).</div></div><div id="sec3_3_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 1-Ethyl-5-(1-methyl-1<i>H</i>-imidazol-2-yl)-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole TFA Salt (<b>52</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a solution of <i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-pyrazole-1-sulfonamide (8.3 g, 48 mmol) in tetrahydrofuran (110 mL) at −78 °C was added <i>n</i>-butyllithium (2.0 M in pentane, 28 mL, 57 mmol) dropwise. The resulting mixture was stirred at −78 °C for 15 min followed by dropwise addition of 1,2-dibromotetrachloroethane (17 g, 52 mmol) in tetrahydrofuran (25 mL). After stirring at −78 °C for 15 min, the mixture was allowed to warm to room temperature and stirred for 1.5 h. The mixture was then quenched with water and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified by Isco flash column chromatography on SiO<sub>2</sub> (0–25% ethyl acetate/hexanes) to give 5-bromo-<i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-pyrazole-1-sulfonamide (6.9 g, 57%) as a light yellow oil. MS (ESI) <i>m</i>/<i>z</i>: 255.8 (M + 2 + H)<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.60 (d, <i>J</i> = 1.7 Hz, 1H), 6.43 (d, <i>J</i> = 1.7 Hz, 1H), 3.07 (s, 6H).</div><div class="NLM_p"><i>Step 2.</i> To a degassed mixture of naphthalen-1-ylboronic acid (7.0 g, 41 mmol), 5-bromo-<i>N</i>,<i>N</i>-dimethyl-1<i>H</i>-pyrazole-1-sulfonamide (6.9 g, 27 mmol), and K<sub>2</sub>CO<sub>3</sub> (12 g, 90 mmol) in dioxane (100 mL) and water (34 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.94 g, 0.82 mmol). The reaction mixture was heated with stirring at 100 °C for 3 h, cooled to room temperature, and then partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash column chromatography (0–50% ethyl acetate/hexanes) to give <i>N</i>,<i>N</i>-dimethyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrazole-1-sulfonamide (7.8 g, 96%) as a light yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 302.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.94 (t, <i>J</i> = 4.7 Hz, 1H), 7.90 (dd, <i>J</i> = 1.5, 7.8 Hz, 1H), 7.82 (d, <i>J</i> = 1.6 Hz, 1H), 7.61 (dd, <i>J</i> = 1.2, 8.4 Hz, 1H), 7.56–7.43 (m, 4H), 6.46 (d, <i>J</i> = 1.6 Hz, 1H), 2.92 (s, 6H).</div><div class="NLM_p"><i>Step 3.</i> A mixture of <i>N</i>,<i>N</i>-dimethyl-5-(naphthalen-1-yl)-1<i>H</i>-pyrazole-1-sulfonamide (6.3 g, 21 mmol) and TFA (8.0 mL, 100 mmol) was stirred at room temperature for 4 h and then concentrated in vacuo. The residue was taken up in ethyl acetate and washed with aqueous 1.5 M K<sub>2</sub>HPO<sub>4</sub> solution. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with brine–water (2:1), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 5-(naphthalen-1-yl)-1<i>H</i>-pyrazole (4.4 g, quantitative yield) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 195.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.32–8.25 (m, 1H), 7.93–7.86 (m, 2H), 7.67 (d, <i>J</i> = 2.1 Hz, 1H), 7.61 (dd, <i>J</i> = 1.2, 7.1 Hz, 1H), 7.54–7.48 (m, 3H), 6.61 (d, <i>J</i> = 2.2 Hz, 1H).</div><div class="NLM_p"><i>Step 4.</i> To a stirring mixture of 5-(naphthalen-1-yl)-1<i>H</i>-pyrazole (3.0 g, 15 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (7.0 g, 22 mmol) in acetonitrile (100 mL) was slowly added iodoethane (1.4 mL, 17 mmol). The reaction mixture was stirred at room temperature overnight, heated to 65 °C for 3.5 h, and then cooled to room temperature. The reaction mixture was then concentrated in vacuo, and the residue was partitioned between ethyl acetate and water. The organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash column chromatography (eluting with 100% hexanes, 100% CH<sub>2</sub>Cl<sub>2</sub>, and then 0–5% ethyl acetate/hexanes) to give the desired isomer of 1-ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole (1.9 g, 55% yield) as a light yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 222.9 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.59–8.45 (m, 1H), 7.95–7.80 (m, 2H), 7.69 (dd, <i>J</i> = 1.3, 7.0 Hz, 1H), 7.57–7.43 (m, 4H), 6.55 (d, <i>J</i> = 2.2 Hz, 1H), 4.31 (q, <i>J</i> = 7.3 Hz, 2H), 1.59 (t, <i>J</i> = 7.3 Hz, 3H).</div><div class="NLM_p"><i>Step 5.</i> To a solution of 1-ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole (1.0 g, 4.5 mmol) in tetrahydrofuran (15 mL) at −78 °C was added <i>n</i>-butyllithium (2.0 M solution in pentane, 2.9 mL, 5.8 mmol) dropwise. The mixture was stirred at −78 °C for 1.5 h and at −40 °C for 1 h. The reaction mixture was recooled to −78 °C followed by slow addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.1 mL, 5.4 mmol). After stirring at −78 °C for 30 min, the mixture was warmed to room temperature and stirred for 90 min. The mixture was then cooled to 0 °C and quenched with water. Acetic acid was then added dropwise to the cold mixture until the pH of the aqueous layer was ∼6–7. The mixture was extracted three times with ethyl acetate. The combined extracts were washed with brine/water (1:1), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 1-ethyl-3-(naphthalen-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (1.6 g, quantitative yield) as an oil, which became a gray solid upon standing. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.59–8.37 (m, 1H), 7.88–7.84 (m, 1H), 7.82 (dt, <i>J</i> = 1.0, 8.3 Hz, 1H), 7.68 (dd, <i>J</i> = 1.3, 7.1 Hz, 1H), 7.51–7.45 (m, 3H), 7.02 (s, 1H), 4.57 (q, <i>J</i> = 7.2 Hz, 2H), 1.53 (t, <i>J</i> = 7.2 Hz, 3H), 1.39 (s, 12H).</div><div class="NLM_p last"><i>Step 6.</i> Prepared according to general method B with 2-iodo-1-methyl-1<i>H</i>-imidazole to give <b>52</b> (12 mg, 58% yield) as a colorless gum. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>19</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 303.2, found 303.1; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.50–8.39 (m, 1H), 7.96–7.86 (m, 2H), 7.74–7.63 (m, 2H), 7.59–7.46 (m, 3H), 7.29 (br s, 1H), 6.88 (s, 1H), 4.31 (q, <i>J</i> = 7.2 Hz, 2H), 3.85 (s, 3H), 1.51 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec3_3_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 1-Ethyl-5-(1-methyl-1<i>H</i>-imidazol-5-yl)-3-(naphthalen-1-yl)-1<i>H</i>-pyrazole, TFA (<b>53</b>)</h3><div class="NLM_p last">Prepared according to general method B with 5-iodo-1-methyl-1<i>H</i>-imidazole to give <b>53</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>19</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 303.2, found 303.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.06 (br s, 1H), 8.52–8.44 (m, 1H), 7.96–7.86 (m, 2H), 7.71 (dd, <i>J</i> = 1.3, 7.0 Hz, 1H), 7.62–7.49 (m, 4H), 6.78 (s, 1H), 4.22 (q, <i>J</i> = 7.2 Hz, 2H), 3.85 (s, 3H), 1.54 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec3_3_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 2-Ethyl-2′-methyl-5-(naphthalen-1-yl)-2<i>H</i>,2′<i>H</i>-3,3′-bipyrazole (<b>54</b>)</h3><div class="NLM_p last">Prepared according to general method B with 5-bromo-1-methyl-1<i>H</i>-pyrazole to give <b>54</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>19</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 303.2, found 303.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.60–8.53 (m, 1H), 7.94–7.85 (m, 2H), 7.74 (dd, <i>J</i> = 1.2, 7.1 Hz, 1H), 7.64 (d, <i>J</i> = 2.0 Hz, 1H), 7.57–7.48 (m, 3H), 6.67 (s, 1H), 6.48 (d, <i>J</i> = 2.0 Hz, 1H), 4.22 (q, <i>J</i> = 7.2 Hz, 2H), 3.91 (s, 3H), 1.50 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec3_3_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 5-(1-Ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)-1-methyl-1<i>H</i>-1,2,4-triazole (<b>55</b>)</h3><div class="NLM_p last">Prepared according to general method B with 5-bromo-1-methyl-1<i>H</i>-1,2,4-triazole to give <b>55</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 304.2, found 304.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.78–8.64 (m, 1H), 8.19 (s, 1H), 8.09–7.90 (m, 2H), 7.81 (d, <i>J</i> = 7.1 Hz, 1H), 7.66–7.51 (m, 3H), 7.29 (s, 1H), 4.54 (q, <i>J</i> = 7.2 Hz, 2H), 4.06 (s, 3H), 1.46 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 5-(1-Ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)-1-methyl-1<i>H</i>-tetrazole (<b>56</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a solution of <i>n</i>-butyllithium (2.0 M solution in pentane, 3.6 mL, 7.3 mmol) in tetrahydrofuran (5.0 mL) at −78 °C was added dropwise 1-methyl-1<i>H</i>-tetrazole (0.5 g, 6.1 mmol) in tetrahydrofuran (2.0 mL). The mixture was stirred at −78 °C for 10 min followed by the addition of a solution of iodine (1.8 g, 7.3 mmol) in tetrahydrofuran (2.0 mL). The reaction mixture was warmed to room temperature, stirred for 1 h, and then concentrated in vacuo. The residue was partitioned between water (30 mL) and diethyl ether (30 mL). The organic layer was separated, and the aqueous layer was further extracted with diethyl ether (3 × 30 mL). The combined organic layers were washed with water, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 5-iodo-1-methyl-1<i>H</i>-tetrazole (0.48 g, 36% yield) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 210.9 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 4.11 (s, 1H).</div><div class="NLM_p last"><i>Step 2.</i> Prepared according to general method B with 5-iodo-1-methyl-1<i>H</i>-tetrazole to give <b>56</b> (6.6 mg, 48% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>17</sub>H<sub>17</sub>N<sub>6</sub>) requires <i>m</i>/<i>z</i> 305.1, found 305.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72–8.64 (m, 1H), 8.04–7.97 (m, 2H), 7.83 (dd, <i>J</i> = 1.2, 7.1 Hz, 1H), 7.64–7.55 (m, 3H), 7.45 (s, 1H), 4.57 (q, <i>J</i> = 7.2 Hz, 2H), 4.27 (s, 3H), 1.51 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec3_3_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 2-(1-Ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)pyridine (<b>57</b>)</h3><div class="NLM_p last">Prepared according to general method B with 2-bromopyridine to give <b>57</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>) requires <i>m</i>/<i>z</i> 300.1, found 300.1; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.81–8.65 (m, 2H), 8.09–7.87 (m, 4H), 7.78 (dd, <i>J</i> = 1.2, 7.1 Hz, 1H), 7.63–7.51 (m, 3H), 7.43 (ddd, <i>J</i> = 2.2, 4.8, 6.7 Hz, 1H), 7.22 (s, 1H), 4.75 (q, <i>J</i> = 7.1 Hz, 2H), 1.44 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 2-(1-Ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)pyrimidine (<b>58</b>)</h3><div class="NLM_p last">Prepared according to general method B with 2-bromopyrimidine to give <b>58</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>17</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 301.1, found 301.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.98 (d, <i>J</i> = 4.9 Hz, 2H), 8.68 (dd, <i>J</i> = 1.7, 7.9 Hz, 2H), 8.03–7.98 (m, 1H), 7.96 (d, <i>J</i> = 8.1 Hz, 1H), 7.79 (dd, <i>J</i> = 1.2, 7.2 Hz, 1H), 7.58 (dddd, <i>J</i> = 2.6, 6.0, 8.3, 12.4 Hz, 2H), 7.51 (t, <i>J</i> = 4.9 Hz, 1H), 7.37 (s, 1H), 4.89 (q, <i>J</i> = 7.1 Hz, 2H), 1.48 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 3-(1-Methyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)pyridazine (<b>59</b>)</h3><div class="NLM_p last">Prepared according to the procedures described for compound <b>51</b> with substitution of 3-bromopyridazine for 2-iodo-1-methyl-1<i>H</i>-imidazole at step 3. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>15</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 287.1, found 287.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.30 (d, <i>J</i> = 4.3 Hz, 1H), 8.79–8.65 (m, 1H), 8.32–8.20 (m, 1H), 8.00 (dd, <i>J</i> = 7.4, 16.0 Hz, 2H), 7.89 (dt, <i>J</i> = 3.9, 8.9 Hz, 1H), 7.83–7.77 (m, 1H), 7.60 (td, <i>J</i> = 3.6, 6.5, 7.1 Hz, 3H), 7.42 (t, <i>J</i> = 2.6 Hz, 1H), 4.35 (t, <i>J</i> = 2.4 Hz, 3H).</div></div><div id="sec3_3_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 3-(1-Ethyl-3-(naphthalen-1-yl)-1<i>H</i>-pyrazol-5-yl)pyridazine (<b>60</b>)</h3><div class="NLM_p last">Prepared according to general method B with 3-bromopyridazine to give <b>60</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>19</sub>H<sub>17</sub>N<sub>4</sub>) requires <i>m</i>/<i>z</i> 301.1, found 301.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (d, <i>J</i> = 4.9 Hz, 1H), 8.72 (d, <i>J</i> = 7.9 Hz, 1H), 8.26–8.21 (m, 1H), 8.02–7.99 (m, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.90–7.85 (m, 1H), 7.79 (d, <i>J</i> = 7.0 Hz, 1H), 7.62–7.55 (m, 3H), 7.39 (d, <i>J</i> = 1.2 Hz, 1H), 4.78 (q, <i>J</i> = 7.1 Hz, 2H), 1.49 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 1-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline, TFA (<b>61</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a degassed mixture of (1<i>H</i>-pyrazol-5-yl)boronic acid (0.54 g, 4.8 mmol), 1-bromoisoquinoline (0.50 g, 2.4 mmol), and K<sub>2</sub>CO<sub>3</sub> (1.0 g, 7.2 mmol) in dioxane (18 mL) and water (6.0 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.17 g, 0.14 mmol). The reaction mixture was heated with stirring to 90 °C. After heating at 90 °C for 12 h, the reaction mixture was cooled to room temperature and additional (1<i>H</i>-pyrazol-5-yl)boronic acid (0.54 g, 4.8 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.17 g, 0.14 mmol) were added and the mixture was further degassed. The reaction was then heated at 90 °C for an additional 10 h, cooled to room temperature, and partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash column chromatography (0–100% ethyl acetate/hexanes) to give 1-(1<i>H</i>-pyrazol-5-yl)isoquinoline (0.37 g, 79% yield) as an orange oil. MS (ESI) <i>m</i>/<i>z</i>: 196.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.78 (d, <i>J</i> = 8.6 Hz, 1H), 8.58 (d, <i>J</i> = 5.7 Hz, 1H), 7.91–7.84 (m, 1H), 7.78–7.69 (m, 2H), 7.67–7.59 (m, 3H), 7.01 (d, <i>J</i> = 2.2 Hz, 1H), 3.49 (s, 1H).</div><div class="NLM_p"><i>Step 2.</i> To a stirring mixture of 1-(1<i>H</i>-pyrazol-5-yl)isoquinoline (0.36 g, 1.9 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (0.85 g, 2.6 mmol) in acetonitrile (18 mL) was slowly added iodoethane (0.17 mL, 2.1 mmol). The reaction mixture was heated to 60 °C for 8 h, concentrated to dryness, and the residue was partitioned between ethyl acetate and water. The organic layer was separated, and the aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash column chromatography (0–50% ethyl acetate/hexanes) to give the desired isomer 1-(1-ethyl-1<i>H</i>-pyrazol-3-yl)isoquinoline (0.22 g, 54% yield) as an off-white solid. MS (ESI) <i>m</i>/<i>z</i>: 224.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.12 (dt, <i>J</i> = 1.1, 8.5 Hz, 1H), 8.58 (d, <i>J</i> = 5.6 Hz, 1H), 7.82 (dt, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.66 (ddd, <i>J</i> = 1.3, 6.8, 8.2 Hz, 1H), 7.63–7.57 (m, 2H), 7.52 (d, <i>J</i> = 2.4 Hz, 1H), 6.94 (d, <i>J</i> = 2.2 Hz, 1H), 4.32 (q, <i>J</i> = 7.4 Hz, 2H), 1.59 (t, <i>J</i> = 7.3 Hz, 3H).</div><div class="NLM_p"><i>Step 3.</i> To a solution of 1-(1-ethyl-1<i>H</i>-pyrazol-3-yl)isoquinoline (0.14 g, 0.62 mmol) in tetrahydrofuran (2.0 mL) at −78 °C was added LDA (0.37 mL, 0.74 mmol) dropwise. The mixture was stirred at −78 °C for 5 min followed by addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.15 mL, 0.74 mmol). After stirring at −78 °C for 30 min, the reaction was quenched with water and then warmed to 0 °C (ice bath). Acetic acid was then added dropwise to the cold mixture until the pH of the aqueous layer was ∼6–7. The mixture was extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 1-(1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline (0.23 g, quantitative yield) as an orange oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.03–8.94 (m, 1H), 8.58 (d, <i>J</i> = 5.6 Hz, 1H), 7.83 (dt, <i>J</i> = 0.9, 8.1 Hz, 1H), 7.67 (ddd, <i>J</i> = 1.3, 6.8, 8.2 Hz, 1H), 7.62–7.58 (m, 2H), 7.37 (s, 1H), 4.59 (q, <i>J</i> = 7.2 Hz, 2H), 1.54 (t, <i>J</i> = 7.2 Hz, 3H), 1.37 (s, 12H).</div><div class="NLM_p last"><i>Step 4.</i> To a degassed mixture of 1-(1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline (31 mg, 0.09 mmol), 3-bromopyridazine (21 mg, 0.13 mmol), and K<sub>3</sub>PO<sub>4</sub> (56 mg, 0.26 mmol) in dioxane (0.73 mL) and water (0.15 mL) was added tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.01 mmol). The reaction mixture was heated with stirring at 90 °C for 12 h, cooled to room temperature, and then purified by preparative HPLC (XBridge C18, 19 mm × 200 mm column; mobile phase A = 5:95 acetonitrile/water with 0.1% trifluoroacetic acid; mobile phase B = 95:5 acetonitrile/water with 0.1% trifluoroacetic acid). Fractions containing the desired product were combined and dried via centrifugal evaporation to give <b>61</b> (14 mg, 37% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.36 (d, <i>J</i> = 8.8 Hz, 1H), 9.29 (d, <i>J</i> = 4.3 Hz, 1H), 8.60 (d, <i>J</i> = 4.7 Hz, 1H), 8.28 (d, <i>J</i> = 8.6 Hz, 1H), 8.08 (d, <i>J</i> = 8.4 Hz, 1H), 7.94 (t, <i>J</i> = 4.4 Hz, 1H), 7.88 (p, <i>J</i> = 4.0, 4.6 Hz, 2H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.69 (d, <i>J</i> = 3.3 Hz, 1H), 4.83 (p, <i>J</i> = 6.3, 7.0 Hz, 2H), 1.52 (q, <i>J</i> = 6.3 Hz, 3H).</div></div><div id="sec3_3_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 4-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline, Formic Acid Salt (<b>62</b>)</h3><div class="NLM_p last">Prepared according to the procedures described for compound <b>61</b> with 4-bromoisoquinoline at step 1. Final purification was accomplished by preparative HPLC (XBridge C18, 19 mm × 200 mm column; mobile phase A = 5:95 acetonitrile/water with 0.1% formic acid; mobile phase B = 95:5 acetonitrile/water with 0.1% formic acid) to give <b>62</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.39 (s, 1H), 9.29 (d, <i>J</i> = 4.8 Hz, 1H), 8.87 (d, <i>J</i> = 8.7 Hz, 1H), 8.84 (s, 1H), 8.25 (t, <i>J</i> = 8.2 Hz, 2H), 7.98–7.87 (m, 2H), 7.80 (t, <i>J</i> = 7.7 Hz, 1H), 7.56 (s, 1H), 4.80 (q, <i>J</i> = 7.2 Hz, 2H), 1.50 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 4-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)quinoline (<b>63</b>)</h3><div class="NLM_p last">Prepared according to the procedures described for compound <b>61</b> with 4-bromoquinoline at step 1. Final purification was accomplished by preparative HPLC (XBridge C18, 19 mm × 200 mm column; mobile phase A = 5:95 acetonitrile/water with 10-mM ammonium acetate; mobile phase B = 95:5 acetonitrile/water with 10-mM ammonium acetate) to give <b>63</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (d, <i>J</i> = 4.7 Hz, 1H), 9.10–8.88 (m, 2H), 8.25 (d, <i>J</i> = 8.7 Hz, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (dt, <i>J</i> = 4.5, 9.3 Hz, 1H), 7.84 (q, <i>J</i> = 6.3, 7.8 Hz, 2H), 7.72 (d, <i>J</i> = 8.9 Hz, 1H), 7.63 (t, <i>J</i> = 2.5 Hz, 1H), 4.81 (p, <i>J</i> = 6.5 Hz, 2H), 1.51 (dt, <i>J</i> = 5.5, 8.5 Hz, 3H).</div></div><div id="sec3_3_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> 5-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)quinoline (<b>64</b>)</h3><div class="NLM_p last">Prepared according to the procedures described for compound <b>61</b> with 5-bromoquinoline at step 1. Final purification was accomplished by preparative HPLC (XBridge C18, 19 mm × 200 mm column; mobile phase A = 5:95 acetonitrile/water with 10-mM ammonium acetate; mobile phase B = 95:5 acetonitrile/water with 10-mM ammonium acetate) to give <b>64</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (d, <i>J</i> = 6.2 Hz, 2H), 8.99 (d, <i>J</i> = 3.9 Hz, 1H), 8.24 (d, <i>J</i> = 8.5 Hz, 1H), 8.08 (d, <i>J</i> = 8.2 Hz, 1H), 7.95 (d, <i>J</i> = 7.3 Hz, 1H), 7.89 (q, <i>J</i> = 7.7, 8.4 Hz, 2H), 7.66 (dd, <i>J</i> = 4.0, 9.1 Hz, 1H), 7.48 (s, 1H), 4.78 (q, <i>J</i> = 7.4 Hz, 2H), 1.50 (t, <i>J</i> = 7.3 Hz, 3H).</div></div><div id="sec3_3_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 5-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline, TFA (<b>65</b>)</h3><div class="NLM_p"><i>Step 1.</i> 5-(1-Ethyl-1<i>H</i>-pyrazol-3-yl)isoquinoline was prepared according to procedures described for compound <b>52</b> (steps 2–4) with isoquinolin-5-ylboronic acid at step 2. Final purification was accomplished by preparative HPLC (Phenomenex Luna Axia C18 30 mm × 100 mm column; mobile phase A = 10:90 methanol/water with 0.1% trifluoroacetic acid; mobile phase B = 90:10 methanol/water with 0.1% trifluoroacetic acid) to give 5-(1-ethyl-1<i>H</i>-pyrazol-3-yl)isoquinoline. MS (ESI) <i>m</i>/<i>z</i>, 224.1 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.27 (app brs, 1H), 8.55 (app brs, 1H), 8.46 (d, <i>J</i> = 5.7 Hz, 1H), 7.96–7.88 (m, 2H), 7.62 (dd, <i>J</i> = 6.5, 8.9 Hz, 1H), 7.52 (d, <i>J</i> = 2.4 Hz, 1H), 6.56 (d, <i>J</i> = 2.2 Hz, 1H), 4.29 (q, <i>J</i> = 7.3 Hz, 2H), 1.58 (td, <i>J</i> = 2.4, 7.3 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of 5-(1-ethyl-1<i>H</i>-pyrazol-3-yl)isoquinoline (0.12 g, 0.56 mmol) in tetrahydrofuran (1.8 mL) at −78 °C was added LDA (0.39 mL, 0.78 mmol) dropwise. The mixture was stirred at −78 °C for 15 min followed by addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.15 mL, 0.72 mmol). The reaction was then gradually warmed to room temperature. After stirring at room temperature for 1 h, the mixture was cooled to 0 °C (ice bath) and quenched with water. Acetic acid was then added dropwise to the cold mixture until the pH of the aqueous layer was ∼6–7. The mixture was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 5-(1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline (0.23 g, quantitative yield) as an orange oil. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.27 (d, <i>J</i> = 1.0 Hz, 1H), 8.54 (d, <i>J</i> = 6.0 Hz, 1H), 8.44 (dt, <i>J</i> = 0.9, 6.0 Hz, 1H), 7.93 (td, <i>J</i> = 1.1, 7.4 Hz, 2H), 7.63 (dd, <i>J</i> = 7.2, 8.2 Hz, 1H), 7.04 (s, 1H), 4.57 (q, <i>J</i> = 7.2 Hz, 2H), 1.54 (t, <i>J</i> = 7.2 Hz, 3H), 1.39 (s, 12H).</div><div class="NLM_p last"><i>Step 3.</i> To a degassed mixture of 5-(1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline (32 mg, 0.09 mmol), 3-bromopyridazine (22 mg, 0.14 mmol), and K<sub>3</sub>PO<sub>4</sub> (58.6 mg, 0.28 mmol) in dioxane (0.77 mL) and water (0.15 mL) was added tetrakis(triphenylphosphine)palladium(0) (16 mg, 0.01 mmol). The resulting mixture was heated at 90 °C for 12 h, cooled to room temperature, and then purified by preparative HPLC (XBridge C18, 19 mm × 200 mm column; mobile phase A = 5:95 acetonitrile/water with 0.1% trifluoroacetic acid; mobile phase B = 95:5 acetonitrile/water with 0.1% trifluoroacetic acid). Fractions containing the desired product were combined and dried via centrifugal evaporation to give <b>65</b> (21 mg, 54% yield). MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.70 (s, 1H), 9.30 (d, <i>J</i> = 4.9 Hz, 1H), 9.06 (d, <i>J</i> = 6.4 Hz, 1H), 8.68 (d, <i>J</i> = 6.5 Hz, 1H), 8.38 (d, <i>J</i> = 8.2 Hz, 1H), 8.34 (d, <i>J</i> = 7.3 Hz, 1H), 8.23 (d, <i>J</i> = 8.6 Hz, 1H), 7.97 (t, <i>J</i> = 7.7 Hz, 1H), 7.94–7.88 (m, 1H), 7.57 (s, 1H), 4.79 (q, <i>J</i> = 7.2 Hz, 2H), 1.51 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 8-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)isoquinoline, TFA (<b>66</b>)</h3><div class="NLM_p last">Prepared according to the procedures described for compound <b>61</b> with 8-bromoisoquinoline at step 1. Final purification was accomplished by preparative HPLC (XBridge Shield RP18, 19 mm × 250 mm column; mobile phase A = 5:95 acetonitrile/water with 0.1% trifluoroacetic acid; mobile phase B = 95:5 acetonitrile/water with 0.1% trifluoroacetic acid) to give <b>66</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.2; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 9.33 (d, <i>J</i> = 4.9 Hz, 1H), 8.68 (d, <i>J</i> = 6.0 Hz, 1H), 8.26 (t, <i>J</i> = 7.4 Hz, 2H), 8.18 (t, <i>J</i> = 7.5 Hz, 2H), 8.09 (t, <i>J</i> = 7.7 Hz, 1H), 7.94 (dd, <i>J</i> = 4.9, 8.6 Hz, 1H), 7.65 (s, 1H), 4.82 (q, <i>J</i> = 7.1 Hz, 2H), 1.54 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> 8-(1-Ethyl-5-(pyridazin-3-yl)-1<i>H</i>-pyrazol-3-yl)quinoline, TFA (<b>67</b>)</h3><div class="NLM_p"><i>Step 1.</i> 8-(1-Ethyl-1<i>H</i>-pyrazol-3-yl)quinoline was prepared according to the procedures described for compound <b>52</b> (steps 2–4) with quinolin-8-ylboronic acid at step 2 to give the desired intermediate. MS (ESI) <i>m</i>/<i>z</i>: 224.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.99 (dd, <i>J</i> = 1.8, 4.1 Hz, 1H), 8.27 (dd, <i>J</i> = 1.5, 7.3 Hz, 1H), 8.17 (dd, <i>J</i> = 1.9, 8.2 Hz, 1H), 7.78 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.59 (dd, <i>J</i> = 7.2, 8.2 Hz, 1H), 7.53 (d, <i>J</i> = 2.2 Hz, 1H), 7.40 (dd, <i>J</i> = 4.1, 8.3 Hz, 1H), 7.22 (d, <i>J</i> = 2.2 Hz, 1H), 4.29 (q, <i>J</i> = 7.3 Hz, 2H), 1.56 (t, <i>J</i> = 7.4 Hz, 3H).</div><div class="NLM_p"><i>Step 2.</i> To a solution of 8-(1-ethyl-1<i>H</i>-pyrazol-3-yl)quinoline (1.8 g, 8.3 mmol) in tetrahydrofuran (28 mL) at −78 °C was added LDA (5.8 mL, 12 mmol) dropwise. The reaction mixture was stirred at −78 °C for 45 min followed by addition of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.0 mL, 9.9 mmol). The mixture was gradually warmed to room temperature. After stirring at room temperature for 1 h, the mixture was cooled to 0 °C (ice bath) and then quenched with water. Acetic acid was then added dropwise to the cold mixture until the pH of the aqueous layer was ∼6–7. The mixture was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resultant orange oil was then coevaporated with CH<sub>2</sub>Cl<sub>2</sub> to yield 8-(1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-3-yl)quinoline (3.1 g, quantitative yield) as a sticky orange solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.98 (dd, <i>J</i> = 1.9, 4.1 Hz, 1H), 8.26 (dd, <i>J</i> = 1.6, 7.2 Hz, 1H), 8.16 (dd, <i>J</i> = 1.9, 8.2 Hz, 1H), 7.77 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.67 (s, 1H), 7.58 (dd, <i>J</i> = 7.2, 8.1 Hz, 1H), 7.40 (dd, <i>J</i> = 4.1, 8.2 Hz, 1H), 4.56 (q, <i>J</i> = 7.2 Hz, 2H), 1.50 (t, <i>J</i> = 7.2 Hz, 3H), 1.37 (s, 12H).</div><div class="NLM_p last"><i>Step 3.</i> To a degassed mixture of 8-(1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazol-3-yl)quinoline (0.04 g, 0.10 mmol), 3-bromopyridazine (0.02 g, 0.15 mmol), and K<sub>3</sub>PO<sub>4</sub> (0.06 g, 0.30 mmol) in dioxane (0.83 mL) and water (0.17 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.02 g, 0.02 mmol). The resulting mixture was heated at 90 °C for 10 h, cooled to room temperature and then purified by preparative HPLC (Phenex Luna AXIA C18 30 mm × 100 mm column; mobile phase A = 10:90 acetonitrile/water with 0.1% trifluoroacetic acid; mobile phase B = 90:10 acetonitrile/water with 0.1% trifluoroacetic acid). Fractions containing the desired product were combined and dried via centrifugal evaporation to give <b>67</b> (10 mg, 24% yield) as a light brown solid. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>) requires <i>m</i>/<i>z</i> 302.1, found 302.1; <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 9.45 (dq, <i>J</i> = 1.8, 5.5 Hz, 1H), 9.30–9.24 (m, 2H), 8.69 (dd, <i>J</i> = 1.3, 7.4 Hz, 1H), 8.36 (dd, <i>J</i> = 1.2, 8.2 Hz, 1H), 8.24 (dd, <i>J</i> = 1.6, 8.6 Hz, 1H), 8.18 (ddd, <i>J</i> = 1.6, 5.3, 7.0 Hz, 1H), 8.08 (t, <i>J</i> = 7.8 Hz, 1H), 7.92 (dd, <i>J</i> = 5.0, 8.6 Hz, 1H), 7.77 (s, 1H), 4.99 (q, <i>J</i> = 7.2 Hz, 2H), 1.62 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec3_3_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 6-(1-Ethyl-3-(isoquinolin-8-yl)-1<i>H</i>-pyrazol-5-yl)pyridazin-3-amine (<b>68</b>)</h3><div class="NLM_p last">Prepared according to procedures described for compound <b>61</b> with 8-bromoisoquinoline at step 1 and 6-chloropyridazin-3-amine at step 3. Final purification was accomplished by Isco flash chromatography on SiO<sub>2</sub> (0–10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give <b>68</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>17</sub>N<sub>6</sub>) requires <i>m</i>/<i>z</i> 317.1, found 317.1; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (d, <i>J</i> = 1.1 Hz, 1H), 8.56 (d, <i>J</i> = 5.6 Hz, 1H), 8.07–7.81 (m, 4H), 7.77 (d, <i>J</i> = 9.2 Hz, 1H), 7.20 (s, 1H), 6.92 (d, <i>J</i> = 9.2 Hz, 1H), 6.67 (s, 2H), 4.69 (q, <i>J</i> = 7.1 Hz, 2H), 1.46 (t, <i>J</i> = 7.1 Hz, 3H).</div></div><div id="sec3_3_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 6-(1-ethyl-3-(quinolin-8-yl)-1<i>H</i>-pyrazol-5-yl)pyridazin-3-amine (<b>69</b>)</h3><div class="NLM_p"><i>Step 1.</i> LDA (8.8 mL, 18 mmol) was added to a–78 °C solution of 1-ethyl-3-nitro-1<i>H</i>-pyrazole (1.9 g, 14 mmol) in tetrahydrofuran (41 mL). After 40 min, 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (3.8 mL, 19 mmol) was added and the reaction was stirred at −78 °C for 1 h. There was still starting material remaining so an additional 1 mL of LDA was added. After 1 h all of the starting material was consumed. The reaction mixture was gradually warmed to 0 °C before being quenched with water and AcOH (3.1 mL, 54 mmol). The mixture was then extracted with ethyl acetate (2 × 75 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give 1-ethyl-3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole as a brown oil. By <sup>1</sup>H NMR the isolated product is the pinacol ester but hydrolyzes to the boronic acid on LCMS. The product was used without further purification in the next step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.28 (s, 1H), 4.51 (q, <i>J</i> = 7.19 Hz, 2H), 1.49 (t, <i>J</i> = 7.26 Hz, 3H), 1.37 (s, 11H).</div><div class="NLM_p"><i>Step 2.</i> Cesium carbonate (9.0 g, 27.5 mmol), (6-chloropyridazin-3-yl)dicarbamic acid <i>tert</i>-butyl ester (3.6 g, 11 mmol), and 1-ethyl-3-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrazole (3.5 g, 13 mmol) were suspended in dioxane (55 mL), and the mixture was deoxygenated by bubbling argon through the suspension for 15 min. After degassing was complete, 1,1′-bis(di-<i>tert</i>-butylphosphino)ferrocene palladium dichloride (0.36 g, 0.55 mmol) and 1,1′-bis(di-<i>tert</i>-butylphosphino)ferrocene (0.37 g, 0.77 mmol) were added and the reaction vessel was sealed and heated to 80 °C for 2.5 h. At this time, LCMS analysis indicated predominantly the desired product with a small amount of unreacted chloropyridazine. The reaction mixture was diluted with ethyl acetate, filtered through Celite, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–50% ethyl acetate/hexanes, Isco 80 g column) to give the desired nitropyrazole (2.7 g, 6.2 mmol, 56% yield) as a tan amorphous solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77–7.82 (m, 1H), 7.71–7.76 (m, 1H), 7.26 (s, 1H), 4.85 (q, <i>J</i> = 7.12 Hz, 2H), 1.54–1.56 (m, 5H), 1.53 (s, 17H).</div><div class="NLM_p"><i>Step 3.</i> Palladium on carbon (10% Degussa type) (0.66 g, 0.62 mmol) was added to a flask containing a solution of the nitropyrazole product from step 2 (2.7 g, 6.2 mmol) in methanol (89 mL) that had been degassed and backfilled with argon. A hydrogen filled balloon was affixed to the flask, and the system was purged with hydrogen for 5 min. The reaction mixture was stirred under hydrogen balloon atmosphere for 3 h, purged with nitrogen, and filtered through Celite. The filtrate was concentrated in vacuo to give the aminopyrazole (2.2 g, 5.3 mmol, 86% yield) as an off-white solid. The product was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 9.02 Hz, 1H), 7.52 (d, <i>J</i> = 9.02 Hz, 1H), 6.00 (s, 1H), 4.56 (q, <i>J</i> = 7.19 Hz, 2H), 3.69 (s, 2H), 1.49 (s, 18H), 1.43 (t, <i>J</i> = 7.15 Hz, 3H).</div><div class="NLM_p"><i>Step 4.</i><i>tert</i>-Butyl nitrite (0.49 mL, 3.7 mmol) was added to a mixture of copper(I) bromide (0.53 g, 3.7 mmol) and lithium bromide (0.27 g, 3.1 mmol) in acetonitrile (18.5 mL). After 10 min this mixture was added to a flask containing a suspension of the aminopyrazole from step 3 (1.0 g, 2.5 mmol) in acetonitrile (6.2 mL). The reaction mixture was stirred at room temperature and after 1 h then heated with stirring at 50 °C for 2 h until the desired product predominated by LCMS analysis. The reaction mixture was diluted with ethyl acetate and then washed with saturated aqueous NaHCO<sub>3</sub> and then brine. The collected organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was purified on SiO<sub>2</sub> via Isco flash chromatography (0–50% ethyl acetate/heptane, Isco 40 g gold column) to give the bromopyrazole (0.67 g, 1.4 mmol, 58% yield) as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.70 (d, <i>J</i> = 8.8 Hz, 1H), 7.61 (d, <i>J</i> = 9.1 Hz, 1H), 6.65 (s, 1H), 4.72 (q, <i>J</i> = 7.2 Hz, 2H), 1.50 (s, 18H), 1.50–1.45 (m, 4H).</div><div class="NLM_p"><i>Step 5.</i> The bromopyrazole product from step 4 (0.25 g, 0.53 mmol), quinolin-8-ylboronic acid (0.10 g, 0.59 mmol), and cesium carbonate (0.44 g, 1.3 mmol) were suspended in dioxane (5.3 mL), and the mixture was degassed by bubbling argon through the suspension for 5 min. 1,1′-Bis(diphenylphosphino)ferrocene palladium dichloride (0.04 g, 0.05 mmol) was added, and the reaction vessel was sealed and heated to 100 °C for 2 h. The reaction mixture was cooled to room temperature, transferred to a round-bottom flask, and concentrated onto SiO<sub>2</sub> (sufficient quantity to give a free-flowing solid). This solid was purified on SiO<sub>2</sub> via Isco flash chromatography (0–100% ethyl acetate/hexanes, Isco 24 g column) to give the desired product (0.24 g, 0.46 mmol, 87% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.02 (dd, <i>J</i> = 4.1, 1.9 Hz, 1H), 8.42 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 8.23 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 1.3 Hz, 1H), 7.80 (s, 1H), 7.70–7.62 (m, 1H), 7.55 (d, <i>J</i> = 9.0 Hz, 1H), 7.46 (dd, <i>J</i> = 8.1, 4.2 Hz, 1H), 4.94 (q, <i>J</i> = 7.0 Hz, 2H), 1.61–1.56 (m, 3H), 1.49 (s, 18H).</div><div class="NLM_p last"><i>Step 6.</i> The product from step 5 (0.24 g, 0.46 mmol) was taken up in TFA (2.0 mL). After 2 h the excess TFA was removed in vacuo. The resulting solid was lyophilized from water to give the TFA salt of <b>69</b> (0.2 g, 0.46 mmol, 99% yield) as a pale-yellow solid. A portion of the product was further purified by preparative HPLC (Phenomenex Luna Axia 5 μm C18 30 mm × 100 mm column; mobile phase A = 10:90 methanol/water with 0.1% trifluoroacetic acid; mobile phase B = 90:10 methanol/water with 0.1% trifluoroacetic acid over 10 min). The desired fractions were partitioned between ethyl acetate and 1 M aqueous K<sub>2</sub>HPO<sub>4</sub>. The aqueous layer was further extracted with two small portions of ethyl acetate and the combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give a pale yellow solid. The solid was lyophilized from water to give <b>69</b>. MS (ESI) mass calculated for [M + H]<sup>+</sup> (C<sub>18</sub>H<sub>17</sub>N<sub>6</sub>) requires <i>m</i>/<i>z</i> 317.1, found 317.1; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.00 (dd, <i>J</i> = 1.9, 4.2 Hz, 1H), 8.38 (dd, <i>J</i> = 1.6, 7.3 Hz, 1H), 8.21 (dd, <i>J</i> = 1.9, 8.3 Hz, 1H), 7.81 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.70 (d, <i>J</i> = 9.2 Hz, 1H), 7.66–7.61 (m, 1H), 7.57 (s, 1H), 7.43 (dd, <i>J</i> = 4.1, 8.3 Hz, 1H), 6.85 (d, <i>J</i> = 9.1 Hz, 1H), 4.89–4.78 (m, 4H), 1.55 (t, <i>J</i> = 7.1 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 157.95, 149.80, 148.13, 146.21, 145.89, 138,64, 136.52, 131.96, 128.99, 128.70, 128.21, 127.74, 126.62, 120.83, 114.62, 109.02, 47.18, 16.90.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Functional Assays for the 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> Receptors</h3><div class="NLM_p last">HEK293E cells stably expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptors were maintained Dulbecco’s modified Eagle medium with high glucose (DMEM; Gibco BRL) containing 10% dialyzed fetal bovine serum (FBS) and 500 μg/mL G418 (Gibco BRL). The recombinant expression system expressed moderate levels of 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, or 5-HT<sub>2C</sub> receptors (∼400–795 fmol/mg of protein). The VNV isoform of 5HT<sub>2C</sub> was used for pharmacological studies.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The cells were lifted with 2 mL of Cellstripper (Mediatech/Cellgro) and plated at a density of (20 000 cells/25 μL)/well onto poly-<span class="smallcaps smallerCapital">d</span>-lysine-coated 384-well plates (Biocoat; Becton Dickinson, Bedford, MA) in phenol red free Dulbecco’s modified Eagle medium (DMEM; Gibco BRL) containing a high concentration of glucose without FBS. Following an overnight (∼15–18 h) incubation at 37 °C, the cell plates were removed from the incubator and dye loading buffer (25 μL of 1× Hanks BSS without calcium and magnesium with 25 mM HEPES) containing 5 μM calcium dye reagent Fluo-4 was added to each well. Following the dye loading of the cells for 1 h at room temperature, the cell plates were transferred to the FLIPR<sup>384</sup> (Molecular Devices, Sunnyvale, CA). Eleven concentrations of test compounds in 25 μL loading buffer were added to the cell plate on the FLIPR<sup>384</sup> to determine a concentration–response curve, and the changes in fluorescence units due to the elevation of intracellular calcium were monitored for a period of 90 s. The raw data from time sequence recording were normalized to the percentage response obtained from the positive control (serotonin 3 μM) on the same plate and analyzed to fit the four-parameter logistic equation in order to assess compound’s potency (EC<sub>50</sub>) and efficacy (intrinsic activity) from the 384-FLIPR agonist assay.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> Rat Pharmacokinetic Study</h3><div class="NLM_p last">All animal protocols were approved by the Bristol- Myers Squibb Co. Animal Care and Use Committee. Male Sprague Dawley rats obtained from Charles River Laboratories weighing between 200 and 250 g were used. Animals were allowed free access to a standard laboratory chow and water. They were housed in a constant temperature–humidity environment. Three rats were used in each of the intravenous (iv) and oral (po) arms of the studies. The vehicle consisted of polyethylene glycol 400/Tween 80/water (15:1:84, v/v). Blood was sampled from the jugular vein at 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 h after dose. Plasma was obtained after centrifugation of the blood samples. Following protein precipitation using acetonitrile and subsequent centrifugation, samples were analyzed using LC/MS–MS.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Rat 20 h Ad Libitum Feeding Assay</h3><div class="NLM_p last">All animal protocols were approved by the Bristol- Myers Squibb Co. Animal Care and Use Committee. Compounds were assessed for their ability to reduce food consumption during a 20 h period, which began at the onset of the dark cycle. Male Sprague Dawley rats, obtained from Charles River Laboratories, were trained in operant chambers (Coulbourn Instruments, Allentown, PA) equipped with a lever, a food hopper, a water bottle with photocells, and an infrared activity monitor. Rats were trained on a fixed ratio three (FR3) response paradigm which required three consecutive bar presses in order to obtain a food pellet (Research Diets custom 45 mg pellets (21.3% protein; 3.8% fat, 54% carbohydrate). The number of bar presses and pellets consumed serve as the measure of food intake by the animal. Rats (<i>n</i> = 6) were administered (po) test compound or vehicle (14% PPG, 1% Tween, 85% water, v/v) 60 min prior to the onset of the dark cycle. Treated animals were then placed in individual operant boxes for a 20 h period (12 h of dark cycle and the first 8 h of the light cycle). Percent reduction in food intake was calculated as the ratio of total food intake of drug-treated animals divided into the total food intake of vehicle-treated counterparts. Simultaneous measurements of water intake and locomotor activity are also measured during the period to evaluate potential adverse effects. Cumulative food intake was analyzed via repeated-measure between-group analysis of variance using StatView software (Scientific Computing, Cary, NC). Time points with overall significance were further analyzed with Bonferroni post hoc tests to determine between-group significance.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00385">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00385" class="ext-link">10.1021/acs.jmedchem.7b00385</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional data for compound <b>69</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_001.pdf">jm7b00385_si_001.pdf (553.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_002.csv">jm7b00385_si_002.csv (4.22 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00385" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11601" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11601" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Carpenter</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0885-1590" title="Orcid link">http://orcid.org/0000-0003-0885-1590</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#adc7c2dec8ddc583ceccdfddc8c3d9c8dfedefe0fe83cec2c0"><span class="__cf_email__" data-cfemail="462c293523362e6825273436232832233406040b156825292b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Wang</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d9a0b0b7bef7aeb8b7be99bbb4aaf7bab6b4"><span class="__cf_email__" data-cfemail="156c7c7b723b62747b72557778663b767a78">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean A. Wacker</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#adc9c8ccc383dacccec6c8dfedcfc0de83cec2c0"><span class="__cf_email__" data-cfemail="c5a1a0a4abebb2a4a6aea0b785a7a8b6eba6aaa8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Wu</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianxin Feng</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiang-Yang Ye</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3739-0930" title="Orcid link">http://orcid.org/0000-0003-3739-0930</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian L. Morales</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Broekema</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen A. Rossi</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Keith J. Miller</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian J. Murphy</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ginger Wu</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah E. Malmstrom</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony V. Azzara</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip M. Sher</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John M. Fevig</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Alt</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert L. Bertekap</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Jane Cullen</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy M. Harper</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kimberly Foster</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily Luk</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qian Xiang</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary F. Grubb</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey A. Robl</span> - <span class="hlFld-Affiliation affiliation">Departments of
Discovery Chemistry, Discovery Biology, Lead Evaluation, Computer-Assisted
Drug Design, Discovery Toxicology, and Pharmaceutical Candidate Optimization, Bristol-Myers Squibb, Pharmaceutical Research Institute, P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d123e8700-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Cindy Li and Purnima Khandelwal for assistance in structural assignments and elucidations.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i94" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i94"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i95" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i95"> Abbreviations Used</h2><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine, serotonin</p></td></tr><tr><td class="NLM_term">D</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">A</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">Phe</td><td class="NLM_def"><p class="first last">phenylalanine</p></td></tr><tr><td class="NLM_term">Tyr</td><td class="NLM_def"><p class="first last">tyrosine</p></td></tr><tr><td class="NLM_term">Trp</td><td class="NLM_def"><p class="first last">tryptophan</p></td></tr><tr><td class="NLM_term">Asp</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulator</p></td></tr><tr><td class="NLM_term">BMS</td><td class="NLM_def"><p class="first last">Bristol-Myers Squibb</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">HEK 293E</td><td class="NLM_def"><p class="first last">human embryonic kidney 293E cell</p></td></tr><tr><td class="NLM_term">mCPP</td><td class="NLM_def"><p class="first last"><i>m</i>-chlorophenylpiperazine</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">Caco-2</td><td class="NLM_def"><p class="first last">human epithelial colorectal adenocarcinoma cells</p></td></tr><tr><td class="NLM_term">Pgp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">Metstab</td><td class="NLM_def"><p class="first last">metabolic stability</p></td></tr><tr><td class="NLM_term"><i>b</i>/<i>p</i></td><td class="NLM_def"><p class="first last">brain to plasma ratio</p></td></tr><tr><td class="NLM_term">H/R</td><td class="NLM_def"><p class="first last">human/rat</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotnitzky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manson, J. E.</span><span> </span><span class="NLM_article-title">Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.7326/0003-4819-122-7-199504010-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.7326%2F0003-4819-122-7-199504010-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=7872581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A280%3ADyaK2M7nslCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1995&pages=481-486&author=G.+A.+Colditzauthor=W.+C.+Willettauthor=A.+Rotnitzkyauthor=J.+E.+Manson&title=Weight+Gain+as+a+Risk+Factor+for+Clinical+Diabetes+Mellitus+in+Women&doi=10.7326%2F0003-4819-122-7-199504010-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Weight gain as a risk factor for clinical diabetes mellitus in women</span></div><div class="casAuthors">Colditz G A; Willett W C; Rotnitzky A; Manson J E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-6</span>
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the relation between adult weight change and the risk for clinical diabetes mellitus among middle-aged women.  DESIGN:  Prospective cohort study with follow-up from 1976 to 1990.  SETTING:  11 U.S. states.  PARTICIPANTS:  114,281 female registered nurses aged 30 to 55 years who did not have diagnosed diabetes mellitus, coronary heart disease, stroke, or cancer in 1976.  OUTCOME MEASURES:  Non-insulin-dependent diabetes mellitus.  RESULTS:  2204 cases of diabetes were diagnosed during 1.49 million person-years of follow-up.  After adjustment for age, body mass index was the dominant predictor of risk for diabetes mellitus.  Risk increased with greater body mass index, and even women with average weight (body mass index, 24.0 kg/m2) had an elevated risk.  Compared with women with stable weight (those who gained or lost less than 5 kg between age 18 years and 1976) and after adjustment for age and body mass index at age 18 years, the relative risk for diabetes mellitus among women who had a weight gain of 5.0 to 7.9 kg was 1.9 (95% CI, 1.5 to 2.3).  The corresponding relative risk for women who gained 8.0 to 10.9 kg was 2.7 (CI, 2.1 to 3.3).  In contrast, women who lost more than 5.0 kg reduced their risk for diabetes mellitus by 50% or more.  These results were independent of family history of diabetes.  CONCLUSION:  The excess risk for diabetes with even modest and typical adult weight gain is substantial.  These findings support the importance of maintaining a constant body weight throughout adult life and suggest that the 1990 U.S.  Department of Agriculture guidelines that allow a substantial weight gain after 35 years of age are misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRR2XUFeYx_W3thwrmtH4OBfW6udTcc2eZipt4gvamQu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7nslCguw%253D%253D&md5=31abd02f5a2c9065f9afbeae5a50a03c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-122-7-199504010-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-122-7-199504010-00001%26sid%3Dliteratum%253Aachs%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DWillett%26aufirst%3DW.%2BC.%26aulast%3DRotnitzky%26aufirst%3DA.%26aulast%3DManson%26aufirst%3DJ.%2BE.%26atitle%3DWeight%2520Gain%2520as%2520a%2520Risk%2520Factor%2520for%2520Clinical%2520Diabetes%2520Mellitus%2520in%2520Women%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1995%26volume%3D122%26spage%3D481%26epage%3D486%26doi%3D10.7326%2F0003-4819-122-7-199504010-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Rexrode, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stampfer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich-Edwards, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speizer, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manson, J. E.</span><span> </span><span class="NLM_article-title">A Prospective Study of Body Mass Index, Weight Change, and Risk of Stroke in Women</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span><span class="refDoi"> DOI: 10.1001/jama.277.19.1539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1001%2Fjama.277.19.1539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=1539-1545&author=K.+M.+Rexrodeauthor=C.+H.+Hennekensauthor=W.+C.+Willettauthor=G.+A.+Colditzauthor=M.+J.+Stampferauthor=J.+W.+Rich-Edwardsauthor=F.+E.+Speizerauthor=J.+E.+Manson&title=A+Prospective+Study+of+Body+Mass+Index%2C+Weight+Change%2C+and+Risk+of+Stroke+in+Women&doi=10.1001%2Fjama.277.19.1539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1001%2Fjama.277.19.1539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.277.19.1539%26sid%3Dliteratum%253Aachs%26aulast%3DRexrode%26aufirst%3DK.%2BM.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DWillett%26aufirst%3DW.%2BC.%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DRich-Edwards%26aufirst%3DJ.%2BW.%26aulast%3DSpeizer%26aufirst%3DF.%2BE.%26aulast%3DManson%26aufirst%3DJ.%2BE.%26atitle%3DA%2520Prospective%2520Study%2520of%2520Body%2520Mass%2520Index%252C%2520Weight%2520Change%252C%2520and%2520Risk%2520of%2520Stroke%2520in%2520Women%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1997%26volume%3D277%26spage%3D1539%26epage%3D1545%26doi%3D10.1001%2Fjama.277.19.1539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mokdad, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinicor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bales, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. S.</span><span> </span><span class="NLM_article-title">Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1001/jama.289.1.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1001%2Fjama.289.1.76" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2003&pages=76-79&author=A.+H.+Mokdadauthor=E.+S.+Fordauthor=B.+A.+Bowmanauthor=W.+H.+Dietzauthor=F.+Vinicorauthor=V.+S.+Balesauthor=J.+S.+Marks&title=Prevalence+of+Obesity%2C+Diabetes%2C+and+Obesity-Related+Health+Risk+Factors%2C+2001&doi=10.1001%2Fjama.289.1.76"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1001%2Fjama.289.1.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.289.1.76%26sid%3Dliteratum%253Aachs%26aulast%3DMokdad%26aufirst%3DA.%2BH.%26aulast%3DFord%26aufirst%3DE.%2BS.%26aulast%3DBowman%26aufirst%3DB.%2BA.%26aulast%3DDietz%26aufirst%3DW.%2BH.%26aulast%3DVinicor%26aufirst%3DF.%26aulast%3DBales%26aufirst%3DV.%2BS.%26aulast%3DMarks%26aufirst%3DJ.%2BS.%26atitle%3DPrevalence%2520of%2520Obesity%252C%2520Diabetes%252C%2520and%2520Obesity-Related%2520Health%2520Risk%2520Factors%252C%25202001%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2003%26volume%3D289%26spage%3D76%26epage%3D79%26doi%3D10.1001%2Fjama.289.1.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span>National Center for Health Statistics. <a href="http://www.cdc.gov/nchs/fastats/overwt.htm" class="extLink">http://www.cdc.gov/nchs/fastats/overwt.htm</a> (accessed March<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Center+for+Health+Statistics.+http%3A%2F%2Fwww.cdc.gov%2Fnchs%2Ffastats%2Foverwt.htm+%28accessed+March+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span> </span><span class="NLM_article-title">Agonists of the Serotonin 5-HT<sub>2C</sub> Receptor: Preclinical and Clinical Progression in Multiple Diseases</span> <span class="citation_source-journal">Curr. Opin. Drug Disc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">438</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18600561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=438-445&author=D.+A.+Wackerauthor=K.+J.+Miller&title=Agonists+of+the+Serotonin+5-HT2C+Receptor%3A+Preclinical+and+Clinical+Progression+in+Multiple+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases</span></div><div class="casAuthors">Wacker, Dean A.; Miller, Keith J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-445</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  The serotonin 5-HT2C receptor is a G-protein-coupled receptor and is 1 of the 14 subtypes that constitute the serotonin receptor family.  Agonists of 5-HT2C have been implicated as potential treatments for diseases of significant unmet medical need, including obesity and schizophrenia.  Despite approx. 10 years of discovery efforts, 5-HT2C agonists have only recently advanced into the clinic, likely because many of the early drug discovery efforts experienced significant difficulties with attaining receptor selectivity.  Several of these issues related to receptor selectivity have now been overcome, resulting in the entry of compds. into advanced clin. trials.  This review summarizes the progress in 5-HT2C agonist discovery and clin. development over the last 3 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eDgqANEVarVg90H21EOLACvtfcHk0lhHH3kASgwhcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D&md5=cd06a22cee150e5a0c658a4ce8876151</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26atitle%3DAgonists%2520of%2520the%2520Serotonin%25205-HT2C%2520Receptor%253A%2520Preclinical%2520and%2520Clinical%2520Progression%2520in%2520Multiple%2520Diseases%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Disc.%26date%3D2008%26volume%3D11%26spage%3D438%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Berger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The Expanded Biology of Serotonin</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1146/annurev.med.60.042307.110802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1146%2Fannurev.med.60.042307.110802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=19630576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=355-366&author=M.+Bergerauthor=J.+A.+Grayauthor=B.+L.+Roth&title=The+Expanded+Biology+of+Serotonin&doi=10.1146%2Fannurev.med.60.042307.110802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The expanded biology of serotonin</span></div><div class="casAuthors">Berger, Miles; Gray, John A.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a wide range of neuropsychol. processes, and drugs that target serotonin receptors are used widely in psychiatry and neurol.  However, most serotonin is found outside the central nervous system, and virtually all of the 15 serotonin receptors are expressed outside as well as within the brain.  Serotonin regulates numerous biol. processes including cardiovascular function, bowel motility, ejaculatory latency, and bladder control.  Addnl., new work suggests that serotonin may regulate some processes, including platelet aggregation, by receptor-independent, transglutaminase-dependent covalent linkage to cellular proteins.  We review this new expanded serotonin biol. and discuss how drugs targeting specific serotonin receptors are beginning to help treat a wide range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoz0HW5hdNOrVg90H21EOLACvtfcHk0ljmAcoGlXnLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D&md5=0557e01e6b79dbfb50559aca03f8b31f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.60.042307.110802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.60.042307.110802%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520Expanded%2520Biology%2520of%2520Serotonin%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2009%26volume%3D60%26spage%3D355%26epage%3D366%26doi%3D10.1146%2Fannurev.med.60.042307.110802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, C. D.</span><span> </span><span class="NLM_article-title">Serotonin Receptors</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1614</span><span class="NLM_x">–</span> <span class="NLM_lpage">1641</span><span class="refDoi"> DOI: 10.1021/cr078224o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr078224o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslOisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=1614-1641&author=D.+E.+Nicholsauthor=C.+D.+Nichols&title=Serotonin+Receptors&doi=10.1021%2Fcr078224o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin Receptors</span></div><div class="casAuthors">Nichols, David E.; Nichols, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1614-1641</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on phylogeny, structural features, oligomerization, classification and functions of serotonin receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnlR5CHbuX7Vg90H21EOLACvtfcHk0ljmAcoGlXnLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslOisL8%253D&md5=55b70829f6be71cbfe4de05c5ef665d8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcr078224o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr078224o%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DNichols%26aufirst%3DC.%2BD.%26atitle%3DSerotonin%2520Receptors%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D1614%26epage%3D1641%26doi%3D10.1021%2Fcr078224o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Voigt, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, H.</span><span> </span><span class="NLM_article-title">Serotonin Controlling Feeding and Satiety</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1016/j.bbr.2014.08.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.bbr.2014.08.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=25217810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2015&pages=14-31&author=J.-P.+Voigtauthor=H.+Fink&title=Serotonin+Controlling+Feeding+and+Satiety&doi=10.1016%2Fj.bbr.2014.08.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin controlling feeding and satiety</span></div><div class="casAuthors">Voigt, Jorg-Peter; Fink, Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-31</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Serotonin has been implicated in the control of satiety for almost four decades.  Historically, the insight that the appetite suppressant effect of fenfluramine is linked to serotonin has stimulated interest in and research into the role of this neurotransmitter in satiety.  Various rodent models, including transgenic models, have been developed to identify the involved 5-HT receptor subtypes.  This approach also required the availability of receptor ligands of different selectivity, and behavioral techniques had to be developed simultaneously which allow differentiating between unspecific pharmacol. effects of these ligands and 'true' satiation and satiety.  Currently, 5-HT1B, 5-HT2C and 5-HT6 receptors have been identified to mediate serotonergic satiety in different ways.  The recently approved anti-obesity drug lorcaserin is a 5-HT2C receptor agonist.  In brain, both hypothalamic (arcuate nucleus, paraventricular nucleus) and extrahypothalamic sites (parabrachial nucleus, nucleus of the solitary tract) have been identified to mediate the serotonergic control of satiety.  Serotonin interacts within the hypothalamus with endogenous orexigenic (Neuropeptide Y/Agouti related protein) and anorectic (α-MSH) peptides.  In the nucleus of the solitary tract serotonin integrates peripheral satiety signals.  Here, the 5-HT3, but possibly also the 5-HT2C receptor play a role.  It has been found that 5-HT acts in concert with such peripheral signals as cholecystokinin and leptin.  Despite the recent advances of our knowledge, many of the complex interactions between 5-HT and other satiety factors are not fully understood yet.  Further progress in research will also advance the development of new serotonergic anti-obesity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2j0oo8j1SeLVg90H21EOLACvtfcHk0ljmAcoGlXnLcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurvP&md5=39612744b52db70f329e69917d4707d7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2014.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2014.08.065%26sid%3Dliteratum%253Aachs%26aulast%3DVoigt%26aufirst%3DJ.-P.%26aulast%3DFink%26aufirst%3DH.%26atitle%3DSerotonin%2520Controlling%2520Feeding%2520and%2520Satiety%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2015%26volume%3D277%26spage%3D14%26epage%3D31%26doi%3D10.1016%2Fj.bbr.2014.08.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Smith, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieto, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallardo, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saldana, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzaghi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeley, N. R.</span><span> </span><span class="NLM_article-title">Discovery and SAR of New Benzazepines as Potent and Selective 5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1470</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.12.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.bmcl.2004.12.080" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1467-1470&author=B.+M.+Smithauthor=J.+M.+Smithauthor=J.+H.+Tsaiauthor=J.+A.+Schultzauthor=C.+A.+Gilsonauthor=S.+A.+Estradaauthor=R.+R.+Chenauthor=D.+M.+Parkauthor=E.+B.+Prietoauthor=C.+S.+Gallardoauthor=D.+Senguptaauthor=W.+J.+Thomsenauthor=H.+R.+Saldanaauthor=K.+T.+Whelanauthor=F.+Menzaghiauthor=R.+R.+Webbauthor=N.+R.+Beeley&title=Discovery+and+SAR+of+New+Benzazepines+as+Potent+and+Selective+5-HT2C+Receptor+Agonists+for+the+Treatment+of+Obesity&doi=10.1016%2Fj.bmcl.2004.12.080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.12.080%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BM.%26aulast%3DTsai%26aufirst%3DJ.%2BH.%26aulast%3DSchultz%26aufirst%3DJ.%2BA.%26aulast%3DGilson%26aufirst%3DC.%2BA.%26aulast%3DEstrada%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DR.%2BR.%26aulast%3DPark%26aufirst%3DD.%2BM.%26aulast%3DPrieto%26aufirst%3DE.%2BB.%26aulast%3DGallardo%26aufirst%3DC.%2BS.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26aulast%3DSaldana%26aufirst%3DH.%2BR.%26aulast%3DWhelan%26aufirst%3DK.%2BT.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DWebb%26aufirst%3DR.%2BR.%26aulast%3DBeeley%26aufirst%3DN.%2BR.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520New%2520Benzazepines%2520as%2520Potent%2520and%2520Selective%25205-HT2C%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1467%26epage%3D1470%26doi%3D10.1016%2Fj.bmcl.2004.12.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Thomsen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grottick, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzaghi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Saldana, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espitia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuskin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. J.</span><span> </span><span class="NLM_article-title">Lorcaserin, a Novel Selective Human 5-hydroxytryptamine2C Agonist: In Vitro and In Vivo Pharmacological Characterization</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1124/jpet.107.133348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1124%2Fjpet.107.133348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18252809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=577-587&author=W.+J.+Thomsenauthor=A.+J.+Grottickauthor=F.+Menzaghiauthor=H.+Reyes-Saldanaauthor=S.+Espitiaauthor=D.+Yuskinauthor=K.+Whelanauthor=M.+Martinauthor=M.+Morganauthor=W.+Chenauthor=H.+Al-Shammaauthor=B.+Smithauthor=D.+Chalmersauthor=D.+J.+Behan&title=Lorcaserin%2C+a+Novel+Selective+Human+5-hydroxytryptamine2C+Agonist%3A+In+Vitro+and+In+Vivo+Pharmacological+Characterization&doi=10.1124%2Fjpet.107.133348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization</span></div><div class="casAuthors">Thomsen, William J.; Grottick, Andrew J.; Menzaghi, Frederique; Reyes-Saldana, Hazel; Espitia, Stephen; Yuskin, Diane; Whelan, Kevin; Martin, Michael; Morgan, Michael; Chen, Weichao; Al-Shamma, Hussein; Smith, Brian; Chalmers, Derek; Behan, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">5-Hydroxytryptamine (5-HT)2C receptor agonists hold promise for the treatment of obesity.  In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT2C full agonist.  Lorcaserin bound to human and rat 5-HT2C receptors with high affinity (Ki = 15±1 nM, 29±7 nM, resp.), and it was a full agonist for the human 5-HT2C receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT2A and 5-HT2B receptors, resp.  Lorcaserin was also highly selective for human 5-HT2C over other human 5-HT receptors (5-HT1A, 5-HT3, 5-HT4C, 5-HT55A, 5-HT6, and 5-HT7), in addn. to a panel of 67 other G protein-coupled receptors and ion channels.  Lorcaserin did not compete for binding of ligands to serotonin, dopamine, and norepinephrine transporters, and it did not alter their function in vitro.  Behavioral observations indicated that unlike the 5-HT2A agonist (±)-1-(2,5-dimethoxy-4-phenyl)-2-aminopropane, lorcaserin did not induce behavioral changes indicative of functional 5-HT2A agonist activity.  Acutely, lorcaserin reduced food intake in rats, an effect that was reversed by pretreatment with the 5-HT2C-selective antagonist 6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl-carbamoyl]indoline (SB242,084) but not the 5-HT2A antagonist (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL 100,907), demonstrating mediation by the 5-HT2C receptor.  Chronic daily treatment with lorcaserin to rats maintained on a high fat diet produced dose-dependent redns. in food intake and body wt. gain that were maintained during the 4-wk study.  Upon discontinuation, body wt. returned to control levels.  These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT2C receptor, with potential for the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDHE28aF3k7Vg90H21EOLACvtfcHk0li9aRoePO7wsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D&md5=0626c3dabb7e89066e45ecd12cbc81f8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.133348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.133348%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DReyes-Saldana%26aufirst%3DH.%26aulast%3DEspitia%26aufirst%3DS.%26aulast%3DYuskin%26aufirst%3DD.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DChalmers%26aufirst%3DD.%26aulast%3DBehan%26aufirst%3DD.%2BJ.%26atitle%3DLorcaserin%252C%2520a%2520Novel%2520Selective%2520Human%25205-hydroxytryptamine2C%2520Agonist%253A%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Pharmacological%2520Characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D577%26epage%3D587%26doi%3D10.1124%2Fjpet.107.133348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Aghajanian, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">Serotonin and Hallucinogens</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">16S</span><span class="NLM_x">–</span> <span class="NLM_lpage">23S</span><span class="refDoi"> DOI: 10.1016/S0893-133X(98)00135-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2FS0893-133X%2898%2900135-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=16S-23S&author=G.+K.+Aghajanianauthor=G.+J.+Marek&title=Serotonin+and+Hallucinogens&doi=10.1016%2FS0893-133X%2898%2900135-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2898%2900135-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252898%252900135-3%26sid%3Dliteratum%253Aachs%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DSerotonin%2520and%2520Hallucinogens%26jtitle%3DNeuropsychopharmacology%26date%3D1999%26volume%3D21%26spage%3D16S%26epage%3D23S%26doi%3D10.1016%2FS0893-133X%2898%2900135-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Nichols, D. E.</span><span> </span><span class="NLM_article-title">Hallucinogens</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.pharmthera.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=14761703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=131-181&author=D.+E.+Nichols&title=Hallucinogens&doi=10.1016%2Fj.pharmthera.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Hallucinogens</span></div><div class="casAuthors">Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes.  They are considered physiol. safe and do not produce dependence or addiction.  Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts.  In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain.  These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, esp. those expressed on neocortical pyramidal cells.  Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents.  These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC).  In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metab., and correlations have been developed between activity in specific brain areas and psychol. elements of the ASC produced by hallucinogens.  The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research.  In addn., it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRl6lKmZ_4Y7Vg90H21EOLACvtfcHk0li9aRoePO7wsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D&md5=7b5246f6479d76736c5a7223c60a9e99</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DHallucinogens%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D101%26spage%3D131%26epage%3D181%26doi%3D10.1016%2Fj.pharmthera.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Evidence for Possible Involvement of 5-HT(2B) Receptors in the Cardiac Valvulopathy Associated with Fenfluramine and Other Serotonergic Medications</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2836</span><span class="NLM_x">–</span> <span class="NLM_lpage">2841</span><span class="refDoi"> DOI: 10.1161/01.CIR.102.23.2836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1161%2F01.CIR.102.23.2836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=11104741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=2836-2841&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=J.+E.+Savageauthor=L.+Rauserauthor=A.+McBrideauthor=S.+J.+Hufeisenauthor=B.+L.+Roth&title=Evidence+for+Possible+Involvement+of+5-HT%282B%29+Receptors+in+the+Cardiac+Valvulopathy+Associated+with+Fenfluramine+and+Other+Serotonergic+Medications&doi=10.1161%2F01.CIR.102.23.2836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.; Savage, Jason E.; Rauser, Laura; McBride, Ace; Hufeisen, Sandra J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2836-2841</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are being investigated as treatments for drug dependence.  The occurrence of fenfluramine-assocd. valvular heart disease (VHD) has raised concerns that other serotonergic medications might also increase the risk of developing VHD.  We hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis.  Medications known or suspected to cause VHD (pos. controls) and medications not assocd. with VHD (neg. controls) were screened for activity at 11 cloned serotonin receptor subtypes by use of ligand-binding methods and functional assays.  The pos. control drugs were (±)-fenfluramine; (+)-fenfluramine; (-)-fenfluramine; its metabolites (±)-norfenfluramine, (+)-norfenfluramine, and (-)-norfenfluramine; ergotamine; and methysergide and its metabolite methylergonovine.  The neg. control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpiperazine.  (±)-, (+)-, And (-)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT2B receptor and were partial to full agonists at the 5-HT2B receptor.  Our data imply that activation of 5-HT2B receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT2B receptors are unlikely to produce VHD.  We suggest that all clin. available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at 5-HT2B receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6spUXOCLtLrVg90H21EOLACvtfcHk0lhicbNQPLCRlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D&md5=6b8c6059885dd9b058859089914c61b3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.102.23.2836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.102.23.2836%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DEvidence%2520for%2520Possible%2520Involvement%2520of%25205-HT%25282B%2529%2520Receptors%2520in%2520the%2520Cardiac%2520Valvulopathy%2520Associated%2520with%2520Fenfluramine%2520and%2520Other%2520Serotonergic%2520Medications%26jtitle%3DCirculation%26date%3D2000%26volume%3D102%26spage%3D2836%26epage%3D2841%26doi%3D10.1161%2F01.CIR.102.23.2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corjay, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbaszade, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartig, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meunier, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. W.</span><span> </span><span class="NLM_article-title">Possible Role of Valvular Serotonin 5-HT<sub>2B</sub> Receptors in the Cardiopathy Associated with Fenfluramine</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10617681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=75-81&author=L.+W.+Fitzgeraldauthor=T.+C.+Burnauthor=B.+S.+Brownauthor=J.+P.+Pattersonauthor=M.+H.+Corjayauthor=P.+A.+Valentineauthor=J.+H.+Sunauthor=J.+R.+Linkauthor=I.+Abbaszadeauthor=J.+M.+Hollisauthor=B.+L.+Largentauthor=P.+R.+Hartigauthor=G.+F.+Hollisauthor=P.+C.+Meunierauthor=A.+J.+Robichaudauthor=D.+W.+Robertson&title=Possible+Role+of+Valvular+Serotonin+5-HT2B+Receptors+in+the+Cardiopathy+Associated+with+Fenfluramine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Burn, Timothy C.; Brown, Barry S.; Patterson, John P.; Corjay, Martha H.; Valentine, Patricia A.; Sun, Jung-Hui; Link, John R.; Abbaszade, Ilgar; Hollis, Jeannine M.; Largent, Brian L.; Hartig, Paul R.; Hollis, Gregory F.; Meunier, Paul C.; Robichaud, Albert J.; Robertson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dexfenfluramine was approved in the United States for longterm use as an appetite suppressant until it was reported to be assocd. with valvular heart disease.  The valvular changes (myofibroblast proliferation) are histopathol. indistinguishable from those obsd. in carcinoid disease or after long-term exposure to 5-hydroxytryptamine (5-HT)2-preferring ergot drugs (ergotamine, methysergide).  5-HT2 receptor stimulation is known to cause fibroblast mitogenesis, which could contribute to this lesion.  To elucidate the mechanism of "fenphen"-assocd. valvular lesions, we examd. the interaction of fenfluramine and its metabolite norfenfluramine with 5-HT2 receptor subtypes and examd. the expression of these receptors in human and porcine heart valves.  Fenfluramine binds weakly to 5-HT2A, 5-HT2B, and 5-HT2C receptors.  In contrast, norfenfluramine exhibited high affinity for 5-HT2B and 5-HT2C receptors and more moderate affinity for 5-HT2A receptors.  In cells expressing recombinant 5-HT2B receptors, norfenfluramine potently stimulated the hydrolysis of inositol phosphates, increased intracellular Ca2+, and activated the mitogen-activated protein kinase cascade, the latter of which has been linked to mitogenic actions of the 5-HT2B receptor.  The level of 5-HT2B and 5-HT2A receptor transcripts in heart valves was at least 300-fold higher than the levels of 5-HT2C receptor transcript, which were barely detectable.  We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmkbFOXGVxcLVg90H21EOLACvtfcHk0lhicbNQPLCRlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D&md5=b99b778d0de695d377aa4f0006b6dc47</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DBrown%26aufirst%3DB.%2BS.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DCorjay%26aufirst%3DM.%2BH.%26aulast%3DValentine%26aufirst%3DP.%2BA.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DLink%26aufirst%3DJ.%2BR.%26aulast%3DAbbaszade%26aufirst%3DI.%26aulast%3DHollis%26aufirst%3DJ.%2BM.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26aulast%3DHollis%26aufirst%3DG.%2BF.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26atitle%3DPossible%2520Role%2520of%2520Valvular%2520Serotonin%25205-HT2B%2520Receptors%2520in%2520the%2520Cardiopathy%2520Associated%2520with%2520Fenfluramine%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D75%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Drugs and Valvular Heart Disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1056/NEJMp068265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1056%2FNEJMp068265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=17202450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=6-9&author=B.+L.+Roth&title=Drugs+and+Valvular+Heart+Disease&doi=10.1056%2FNEJMp068265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and valvular heart disease</span></div><div class="casAuthors">Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaFEwabTP8rVg90H21EOLACvtfcHk0lhicbNQPLCRlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D&md5=e5161a25f1a2596cef68030f0f8a7b61</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMp068265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp068265%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDrugs%2520and%2520Valvular%2520Heart%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D6%26epage%3D9%26doi%3D10.1056%2FNEJMp068265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT<sub>2C</sub>) Receptor Agonists for the Treatment of CNS Disorders</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1963</span><span class="NLM_x">–</span> <span class="NLM_lpage">1967</span><span class="refDoi"> DOI: 10.1002/cmdc.201500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1002%2Fcmdc.201500437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=26507582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1963-1967&author=J.+Chengauthor=A.+P.+Kozikowski&title=We+Need+2C+but+Not+2B%3A+Developing+Serotonin+2C+%285-HT2C%29+Receptor+Agonists+for+the+Treatment+of+CNS+Disorders&doi=10.1002%2Fcmdc.201500437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders</span></div><div class="casAuthors">Cheng, Jianjun; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serotonin 2C (5-HT2C) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia.  In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group.  Challenges in this field and the possible future directions are described.  Homol. modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed.  Compared to known ligands, the improved pharmacol. profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr43VsLXn0mBLVg90H21EOLACvtfcHk0lg7uRXoxTxGGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J&md5=4a7f2040f4c57da292c7ebac2de8d726</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWe%2520Need%25202C%2520but%2520Not%25202B%253A%2520Developing%2520Serotonin%25202C%2520%25285-HT2C%2529%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520CNS%2520Disorders%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fcmdc.201500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bray, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, W. A.</span><span> </span><span class="NLM_article-title">The Structure of Human Serotonin 2C G-Protein-Coupled Receptor Bound to Agonists and Antagonists</span> <span class="citation_source-journal">J. Mol. Graphics Modell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.jmgm.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.jmgm.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18499489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVejsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=66-81&author=J.+K.+Brayauthor=W.+A.+Goddard&title=The+Structure+of+Human+Serotonin+2C+G-Protein-Coupled+Receptor+Bound+to+Agonists+and+Antagonists&doi=10.1016%2Fj.jmgm.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists</span></div><div class="casAuthors">Bray, Jenelle K.; Goddard, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-81</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The authors used the MembStruk computational procedure to predict the three-dimensional (3D) structure for the serotonin 5-HT2C G-protein-coupled receptor (GPCR).  Using this structure, the authors used the MSCDock computational procedure to predict the 3D structures for bound ligand-protein complexes for agonists such as serotonin and antagonists such as ritanserin, metergoline, and methiothepin.  In addn., the authors predicted the SAR data for a series of psilocybin analogs, both agonists and antagonists.  The authors performed mol. dynamics (MD) on serotonin bound to 5-HT2C and the authors find the protein and binding site to be stable after 5 ns.  The authors find good agreement with the currently known exptl. data and the authors predict a no. of new mutations which could be used to validate further the authors' predicted structures.  This agreement between theory and expt. suggests that the authors' 3D structure is sufficiently accurate for use in drug design.  The authors also compare a preliminary prediction for 5-HT2B with the authors' prediction for 5-HT2C and find a difference in TM5 that contributes to different serotonin binding modes in 5-HT2B and 5-HT2C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhAD9j85USf7Vg90H21EOLACvtfcHk0lg7uRXoxTxGGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVejsbzP&md5=a2d42e43b0e18604c0b81f1524cc9700</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DJ.%2BK.%26aulast%3DGoddard%26aufirst%3DW.%2BA.%26atitle%3DThe%2520Structure%2520of%2520Human%2520Serotonin%25202C%2520G-Protein-Coupled%2520Receptor%2520Bound%2520to%2520Agonists%2520and%2520Antagonists%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2008%26volume%3D27%26spage%3D66%26epage%3D81%26doi%3D10.1016%2Fj.jmgm.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Dunlop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coupet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazandarani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawoschik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangalos, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramamoorthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schechter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span> </span><span class="NLM_article-title">Characterization of Vabicaserin (SCA-136), a Selective 5-Hydroxytryptamine 2C Receptor Agonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">680</span><span class="refDoi"> DOI: 10.1124/jpet.111.179572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1124%2Fjpet.111.179572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=21402690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=673-680&author=J.+Dunlopauthor=S.+W.+Wattsauthor=J.+E.+Barrettauthor=J.+Coupetauthor=B.+Harrisonauthor=H.+Mazandaraniauthor=S.+Nawoschikauthor=M.+N.+Pangalosauthor=S.+Ramamoorthyauthor=L.+Schechterauthor=D.+Smithauthor=G.+Stackauthor=J.+Zhangauthor=G.+Zhangauthor=S.+Rosenzweig-Lipson&title=Characterization+of+Vabicaserin+%28SCA-136%29%2C+a+Selective+5-Hydroxytryptamine+2C+Receptor+Agonist&doi=10.1124%2Fjpet.111.179572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist</span></div><div class="casAuthors">Dunlop, John; Watts, Stephanie W.; Barrett, James E.; Coupet, Joseph; Harrison, Boyd; Mazandarani, Hossein; Nawoschik, Stanley; Pangalos, Menelas N.; Ramamoorthy, Siva; Schechter, Lee; Smith, Deborah; Stack, Gary; Zhang, Jean; Zhang, Guoming; Rosenzweig-Lipson, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-680</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The 5-hydroxytryptamine 2C (5-HT2C) receptor subtype has received considerable attention as a target for drug discovery, having been implicated in a wide variety of disorders.  Here, we describe the in vitro pharmacol. profile of the novel 5-HT2C receptor-selective agonist vabicaserin [(-)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c] [1,4]diazepino[6,7,1-ij]quinoline hydrochloride] (SCA-136), including a comprehensive strategy to assess 5-HT2B receptor selectivity using diverse prepns. and assays of receptor activation.  Vabicaserin displaced 125I-(2,5-dimethoxy)phenylisopropylamine binding from human 5-HT2C receptor sites in Chinese hamster ovary cell membranes with a Ki value of 3 nM and was > 50-fold selective over a no. of serotonergic, noradrenergic, and dopaminergic receptors.  Binding affinity detd. for the human 5-HT2B receptor subtype using [3H]5HT was 14 nM.  Vabicaserin was a potent and full agonist (EC50, 8 nM; Emax, 100%) in stimulating 5-HT2C receptor-coupled calcium mobilization and exhibited 5-HT2A receptor antagonism and 5-HT2B antagonist or partial agonist activity in transfected cells, depending on the level of receptor expression.  In rat stomach fundus and human colonic longitudinal muscle endogenously expressing 5-HT2B receptors, vabicaserin failed to induce a 5-HT2B receptor-dependent contraction and produced a rightward shift of the 5-HT and α-methyl-5-HT concn.-response curves in these prepns., resp., consistent with 5-HT2B competitive antagonism.  Likewise, vabicaserin failed to induce a 5-HT2B receptor-mediated contraction in arteries from deoxycorticosterone acetate-salt-treated rats, a model of hypersensitized 5-HT2B receptor function, and produced a rightward shift in the 5-HT-induced response that was consistent with 5-HT2B receptor antagonism.  In summary, vabicaserin is a novel, potent, and selective 5-HT2C receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCYu5_bxpVxbVg90H21EOLACvtfcHk0lg7uRXoxTxGGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeiur8%253D&md5=0426498cda326da150beedcebcb56aa5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.179572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.179572%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DWatts%26aufirst%3DS.%2BW.%26aulast%3DBarrett%26aufirst%3DJ.%2BE.%26aulast%3DCoupet%26aufirst%3DJ.%26aulast%3DHarrison%26aufirst%3DB.%26aulast%3DMazandarani%26aufirst%3DH.%26aulast%3DNawoschik%26aufirst%3DS.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26aulast%3DRamamoorthy%26aufirst%3DS.%26aulast%3DSchechter%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520Vabicaserin%2520%2528SCA-136%2529%252C%2520a%2520Selective%25205-Hydroxytryptamine%25202C%2520Receptor%2520Agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D673%26epage%3D680%26doi%3D10.1124%2Fjpet.111.179572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunlop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, K. L.</span><span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> Receptor Agonists as an Innovative Approach for Psychiatric Disorders</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1358/dnp.2007.20.9.1162244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1358%2Fdnp.2007.20.9.1162244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18176661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitFKiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=565-571&issue=9&author=S.+Rosenzweig-Lipsonauthor=J.+Dunlopauthor=K.+L.+Marquis&title=5-HT2C+Receptor+Agonists+as+an+Innovative+Approach+for+Psychiatric+Disorders&doi=10.1358%2Fdnp.2007.20.9.1162244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C receptor agonists as an innovative approach for psychiatric disorders</span></div><div class="casAuthors">Rosenzweig-Lipson, Sharon; Dunlop, John; Marquis, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">565-571</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Modulating activity at the 5-HT2C receptor holds a tremendous amt. of therapeutic promise in multiple psychiatric indications.  However, the signaling and regulation of the 5-HT2C receptor is highly complex due to multiple signaling pathways and agonist-directed trafficking of this receptor.  Moreover, the 5-HT2C receptor is differentially regulated via RNA editing in multiple psychiatric disorders and following either pharmacol. or environmental manipulation.  Direct and indirect data suggest that both agonists and antagonists may provide benefits in several disorders.  The current review highlights the underlying complexities of this area and provides the rationale for using 5-HT2C agonists in the treatment of both schizophrenia and depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_al0DDqbYmrVg90H21EOLACvtfcHk0lgmiFfef4bwWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitFKiurY%253D&md5=0b70b5f0ac66823e26b2f7a82651e7d3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2007.20.9.1162244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2007.20.9.1162244%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DMarquis%26aufirst%3DK.%2BL.%26atitle%3D5-HT2C%2520Receptor%2520Agonists%2520as%2520an%2520Innovative%2520Approach%2520for%2520Psychiatric%2520Disorders%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2007%26volume%3D20%26issue%3D9%26spage%3D565%26epage%3D571%26doi%3D10.1358%2Fdnp.2007.20.9.1162244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malmstrom, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ung, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuvich, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janovitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehman-McKeeman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devenny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span> </span><span class="NLM_article-title">Discovery of (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a Selective, Orally Active Agonist of the 5-HT<sub>2C</sub> Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1379</span><span class="refDoi"> DOI: 10.1021/jm0612968</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0612968" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1365-1379&author=D.+A.+Wackerauthor=J.+G.+Varnesauthor=S.+E.+Malmstromauthor=X.+Caoauthor=C.+P.+Hungauthor=T.+Ungauthor=G.+Wuauthor=G.+Zhangauthor=E.+Zuvichauthor=M.+A.+Thomasauthor=W.+J.+Keimauthor=M.+J.+Cullenauthor=K.+W.+Rohrbachauthor=Q.+Quauthor=R.+Narayananauthor=K.+Rossiauthor=E.+Janovitzauthor=L.+Lehman-McKeemanauthor=M.+F.+Malleyauthor=J.+Devennyauthor=M.+A.+Pelleymounterauthor=K.+J.+Millerauthor=J.+A.+Robl&title=Discovery+of+%28R%29-9-Ethyl-1%2C3%2C4%2C10b-tetrahydro-7-trifluoromethylpyrazino%5B2%2C1-a%5Disoindol-+6%282H%29-one%2C+a+Selective%2C+Orally+Active+Agonist+of+the+5-HT2C+Receptor&doi=10.1021%2Fjm0612968"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm0612968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0612968%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DMalmstrom%26aufirst%3DS.%2BE.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHung%26aufirst%3DC.%2BP.%26aulast%3DUng%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZuvich%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DM.%2BA.%26aulast%3DKeim%26aufirst%3DW.%2BJ.%26aulast%3DCullen%26aufirst%3DM.%2BJ.%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DQu%26aufirst%3DQ.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DRossi%26aufirst%3DK.%26aulast%3DJanovitz%26aufirst%3DE.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%26aulast%3DMalley%26aufirst%3DM.%2BF.%26aulast%3DDevenny%26aufirst%3DJ.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520%2528R%2529-9-Ethyl-1%252C3%252C4%252C10b-tetrahydro-7-trifluoromethylpyrazino%255B2%252C1-a%255Disoindol-%25206%25282H%2529-one%252C%2520a%2520Selective%252C%2520Orally%2520Active%2520Agonist%2520of%2520the%25205-HT2C%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1365%26epage%3D1379%26doi%3D10.1021%2Fjm0612968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Briner, K.; Burkholder, T. P.; Heiman, M. L.; Nelson, D. L. G.</span><span> </span><span class="NLM_article-title">Preparation of 1-(4-Trifluoromethylbenzofur-7-yl)piperazines Useful as Serotonin Agonists</span>. PCT Int. Appl. WO2001009123 A1,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">, </span>(Eli Lilly and Co., U.S.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=K.+Briner&author=T.+P.+Burkholder&author=M.+L.+Heiman&author=D.+L.+G.+Nelson&title=Preparation+of+1-%284-Trifluoromethylbenzofur-7-yl%29piperazines+Useful+as+Serotonin+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBriner%26aufirst%3DK.%26atitle%3DPreparation%2520of%25201-%25284-Trifluoromethylbenzofur-7-yl%2529piperazines%2520Useful%2520as%2520Serotonin%2520Agonists%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Jackson, M.; Hester, B.,  Jr.</span><span> </span><span class="NLM_article-title">6-Alkyl-1,2,3,4,5,6-hexahydrozepino[4,5-b]indoles</span>. U.S. Patent US3652588 A,<span class="NLM_x"> </span><span class="NLM_year">1972</span><span class="NLM_x">, </span>(The Upjohn Company).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1972&author=M.+Jackson&author=B.+Hester&title=6-Alkyl-1%2C2%2C3%2C4%2C5%2C6-hexahydrozepino%5B4%2C5-b%5Dindoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DM.%26atitle%3D6-Alkyl-1%252C2%252C3%252C4%252C5%252C6-hexahydrozepino%255B4%252C5-b%255Dindoles%26date%3D1972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Savage, D. S.; Sleigh, T.; Kellock, J.</span><span> </span><span class="NLM_article-title">Pharmaceutical 4-aminobenzo[b]biclyco[3.3.1]nonene Derivatives</span>. Ger. Offen. DE 2747987 A1,<span class="NLM_x"> </span><span class="NLM_year">1978</span><span class="NLM_x">, </span>(Organon).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1978&author=D.+S.+Savage&author=T.+Sleigh&author=J.+Kellock&title=Pharmaceutical+4-aminobenzo%5Bb%5Dbiclyco%5B3.3.1%5Dnonene+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSavage%26aufirst%3DD.%2BS.%26atitle%3DPharmaceutical%25204-aminobenzo%255Bb%255Dbiclyco%255B3.3.1%255Dnonene%2520Derivatives%26date%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Bentley, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benwell, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerdike, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, J. E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dourish, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncton, M. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamlyn, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennett, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansell, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monck, N. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roffey, J. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliffe, I. A.</span><span> </span><span class="NLM_article-title">Indoline Derivatives as 5-HT<sub>2C</sub> Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2367</span><span class="NLM_x">–</span> <span class="NLM_lpage">2370</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.bmcl.2003.05.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2367-2370&author=J.+M.+Bentleyauthor=D.+R.+Adamsauthor=D.+Bebbingtonauthor=K.+R.+Benwellauthor=M.+J.+Bickerdikeauthor=J.+E.+P.+Davidsonauthor=C.+E.+Dawsonauthor=C.+T.+Dourishauthor=M.+A.+J.+Dunctonauthor=S.+Gaurauthor=A.+R.+Georgeauthor=P.+R.+Gilesauthor=R.+J.+Hamlynauthor=G.+A.+Kennettauthor=A.+R.+Knightauthor=C.+S.+Malcolmauthor=H.+L.+Mansellauthor=A.+Misraauthor=N.+J.+T.+Monckauthor=R.+M.+Prattauthor=K.+Quirkauthor=J.+R.+A.+Roffeyauthor=S.+P.+Vickersauthor=I.+A.+Cliffe&title=Indoline+Derivatives+as+5-HT2C+Receptor+Agonists&doi=10.1016%2Fj.bmcl.2003.05.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DJ.%2BM.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DBenwell%26aufirst%3DK.%2BR.%26aulast%3DBickerdike%26aufirst%3DM.%2BJ.%26aulast%3DDavidson%26aufirst%3DJ.%2BE.%2BP.%26aulast%3DDawson%26aufirst%3DC.%2BE.%26aulast%3DDourish%26aufirst%3DC.%2BT.%26aulast%3DDuncton%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DGaur%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DA.%2BR.%26aulast%3DGiles%26aufirst%3DP.%2BR.%26aulast%3DHamlyn%26aufirst%3DR.%2BJ.%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DKnight%26aufirst%3DA.%2BR.%26aulast%3DMalcolm%26aufirst%3DC.%2BS.%26aulast%3DMansell%26aufirst%3DH.%2BL.%26aulast%3DMisra%26aufirst%3DA.%26aulast%3DMonck%26aufirst%3DN.%2BJ.%2BT.%26aulast%3DPratt%26aufirst%3DR.%2BM.%26aulast%3DQuirk%26aufirst%3DK.%26aulast%3DRoffey%26aufirst%3DJ.%2BR.%2BA.%26aulast%3DVickers%26aufirst%3DS.%2BP.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26atitle%3DIndoline%2520Derivatives%2520as%25205-HT2C%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2367%26epage%3D2370%26doi%3D10.1016%2Fj.bmcl.2003.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hruban, Z.</span><span> </span><span class="NLM_article-title">Pulmonary Changes Induced by Amphophilic Drugs</span> <span class="citation_source-journal">Environ. Health Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1289/ehp.7616111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1289%2Fehp.7616111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1976&pages=111-118&author=Z.+Hruban&title=Pulmonary+Changes+Induced+by+Amphophilic+Drugs&doi=10.1289%2Fehp.7616111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1289%2Fehp.7616111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.7616111%26sid%3Dliteratum%253Aachs%26aulast%3DHruban%26aufirst%3DZ.%26atitle%3DPulmonary%2520Changes%2520Induced%2520by%2520Amphophilic%2520Drugs%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D1976%26volume%3D16%26spage%3D111%26epage%3D118%26doi%3D10.1289%2Fehp.7616111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Robison, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visscher, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, F. H.</span><span> </span><span class="NLM_article-title">Generalized Phospholipidosis Induced by an Amphiphilic Cationic Psychotropic Drug</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span><span class="refDoi"> DOI: 10.1177/019262338501300410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1177%2F019262338501300410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=3834585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADyaL28XktVSnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1985&pages=335-348&author=R.+L.+Robisonauthor=G.+E.+Visscherauthor=S.+A.+Robertsauthor=R.+G.+Engstromauthor=H.+A.+Hartmanauthor=F.+H.+Ballard&title=Generalized+Phospholipidosis+Induced+by+an+Amphiphilic+Cationic+Psychotropic+Drug&doi=10.1177%2F019262338501300410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug</span></div><div class="casAuthors">Robison, Rodney L.; Visscher, George E.; Roberts, Stanley A.; Engstrom, Robert G.; Hartman, Howard A.; Ballard, Frances H.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-48</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    </div><div class="casAbstract">In rats, generalized phospholipidosis was induced by Sandoz 200-125 (I)  [102636-45-3] administered orally at 500 mg/kg/day for 4 wk; characteristic pulmonary lesions including extensive accumulations of large pale foamy macrophages and granular eosinophilic extracellular material were obsd.  Marked increases in phospholipids and cholesterol in the lungs were noted.  The phospholipidosis had nearly disappeared 4 wk after drug withdrawal.  The potential pulmonary toxicity in humans from amphiphilic drugs is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU4I-U6p1PtbVg90H21EOLACvtfcHk0ljn-vXAq3Kq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XktVSnurs%253D&md5=eb945ff71cf4b7567226966b8c22a5de</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F019262338501300410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F019262338501300410%26sid%3Dliteratum%253Aachs%26aulast%3DRobison%26aufirst%3DR.%2BL.%26aulast%3DVisscher%26aufirst%3DG.%2BE.%26aulast%3DRoberts%26aufirst%3DS.%2BA.%26aulast%3DEngstrom%26aufirst%3DR.%2BG.%26aulast%3DHartman%26aufirst%3DH.%2BA.%26aulast%3DBallard%26aufirst%3DF.%2BH.%26atitle%3DGeneralized%2520Phospholipidosis%2520Induced%2520by%2520an%2520Amphiphilic%2520Cationic%2520Psychotropic%2520Drug%26jtitle%3DToxicol.%2520Pathol.%26date%3D1985%26volume%3D13%26spage%3D335%26epage%3D348%26doi%3D10.1177%2F019262338501300410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Nonoyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, R. J.</span><span> </span><span class="NLM_article-title">Drug-Induced Phospholipidosis-Pathological Aspects and Its Prediction</span> <span class="citation_source-journal">J. Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1293/tox.21.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1293%2Ftox.21.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=9-24&author=T.+Nonoyamaauthor=R.+J.+Fukuda&title=Drug-Induced+Phospholipidosis-Pathological+Aspects+and+Its+Prediction&doi=10.1293%2Ftox.21.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced phospholipidosis-pathological aspects and its prediction</span></div><div class="casAuthors">Nonoyama, Takashi; Fukuda, Ryo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-24</span>CODEN:
                <span class="NLM_cas:coden">JTPAE7</span>;
        ISSN:<span class="NLM_cas:issn">0914-9198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicologic Pathology</span>)
        </div><div class="casAbstract">A review.  Drug-induced phospholipidosis (PLDsis) is an excessive accumulation of polar phospholipids in cells or tissues/organs caused by xenobiotics.  Numerous drugs and chems. are capable of inducing the storage disorder in animals and humans; however, despite their diverse pharmacol. activities, each of these drugs shares common physicochem. properties: a hydrophobic arom. ring structure on the mol. and a hydrophilic side chain with a charged cationic amine group and therefore are in the group of cationic amphiphilic drugs.  In affected cells the appearance of membrane-bound inclusions, primarily lysosomal in origin, with a lamellar structure (lamellar bodies) is a definitive morphol. hallmark.  Massive accumulations can occur in animal tissues such as the lung with little effect on organ function.  The inducing drug also accumulates in assocn. with the excess phospholipid.  Although these alterations are generally reversible after cessation of drug treatment, PLDsis is of regulatory concern and an issue for drug safety for pharmaceutical companies.  Thus, the assessment of potential target organ dysfunction and the identification of clin. biomarkers are important objectives for new drug development.  Recent advances in biotechnol. such as metabonomics and toxicogenomics have been providing novel tools to elucidate the mechanisms of PLDsis and to establish biomarkers for screening tests in the preclin. stages and for monitoring in the clin. phases in addn. to conventional approaches such as morphol. (lamellar bodies) and biochem. methods including assays of specific metabolites and phospholipase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNnyTDVHV3bVg90H21EOLACvtfcHk0ljn-vXAq3Kq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbs%253D&md5=d91505b54cbf951cf30f8144f0c51ed9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1293%2Ftox.21.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1293%252Ftox.21.9%26sid%3Dliteratum%253Aachs%26aulast%3DNonoyama%26aufirst%3DT.%26aulast%3DFukuda%26aufirst%3DR.%2BJ.%26atitle%3DDrug-Induced%2520Phospholipidosis-Pathological%2520Aspects%2520and%2520Its%2520Prediction%26jtitle%3DJ.%2520Toxicol.%2520Pathol.%26date%3D2008%26volume%3D21%26spage%3D9%26epage%3D24%26doi%3D10.1293%2Ftox.21.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Predicting New Molecular Targets for Known Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nature08506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+H.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=Predicting+New+Molecular+Targets+for+Known+Drugs&doi=10.1038%2Fnature08506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0ljn-vXAq3Kq4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%2BH.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPredicting%2520New%2520Molecular%2520Targets%2520for%2520Known%2520Drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D175%26epage%3D181%26doi%3D10.1038%2Fnature08506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Nickols, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Development of Allosteric Modulators of GPCRs For Treatment of CNS Disorders</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1016/j.nbd.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.nbd.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=24076101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FitVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=55-71&author=H.+H.+Nickolsauthor=P.+J.+Conn&title=Development+of+Allosteric+Modulators+of+GPCRs+For+Treatment+of+CNS+Disorders&doi=10.1016%2Fj.nbd.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Development of allosteric modulators of GPCRs for treatment of CNS disorders</span></div><div class="casAuthors">Nickols Hilary Highfield; Conn P Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy with potential for developing novel treatments for a variety of central nervous system (CNS) disorders.  Traditional drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind endogenous ligands.  Allosteric modulators target a site separate from the orthosteric site to modulate receptor function.  These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than orthosteric ligands for the same receptors.  Experimental evidence has revealed more nuanced pharmacological modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with positive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as "bitopic" ligands that interact with both the allosteric and orthosteric sites.  Drugs targeting the allosteric site allow for increased drug selectivity and potentially decreased adverse side effects.  Promising evidence has demonstrated potential utility of a number of allosteric modulators of GPCRs in multiple CNS disorders, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as psychiatric or neurobehavioral diseases such as anxiety, schizophrenia, and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5AaOVGoQQ2DEC-75aqa5AfW6udTcc2eafDTph0LCGkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FitVejsA%253D%253D&md5=a1535b4448734bcae63e9797d2009737</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DNickols%26aufirst%3DH.%2BH.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDevelopment%2520of%2520Allosteric%2520Modulators%2520of%2520GPCRs%2520For%2520Treatment%2520of%2520CNS%2520Disorders%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D61%26spage%3D55%26epage%3D71%26doi%3D10.1016%2Fj.nbd.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Im, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chio, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span> </span><span class="NLM_article-title">Positive Allosteric Modulator of the Human 5-HT<sub>2C</sub> Receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1124/mol.64.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1124%2Fmol.64.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=12815163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=78-84&author=W.+B.+Imauthor=C.+L.+Chioauthor=G.+L.+Albertsauthor=D.+M.+Dinh&title=Positive+Allosteric+Modulator+of+the+Human+5-HT2C+Receptor&doi=10.1124%2Fmol.64.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulator of the human 5-HT2C receptor</span></div><div class="casAuthors">Im, Wha Bin; Chio, Christopher L.; Alberts, Glen L.; Dinh, Dac M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-84</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human 5-hydroxytryptamine-2C (5-HT2C) receptor has been the target of potential anxiolytics and antiobesity drugs, and its pos. allosteric modulator was discovered to be L-threo-α-D-galacto-octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(4-undecyl-2-piperidinyl)carbonyl]amino]-1-thiomonohydrochloride (2S-cis) (PNU-69176E).  The drug at low micromolar concns. (<25 μM) markedly enhanced [3H]5-HT binding (more than 300%) by increasing its affinity for low-affinity sites but with no appreciable effect on antagonist ([3H]mesulergine) binding.  Functionally, PNU-69176E alone rendered receptors constitutively active, producing the phenotypes of 5-HT-activated receptors, as measured with mesulergine-sensitive guanosine 5'-O-(3-[35S]thio)triphosphate binding, transient inositol 1,4,5-triphosphate release, and [3H]inositol phosphate accumulation.  These actions of PNU-69176E were obsd. with the human 5-HT2C receptor expressed in several mammalian cell lines (human embryonic kidney 293, NIH3T3, and SH-EP) at variable receptor densities (6 to 45 pmol/mg of protein), but not with analogous 5-HT and dopamine receptors (human 5-HT2A, 5-HT2B, 5-HT6, 5-HT7, and dopamine D2-long and D3 receptors).  Structurally, PNU-69176E consists of a long alkyl chain and a polar moiety, including the α-D-galactopyranoside.  Its analogs with shorter alkyl chains (Me to n-hexyl instead of n-undecyl group) failed to enhance [3H]5-HT binding, and also long alkyl amides are without allosteric modulation.  We propose that PNU-69176E may represent a new class of membrane receptor modulators, which probably need a long alkyl chain as a membrane anchor and target a selective polar head group to receptor modulatory sites near the membrane surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdPZHNbAJJbVg90H21EOLACvtfcHk0lhqLI_u_64dWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D&md5=26c9f18b3097e2a8921b7803bc836489</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fmol.64.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.64.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DChio%26aufirst%3DC.%2BL.%26aulast%3DAlberts%26aufirst%3DG.%2BL.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26atitle%3DPositive%2520Allosteric%2520Modulator%2520of%2520the%2520Human%25205-HT2C%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D64%26spage%3D78%26epage%3D84%26doi%3D10.1124%2Fmol.64.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="note"><p class="first last">It is worth noting that the apparent reduction in selectivity for compounds <b>67</b> and <b>69</b> vs 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> is possibly due to baseline drift in the functional assay, as the HEK293E cell lines that overexpress the respective receptor can appear to produce a functional response at high concentration. Indeed, each compound was tested several times in the 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> functional assay, and while some concentration response curves looked like a true concentration dependent response, others indicated little response with intrinsic activities of only ∼10% relative to serotonin. A more detailed evaluation of compounds appearing to be active toward either 5-HT<sub>2A</sub> or 5-HT<sub>2B</sub> is beyond the scope of this publication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Tanyi, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span> </span><span class="NLM_article-title">Disconnection Between the Early Onset Anorectic Effects by C75 and Hypothalamic Fatty Acid Synthase Inhibition in Rodents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2005.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.ejphar.2005.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=15777777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2005&pages=31-41&author=K.+W.+Rohrbachauthor=S.+Hanauthor=J.+Ganauthor=E.+J.+O%E2%80%99Tanyiauthor=H.+Zhangauthor=C.+L.+Chiauthor=R.+Taubauthor=B.+L.+Largentauthor=D.+Cheng&title=Disconnection+Between+the+Early+Onset+Anorectic+Effects+by+C75+and+Hypothalamic+Fatty+Acid+Synthase+Inhibition+in+Rodents&doi=10.1016%2Fj.ejphar.2005.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents</span></div><div class="casAuthors">Rohrbach, Kenneth W.; Han, Songping; Gan, Jinping; O'Tanyi, Eva J.; Zhang, Hongwei; Chi, Cecilia L.; Taub, Rebecca; Largent, Brian L.; Cheng, Dong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to explore the relationship between the anorectic effect of 3-carboxy-4-octyl-2-methylenebutyrolactone (C75) and its pharmacokinetic properties, studies of in vivo and in vitro pharmacol. characterization of C75 were performed in Fischer rats.  In a quant. measurement of food intake, we detd. that appetite suppression by C75 takes place within 4 h.  The C max for C75 of 2.6±1.5 μM was reached within 1-4 h after i.p. administration at 30 mg/kg, a drug level that causes complete blockade of food intake.  However, this concn. is substantially lower than the effective concn. used to inhibit rat fatty acid synthase enzyme activity in vitro (IC50: ∼200 μM) and hypothalamic enzyme activity was found not to be inhibited by i.p. administration of C75 at 30 mg/kg.  Instead, a dramatic induction of c-Fos expression was found in area postrema.  Collectively, these data indicate that the anorectic effect of C75 is independent of its inhibition of fatty acid synthase in the hypothalamus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphbCknlWT3JrVg90H21EOLACvtfcHk0lhqLI_u_64dWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D&md5=bae875aacd7aa736cb95107bf170c6ab</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Tanyi%26aufirst%3DE.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DC.%2BL.%26aulast%3DTaub%26aufirst%3DR.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DCheng%26aufirst%3DD.%26atitle%3DDisconnection%2520Between%2520the%2520Early%2520Onset%2520Anorectic%2520Effects%2520by%2520C75%2520and%2520Hypothalamic%2520Fatty%2520Acid%2520Synthase%2520Inhibition%2520in%2520Rodents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D511%26spage%3D31%26epage%3D41%26doi%3D10.1016%2Fj.ejphar.2005.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckworth, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaster, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulholland, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennett, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lightowler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. D.</span><span> </span><span class="NLM_article-title">Biarylcarbamoylindolines Are Novel and Selective 5-HT<sub>2C</sub> Receptor Inverse Agonists: Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1021/jm990388c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990388c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1123-1134&author=S.+M.+Bromidgeauthor=S.+Dabbsauthor=D.+T.+Daviesauthor=S.+Daviesauthor=D.+M.+Duckworthauthor=I.+T.+Forbesauthor=L.+M.+Gasterauthor=P.+Hamauthor=G.+E.+Jonesauthor=F.+D.+Kingauthor=K.+R.+Mulhollandauthor=D.+V.+Saundersauthor=P.+A.+Wymanauthor=F.+E.+Blaneyauthor=S.+E.+Clarkeauthor=T.+P.+Blackburnauthor=V.+Hollandauthor=G.+A.+Kennettauthor=S.+Lightowlerauthor=D.+N.+Middlemissauthor=B.+Trailauthor=G.+J.+Rileyauthor=M.+D.+Wood&title=Biarylcarbamoylindolines+Are+Novel+and+Selective+5-HT2C+Receptor+Inverse+Agonists%3A+Identification+of+5-Methyl-1-%5B%5B2-%5B%282-methyl-3-pyridyl%29oxy%5D-5-pyridyl%5Dcarbamoyl%5D-6-trifluoromethylindoline+%28SB-243213%29+as+a+Potential+Antidepressant%2FAnxiolytic+Agent&doi=10.1021%2Fjm990388c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1021%2Fjm990388c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990388c%26sid%3Dliteratum%253Aachs%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DDabbs%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DD.%2BT.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDuckworth%26aufirst%3DD.%2BM.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DGaster%26aufirst%3DL.%2BM.%26aulast%3DHam%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DKing%26aufirst%3DF.%2BD.%26aulast%3DMulholland%26aufirst%3DK.%2BR.%26aulast%3DSaunders%26aufirst%3DD.%2BV.%26aulast%3DWyman%26aufirst%3DP.%2BA.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DClarke%26aufirst%3DS.%2BE.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26aulast%3DHolland%26aufirst%3DV.%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DLightowler%26aufirst%3DS.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DTrail%26aufirst%3DB.%26aulast%3DRiley%26aufirst%3DG.%2BJ.%26aulast%3DWood%26aufirst%3DM.%2BD.%26atitle%3DBiarylcarbamoylindolines%2520Are%2520Novel%2520and%2520Selective%25205-HT2C%2520Receptor%2520Inverse%2520Agonists%253A%2520Identification%2520of%25205-Methyl-1-%255B%255B2-%255B%25282-methyl-3-pyridyl%2529oxy%255D-5-pyridyl%255Dcarbamoyl%255D-6-trifluoromethylindoline%2520%2528SB-243213%2529%2520as%2520a%2520Potential%2520Antidepressant%252FAnxiolytic%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1123%26epage%3D1134%26doi%3D10.1021%2Fjm990388c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wood, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reavill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennett, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lightowler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gager, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span> </span><span class="NLM_article-title">SB-243213; a Selective 5-HT<sub>2C</sub> Receptor Inverse Agonist with Improved Anxiolytic Profile: Lack of Tolerance and Withdrawal Anxiety</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span><span class="refDoi"> DOI: 10.1016/S0028-3908(01)00054-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2FS0028-3908%2801%2900054-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=186-199&author=M.+D.+Woodauthor=C.+Reavillauthor=B.+Trailauthor=A.+Wilsonauthor=T.+Steanauthor=G.+A.+Kennettauthor=S.+Lightowlerauthor=T.+P.+Blackburnauthor=D.+Thomasauthor=T.+L.+Gagerauthor=G.+Rileyauthor=V.+Hollandauthor=S.+M.+Bromidgeauthor=I.+T.+Forbesauthor=D.+N.+Middlemiss&title=SB-243213%3B+a+Selective+5-HT2C+Receptor+Inverse+Agonist+with+Improved+Anxiolytic+Profile%3A+Lack+of+Tolerance+and+Withdrawal+Anxiety&doi=10.1016%2FS0028-3908%2801%2900054-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2801%2900054-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252801%252900054-5%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DReavill%26aufirst%3DC.%26aulast%3DTrail%26aufirst%3DB.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DStean%26aufirst%3DT.%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DLightowler%26aufirst%3DS.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DGager%26aufirst%3DT.%2BL.%26aulast%3DRiley%26aufirst%3DG.%26aulast%3DHolland%26aufirst%3DV.%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26atitle%3DSB-243213%253B%2520a%2520Selective%25205-HT2C%2520Receptor%2520Inverse%2520Agonist%2520with%2520Improved%2520Anxiolytic%2520Profile%253A%2520Lack%2520of%2520Tolerance%2520and%2520Withdrawal%2520Anxiety%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D41%26spage%3D186%26epage%3D199%26doi%3D10.1016%2FS0028-3908%2801%2900054-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostich, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartig, P. R.</span><span> </span><span class="NLM_article-title">High-Affinity Agonist Binding Correlates with Efficacy (Intrinsic Activity) at the Human Serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> Receptors: Evidence Favoring the Ternary Complex and Two-State Models of Agonist Action</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">2134</span><span class="refDoi"> DOI: 10.1046/j.1471-4159.1999.0722127.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1046%2Fj.1471-4159.1999.0722127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10217294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=2127-2134&author=L.+W.+Fitzgeraldauthor=D.+S.+Conklinauthor=C.+M.+Krauseauthor=A.+P.+Marshallauthor=J.+P.+Pattersonauthor=D.+P.+Tranauthor=G.+Iyerauthor=W.+A.+Kostichauthor=B.+L.+Largentauthor=P.+R.+Hartig&title=High-Affinity+Agonist+Binding+Correlates+with+Efficacy+%28Intrinsic+Activity%29+at+the+Human+Serotonin+5-HT2A+and+5-HT2C+Receptors%3A+Evidence+Favoring+the+Ternary+Complex+and+Two-State+Models+of+Agonist+Action&doi=10.1046%2Fj.1471-4159.1999.0722127.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Conklin, Deborah S.; Krause, Carol M.; Marshall, Anne P.; Patterson, John P.; Tran, David P.; Iyer, Geeta; Kostich, Walter A.; Largent, Brian L.; Hartig, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2127-2134</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Many modern models of receptor-G protein function assume that there is a direct relationship between high-affinity agonist binding and efficacy.  The validity of this assumption has been recently questioned for the serotonin 5-HT2A receptor.  The authors examd. the intrinsic activities of various ligands in activating phosphoinositide hydrolysis and measured their resp. binding affinities to the high- and low-affinity states of the 5-HT2C (VNV isoform) and 5-HT2A receptors.  Ligand binding affinities for the high-affinity state of the receptors were detd. using 1-(4-[125I]iodo-2,5-dimethoxyphenyl)-2-aminopropane, whereas [3H]mesulergine and N-[3H]-methylspiperone were used, in the presence of excess guanine nucleotide [guanosine 5'-O-(3-thiotriphosphate)], to define binding to the low-affinity state of the 5-HT2C and 5-HT2A receptors, resp.  Antagonists labeled the high- and low-affinity states of each receptor with comparable affinities.  Previously identified inverse agonists of the 5-HT2C receptor behaved as silent antagonists in the authors' systems even when the receptor was over-expressed at a relatively high d.  In contrast, the ability of agonists to bind differentially to the high- and low-affinity states of the 5-HT2A and 5-HT2C receptors was highly correlated (R2 = 0.86 and 0.96, resp.) with their intrinsic activities.  These data suggest that high-affinity agonist states can account for agonist efficacy at human 5-HT2A or 5-HT2C receptors without the need for considering addnl. transition or active states of the receptor-ligand complex.  The procedure described herein may expedite drug discovery efforts by predicting intrinsic activities of ligands solely from ligand binding assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozA61mRFBtzbVg90H21EOLACvtfcHk0lickEBmV9LHTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D&md5=76a7600ee51a0dff38298d091640ffd7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1999.0722127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1999.0722127.x%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DConklin%26aufirst%3DD.%2BS.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DA.%2BP.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DTran%26aufirst%3DD.%2BP.%26aulast%3DIyer%26aufirst%3DG.%26aulast%3DKostich%26aufirst%3DW.%2BA.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26atitle%3DHigh-Affinity%2520Agonist%2520Binding%2520Correlates%2520with%2520Efficacy%2520%2528Intrinsic%2520Activity%2529%2520at%2520the%2520Human%2520Serotonin%25205-HT2A%2520and%25205-HT2C%2520Receptors%253A%2520Evidence%2520Favoring%2520the%2520Ternary%2520Complex%2520and%2520Two-State%2520Models%2520of%2520Agonist%2520Action%26jtitle%3DJ.%2520Neurochem.%26date%3D1999%26volume%3D72%26spage%3D2127%26epage%3D2134%26doi%3D10.1046%2Fj.1471-4159.1999.0722127.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':[],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vrushabendra  Basavanna</span>, <span class="hlFld-ContribAuthor ">Srikantamurthy  Ningaiah</span>, <span class="hlFld-ContribAuthor ">Manasa  Chandramouli</span>, <span class="hlFld-ContribAuthor ">Anjali  Sobha</span>, <span class="hlFld-ContribAuthor ">Shridevi  Doddamani</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolinyl-pyrazoles: synthesis and pharmacological evolution in the recent decennial. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Iranian Chemical Society</span><span> <strong>2021,</strong> <em>18 </em>
                                    (7)
                                     , 1479-1522. <a href="https://doi.org/10.1007/s13738-020-02152-1" title="DOI URL">https://doi.org/10.1007/s13738-020-02152-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13738-020-02152-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13738-020-02152-1%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Iranian%2520Chemical%2520Society%26atitle%3DQuinolinyl-pyrazoles%25253A%252Bsynthesis%252Band%252Bpharmacological%252Bevolution%252Bin%252Bthe%252Brecent%252Bdecennial%26aulast%3DBasavanna%26aufirst%3DVrushabendra%26date%3D2021%26date%3D2021%26volume%3D18%26issue%3D7%26spage%3D1479%26epage%3D1522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liqiang  Hao</span>, <span class="hlFld-ContribAuthor ">Hongyan  Liu</span>, <span class="hlFld-ContribAuthor ">Zheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Fuqiang  Wen</span>, <span class="hlFld-ContribAuthor ">Chengcai  Xia</span>, <span class="hlFld-ContribAuthor ">Zengfen  Pang</span>. </span><span class="cited-content_cbyCitation_article-title">Cascade reaction to 1H-pyrazoles from hydrazones via sodium Ni-trite promoted dual C–C/C–N formation, annulation and aromatization with 1,2-dichloroethane. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>32 </em>
                                    (7)
                                     , 2309-2312. <a href="https://doi.org/10.1016/j.cclet.2021.02.025" title="DOI URL">https://doi.org/10.1016/j.cclet.2021.02.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2021.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2021.02.025%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DCascade%252Breaction%252Bto%252B1H-pyrazoles%252Bfrom%252Bhydrazones%252Bvia%252Bsodium%252BNi-trite%252Bpromoted%252Bdual%252BC%2525E2%252580%252593C%25252FC%2525E2%252580%252593N%252Bformation%25252C%252Bannulation%252Band%252Baromatization%252Bwith%252B1%25252C2-dichloroethane%26aulast%3DHao%26aufirst%3DLiqiang%26date%3D2021%26volume%3D32%26issue%3D7%26spage%3D2309%26epage%3D2312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heidi  Yuen</span>, <span class="hlFld-ContribAuthor ">Andrew  Hung</span>, <span class="hlFld-ContribAuthor ">Angela Wei Hong  Yang</span>, <span class="hlFld-ContribAuthor ">George Binh  Lenon</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanisms of Action of Cassiae Semen for Weight Management: A Computational Molecular Docking Study of Serotonin Receptor 5-HT2C. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (4)
                                     , 1326. <a href="https://doi.org/10.3390/ijms21041326" title="DOI URL">https://doi.org/10.3390/ijms21041326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21041326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21041326%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMechanisms%252Bof%252BAction%252Bof%252BCassiae%252BSemen%252Bfor%252BWeight%252BManagement%25253A%252BA%252BComputational%252BMolecular%252BDocking%252BStudy%252Bof%252BSerotonin%252BReceptor%252B5-HT2C%26aulast%3DYuen%26aufirst%3DHeidi%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D4%26spage%3D1326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valérie  Compan</span>. </span><span class="cited-content_cbyCitation_article-title">Serotonin in eating behavior. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 489-503. <a href="https://doi.org/10.1016/B978-0-444-64125-0.00028-1" title="DOI URL">https://doi.org/10.1016/B978-0-444-64125-0.00028-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-444-64125-0.00028-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-444-64125-0.00028-1%26sid%3Dliteratum%253Aachs%26atitle%3DSerotonin%252Bin%252Beating%252Bbehavior%26aulast%3DCompan%26aufirst%3DVal%25C3%25A9rie%26date%3D2020%26spage%3D489%26epage%3D503%26pub%3DElsevier%26atitle%3DHandbook%252Bof%252Bthe%252BBehavioral%252BNeurobiology%252Bof%252BSerotonin%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veeramachaneni</span>, <span class="hlFld-ContribAuthor ">Thunuguntla</span>, <span class="hlFld-ContribAuthor ">Bhaswant</span>, <span class="hlFld-ContribAuthor ">Mathai</span>, <span class="hlFld-ContribAuthor ">Bondili</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT2C Receptor. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 556. <a href="https://doi.org/10.3390/biom9100556" title="DOI URL">https://doi.org/10.3390/biom9100556</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9100556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9100556%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DPharmacophore%252BDirected%252BScreening%252Bof%252BAgonistic%252BNatural%252BMolecules%252BShowing%252BAffinity%252Bto%252B5HT2C%252BReceptor%26aulast%3DVeeramachaneni%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D10%26spage%3D556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eric A.  Wold</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Wild</span>, <span class="hlFld-ContribAuthor ">Kathryn A.  Cunningham</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (16)
                                     , 1381-1398. <a href="https://doi.org/10.2174/1568026619666190709101449" title="DOI URL">https://doi.org/10.2174/1568026619666190709101449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190709101449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190709101449%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252B5-HT2C%252BReceptor%252Bin%252BBiological%252BContext%252Band%252Bthe%252BCurrent%252BState%252Bof%252B5-HT2C%252BReceptor%252BLigand%252BDevelopment%26aulast%3DWold%26aufirst%3DEric%2BA.%26date%3D2019%26volume%3D19%26issue%3D16%26spage%3D1381%26epage%3D1398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kartikey  Singh</span>, <span class="hlFld-ContribAuthor ">Chandan  Sona</span>, <span class="hlFld-ContribAuthor ">Vikash  Ojha</span>, <span class="hlFld-ContribAuthor ">Maninder  Singh</span>, <span class="hlFld-ContribAuthor ">Ankita  Mishra</span>, <span class="hlFld-ContribAuthor ">Ajeet  Kumar</span>, <span class="hlFld-ContribAuthor ">Mohammad Imran  Siddiqi</span>, <span class="hlFld-ContribAuthor ">Rama P.  Tripathi</span>, <span class="hlFld-ContribAuthor ">Prem N.  Yadav</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT2C and negative allosteric modulator of 5-HT2B receptors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>164 </em>, 499-516. <a href="https://doi.org/10.1016/j.ejmech.2018.12.070" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.070%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bdual%252Brole%252Bof%252Bpiperazine-linked%252Bphenyl%252Bcyclopropyl%252Bmethanone%252Bas%252Bpositive%252Ballosteric%252Bmodulator%252Bof%252B5-HT2C%252Band%252Bnegative%252Ballosteric%252Bmodulator%252Bof%252B5-HT2B%252Breceptors%26aulast%3DSingh%26aufirst%3DKartikey%26date%3D2019%26volume%3D164%26spage%3D499%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Waleed M.  Hussein</span>, <span class="hlFld-ContribAuthor ">Daniel  Feder</span>, <span class="hlFld-ContribAuthor ">Gerhard  Schenk</span>, <span class="hlFld-ContribAuthor ">Luke W.  Guddat</span>, <span class="hlFld-ContribAuthor ">Ross P.  McGeary</span>. </span><span class="cited-content_cbyCitation_article-title">Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 462-479. <a href="https://doi.org/10.1016/j.ejmech.2018.08.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPurple%252Bacid%252Bphosphatase%252Binhibitors%252Bas%252Bleads%252Bfor%252Bosteoporosis%252Bchemotherapeutics%26aulast%3DHussein%26aufirst%3DWaleed%2BM.%26date%3D2018%26volume%3D157%26spage%3D462%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. 5-HT<sub>2C</sub> agonist structures.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Screening hits with embedded 5-HT<sub>2C</sub> agonist substructures indicated in red.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Novel thiazole-based leads from HTS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Key Compounds <b>31</b>, <b>41</b>, <b>47</b>, and <b>69</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EtOH, 80 °C, sealed tube. (b) LiOH, THF/H<sub>2</sub>O/MeOH, rt. (c) Piperidin-4-ylmethanol, T<sub>3</sub>P, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, rt. (d) NBS, DMF, rt. (e) PdCl<sub>2</sub>(dppf)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 90–100 °C, sealed tube. (f) Hydrazine, AcOH, 90 °C. (g) CH<sub>3</sub>I, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, rt. (h) LDA, isopropyl pinacol borate, – 78 °C to rt, THF. (i) PdCl<sub>2</sub>(dtbpf)<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 80 °C, sealed tube. (j) H<sub>2</sub>, Pd/C, MeOH, rt. (k) <i><sup>t</sup></i>BuONO, Cu(I)Br, LiBr, acetonitrile, 50 °C. (l) TFA, rt.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Rat ad libitum feeding model with 5-HT<sub>2C</sub> agonist <b>69</b>. The values represent the average of six male animals. Cumulative food intake was analyzed via repeated-measure between-group analysis of variance using StatView software (Scientific Computing, Cary, NC). Time points with overall significance were further analyzed with Bonferroni post hoc tests to determine between-group significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/medium/jm-2017-00385q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Reversal in the rat ad libitum feeding model with 5-HT<sub>2C</sub> antagonist <b>70</b>. The values represent the average of six male animals. Cumulative food intake was analyzed via repeated-measure between-group analysis of variance using StatView software (Scientific Computing, Cary, NC). Time points with overall significance were further analyzed with Bonferroni post hoc tests to determine between-group significance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00385/20170721/images/large/jm-2017-00385q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00385&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotnitzky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manson, J. E.</span><span> </span><span class="NLM_article-title">Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women</span> <span class="citation_source-journal">Ann. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.7326/0003-4819-122-7-199504010-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.7326%2F0003-4819-122-7-199504010-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=7872581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A280%3ADyaK2M7nslCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1995&pages=481-486&author=G.+A.+Colditzauthor=W.+C.+Willettauthor=A.+Rotnitzkyauthor=J.+E.+Manson&title=Weight+Gain+as+a+Risk+Factor+for+Clinical+Diabetes+Mellitus+in+Women&doi=10.7326%2F0003-4819-122-7-199504010-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Weight gain as a risk factor for clinical diabetes mellitus in women</span></div><div class="casAuthors">Colditz G A; Willett W C; Rotnitzky A; Manson J E</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">481-6</span>
        ISSN:<span class="NLM_cas:issn">0003-4819</span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the relation between adult weight change and the risk for clinical diabetes mellitus among middle-aged women.  DESIGN:  Prospective cohort study with follow-up from 1976 to 1990.  SETTING:  11 U.S. states.  PARTICIPANTS:  114,281 female registered nurses aged 30 to 55 years who did not have diagnosed diabetes mellitus, coronary heart disease, stroke, or cancer in 1976.  OUTCOME MEASURES:  Non-insulin-dependent diabetes mellitus.  RESULTS:  2204 cases of diabetes were diagnosed during 1.49 million person-years of follow-up.  After adjustment for age, body mass index was the dominant predictor of risk for diabetes mellitus.  Risk increased with greater body mass index, and even women with average weight (body mass index, 24.0 kg/m2) had an elevated risk.  Compared with women with stable weight (those who gained or lost less than 5 kg between age 18 years and 1976) and after adjustment for age and body mass index at age 18 years, the relative risk for diabetes mellitus among women who had a weight gain of 5.0 to 7.9 kg was 1.9 (95% CI, 1.5 to 2.3).  The corresponding relative risk for women who gained 8.0 to 10.9 kg was 2.7 (CI, 2.1 to 3.3).  In contrast, women who lost more than 5.0 kg reduced their risk for diabetes mellitus by 50% or more.  These results were independent of family history of diabetes.  CONCLUSION:  The excess risk for diabetes with even modest and typical adult weight gain is substantial.  These findings support the importance of maintaining a constant body weight throughout adult life and suggest that the 1990 U.S.  Department of Agriculture guidelines that allow a substantial weight gain after 35 years of age are misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRR2XUFeYx_W3thwrmtH4OBfW6udTcc2eZR0kR4p03SP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2M7nslCguw%253D%253D&md5=31abd02f5a2c9065f9afbeae5a50a03c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-122-7-199504010-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-122-7-199504010-00001%26sid%3Dliteratum%253Aachs%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DWillett%26aufirst%3DW.%2BC.%26aulast%3DRotnitzky%26aufirst%3DA.%26aulast%3DManson%26aufirst%3DJ.%2BE.%26atitle%3DWeight%2520Gain%2520as%2520a%2520Risk%2520Factor%2520for%2520Clinical%2520Diabetes%2520Mellitus%2520in%2520Women%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D1995%26volume%3D122%26spage%3D481%26epage%3D486%26doi%3D10.7326%2F0003-4819-122-7-199504010-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Rexrode, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennekens, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colditz, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stampfer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rich-Edwards, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speizer, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manson, J. E.</span><span> </span><span class="NLM_article-title">A Prospective Study of Body Mass Index, Weight Change, and Risk of Stroke in Women</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">–</span> <span class="NLM_lpage">1545</span><span class="refDoi"> DOI: 10.1001/jama.277.19.1539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1001%2Fjama.277.19.1539" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=1539-1545&author=K.+M.+Rexrodeauthor=C.+H.+Hennekensauthor=W.+C.+Willettauthor=G.+A.+Colditzauthor=M.+J.+Stampferauthor=J.+W.+Rich-Edwardsauthor=F.+E.+Speizerauthor=J.+E.+Manson&title=A+Prospective+Study+of+Body+Mass+Index%2C+Weight+Change%2C+and+Risk+of+Stroke+in+Women&doi=10.1001%2Fjama.277.19.1539"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1001%2Fjama.277.19.1539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.277.19.1539%26sid%3Dliteratum%253Aachs%26aulast%3DRexrode%26aufirst%3DK.%2BM.%26aulast%3DHennekens%26aufirst%3DC.%2BH.%26aulast%3DWillett%26aufirst%3DW.%2BC.%26aulast%3DColditz%26aufirst%3DG.%2BA.%26aulast%3DStampfer%26aufirst%3DM.%2BJ.%26aulast%3DRich-Edwards%26aufirst%3DJ.%2BW.%26aulast%3DSpeizer%26aufirst%3DF.%2BE.%26aulast%3DManson%26aufirst%3DJ.%2BE.%26atitle%3DA%2520Prospective%2520Study%2520of%2520Body%2520Mass%2520Index%252C%2520Weight%2520Change%252C%2520and%2520Risk%2520of%2520Stroke%2520in%2520Women%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1997%26volume%3D277%26spage%3D1539%26epage%3D1545%26doi%3D10.1001%2Fjama.277.19.1539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mokdad, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dietz, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinicor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bales, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, J. S.</span><span> </span><span class="NLM_article-title">Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">76</span><span class="NLM_x">–</span> <span class="NLM_lpage">79</span><span class="refDoi"> DOI: 10.1001/jama.289.1.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1001%2Fjama.289.1.76" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2003&pages=76-79&author=A.+H.+Mokdadauthor=E.+S.+Fordauthor=B.+A.+Bowmanauthor=W.+H.+Dietzauthor=F.+Vinicorauthor=V.+S.+Balesauthor=J.+S.+Marks&title=Prevalence+of+Obesity%2C+Diabetes%2C+and+Obesity-Related+Health+Risk+Factors%2C+2001&doi=10.1001%2Fjama.289.1.76"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1001%2Fjama.289.1.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.289.1.76%26sid%3Dliteratum%253Aachs%26aulast%3DMokdad%26aufirst%3DA.%2BH.%26aulast%3DFord%26aufirst%3DE.%2BS.%26aulast%3DBowman%26aufirst%3DB.%2BA.%26aulast%3DDietz%26aufirst%3DW.%2BH.%26aulast%3DVinicor%26aufirst%3DF.%26aulast%3DBales%26aufirst%3DV.%2BS.%26aulast%3DMarks%26aufirst%3DJ.%2BS.%26atitle%3DPrevalence%2520of%2520Obesity%252C%2520Diabetes%252C%2520and%2520Obesity-Related%2520Health%2520Risk%2520Factors%252C%25202001%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2003%26volume%3D289%26spage%3D76%26epage%3D79%26doi%3D10.1001%2Fjama.289.1.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span>National Center for Health Statistics. <a href="http://www.cdc.gov/nchs/fastats/overwt.htm" class="extLink">http://www.cdc.gov/nchs/fastats/overwt.htm</a> (accessed March<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Center+for+Health+Statistics.+http%3A%2F%2Fwww.cdc.gov%2Fnchs%2Ffastats%2Foverwt.htm+%28accessed+March+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span> </span><span class="NLM_article-title">Agonists of the Serotonin 5-HT<sub>2C</sub> Receptor: Preclinical and Clinical Progression in Multiple Diseases</span> <span class="citation_source-journal">Curr. Opin. Drug Disc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">438</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18600561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=438-445&author=D.+A.+Wackerauthor=K.+J.+Miller&title=Agonists+of+the+Serotonin+5-HT2C+Receptor%3A+Preclinical+and+Clinical+Progression+in+Multiple+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases</span></div><div class="casAuthors">Wacker, Dean A.; Miller, Keith J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">438-445</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  The serotonin 5-HT2C receptor is a G-protein-coupled receptor and is 1 of the 14 subtypes that constitute the serotonin receptor family.  Agonists of 5-HT2C have been implicated as potential treatments for diseases of significant unmet medical need, including obesity and schizophrenia.  Despite approx. 10 years of discovery efforts, 5-HT2C agonists have only recently advanced into the clinic, likely because many of the early drug discovery efforts experienced significant difficulties with attaining receptor selectivity.  Several of these issues related to receptor selectivity have now been overcome, resulting in the entry of compds. into advanced clin. trials.  This review summarizes the progress in 5-HT2C agonist discovery and clin. development over the last 3 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eDgqANEVarVg90H21EOLACvtfcHk0lj6NVhhf5UZrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFWmtbk%253D&md5=cd06a22cee150e5a0c658a4ce8876151</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26atitle%3DAgonists%2520of%2520the%2520Serotonin%25205-HT2C%2520Receptor%253A%2520Preclinical%2520and%2520Clinical%2520Progression%2520in%2520Multiple%2520Diseases%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Disc.%26date%3D2008%26volume%3D11%26spage%3D438%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Berger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The Expanded Biology of Serotonin</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">355</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1146/annurev.med.60.042307.110802</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1146%2Fannurev.med.60.042307.110802" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=19630576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=355-366&author=M.+Bergerauthor=J.+A.+Grayauthor=B.+L.+Roth&title=The+Expanded+Biology+of+Serotonin&doi=10.1146%2Fannurev.med.60.042307.110802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The expanded biology of serotonin</span></div><div class="casAuthors">Berger, Miles; Gray, John A.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin is perhaps best known as a neurotransmitter that modulates neural activity and a wide range of neuropsychol. processes, and drugs that target serotonin receptors are used widely in psychiatry and neurol.  However, most serotonin is found outside the central nervous system, and virtually all of the 15 serotonin receptors are expressed outside as well as within the brain.  Serotonin regulates numerous biol. processes including cardiovascular function, bowel motility, ejaculatory latency, and bladder control.  Addnl., new work suggests that serotonin may regulate some processes, including platelet aggregation, by receptor-independent, transglutaminase-dependent covalent linkage to cellular proteins.  We review this new expanded serotonin biol. and discuss how drugs targeting specific serotonin receptors are beginning to help treat a wide range of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoz0HW5hdNOrVg90H21EOLACvtfcHk0lj6NVhhf5UZrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlyntb8%253D&md5=0557e01e6b79dbfb50559aca03f8b31f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.60.042307.110802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.60.042307.110802%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520Expanded%2520Biology%2520of%2520Serotonin%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2009%26volume%3D60%26spage%3D355%26epage%3D366%26doi%3D10.1146%2Fannurev.med.60.042307.110802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, C. D.</span><span> </span><span class="NLM_article-title">Serotonin Receptors</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">1614</span><span class="NLM_x">–</span> <span class="NLM_lpage">1641</span><span class="refDoi"> DOI: 10.1021/cr078224o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr078224o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlslOisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2008&pages=1614-1641&author=D.+E.+Nicholsauthor=C.+D.+Nichols&title=Serotonin+Receptors&doi=10.1021%2Fcr078224o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin Receptors</span></div><div class="casAuthors">Nichols, David E.; Nichols, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1614-1641</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on phylogeny, structural features, oligomerization, classification and functions of serotonin receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnlR5CHbuX7Vg90H21EOLACvtfcHk0lj6NVhhf5UZrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlslOisL8%253D&md5=55b70829f6be71cbfe4de05c5ef665d8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcr078224o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr078224o%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DNichols%26aufirst%3DC.%2BD.%26atitle%3DSerotonin%2520Receptors%26jtitle%3DChem.%2520Rev.%26date%3D2008%26volume%3D108%26spage%3D1614%26epage%3D1641%26doi%3D10.1021%2Fcr078224o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Voigt, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, H.</span><span> </span><span class="NLM_article-title">Serotonin Controlling Feeding and Satiety</span> <span class="citation_source-journal">Behav. Brain Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">14</span><span class="NLM_x">–</span> <span class="NLM_lpage">31</span><span class="refDoi"> DOI: 10.1016/j.bbr.2014.08.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.bbr.2014.08.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=25217810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2015&pages=14-31&author=J.-P.+Voigtauthor=H.+Fink&title=Serotonin+Controlling+Feeding+and+Satiety&doi=10.1016%2Fj.bbr.2014.08.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin controlling feeding and satiety</span></div><div class="casAuthors">Voigt, Jorg-Peter; Fink, Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14-31</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Serotonin has been implicated in the control of satiety for almost four decades.  Historically, the insight that the appetite suppressant effect of fenfluramine is linked to serotonin has stimulated interest in and research into the role of this neurotransmitter in satiety.  Various rodent models, including transgenic models, have been developed to identify the involved 5-HT receptor subtypes.  This approach also required the availability of receptor ligands of different selectivity, and behavioral techniques had to be developed simultaneously which allow differentiating between unspecific pharmacol. effects of these ligands and 'true' satiation and satiety.  Currently, 5-HT1B, 5-HT2C and 5-HT6 receptors have been identified to mediate serotonergic satiety in different ways.  The recently approved anti-obesity drug lorcaserin is a 5-HT2C receptor agonist.  In brain, both hypothalamic (arcuate nucleus, paraventricular nucleus) and extrahypothalamic sites (parabrachial nucleus, nucleus of the solitary tract) have been identified to mediate the serotonergic control of satiety.  Serotonin interacts within the hypothalamus with endogenous orexigenic (Neuropeptide Y/Agouti related protein) and anorectic (α-MSH) peptides.  In the nucleus of the solitary tract serotonin integrates peripheral satiety signals.  Here, the 5-HT3, but possibly also the 5-HT2C receptor play a role.  It has been found that 5-HT acts in concert with such peripheral signals as cholecystokinin and leptin.  Despite the recent advances of our knowledge, many of the complex interactions between 5-HT and other satiety factors are not fully understood yet.  Further progress in research will also advance the development of new serotonergic anti-obesity drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2j0oo8j1SeLVg90H21EOLACvtfcHk0lgY6PaC0ny-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurvP&md5=39612744b52db70f329e69917d4707d7</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2014.08.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2014.08.065%26sid%3Dliteratum%253Aachs%26aulast%3DVoigt%26aufirst%3DJ.-P.%26aulast%3DFink%26aufirst%3DH.%26atitle%3DSerotonin%2520Controlling%2520Feeding%2520and%2520Satiety%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2015%26volume%3D277%26spage%3D14%26epage%3D31%26doi%3D10.1016%2Fj.bbr.2014.08.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Smith, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilson, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrada, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prieto, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallardo, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sengupta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saldana, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzaghi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beeley, N. R.</span><span> </span><span class="NLM_article-title">Discovery and SAR of New Benzazepines as Potent and Selective 5-HT<sub>2C</sub> Receptor Agonists for the Treatment of Obesity</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1467</span><span class="NLM_x">–</span> <span class="NLM_lpage">1470</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2004.12.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.bmcl.2004.12.080" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1467-1470&author=B.+M.+Smithauthor=J.+M.+Smithauthor=J.+H.+Tsaiauthor=J.+A.+Schultzauthor=C.+A.+Gilsonauthor=S.+A.+Estradaauthor=R.+R.+Chenauthor=D.+M.+Parkauthor=E.+B.+Prietoauthor=C.+S.+Gallardoauthor=D.+Senguptaauthor=W.+J.+Thomsenauthor=H.+R.+Saldanaauthor=K.+T.+Whelanauthor=F.+Menzaghiauthor=R.+R.+Webbauthor=N.+R.+Beeley&title=Discovery+and+SAR+of+New+Benzazepines+as+Potent+and+Selective+5-HT2C+Receptor+Agonists+for+the+Treatment+of+Obesity&doi=10.1016%2Fj.bmcl.2004.12.080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2004.12.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2004.12.080%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BM.%26aulast%3DTsai%26aufirst%3DJ.%2BH.%26aulast%3DSchultz%26aufirst%3DJ.%2BA.%26aulast%3DGilson%26aufirst%3DC.%2BA.%26aulast%3DEstrada%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DR.%2BR.%26aulast%3DPark%26aufirst%3DD.%2BM.%26aulast%3DPrieto%26aufirst%3DE.%2BB.%26aulast%3DGallardo%26aufirst%3DC.%2BS.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26aulast%3DSaldana%26aufirst%3DH.%2BR.%26aulast%3DWhelan%26aufirst%3DK.%2BT.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DWebb%26aufirst%3DR.%2BR.%26aulast%3DBeeley%26aufirst%3DN.%2BR.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520New%2520Benzazepines%2520as%2520Potent%2520and%2520Selective%25205-HT2C%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1467%26epage%3D1470%26doi%3D10.1016%2Fj.bmcl.2004.12.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Thomsen, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grottick, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzaghi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes-Saldana, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espitia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuskin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Shamma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behan, D. J.</span><span> </span><span class="NLM_article-title">Lorcaserin, a Novel Selective Human 5-hydroxytryptamine2C Agonist: In Vitro and In Vivo Pharmacological Characterization</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">325</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1124/jpet.107.133348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1124%2Fjpet.107.133348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18252809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=325&publication_year=2008&pages=577-587&author=W.+J.+Thomsenauthor=A.+J.+Grottickauthor=F.+Menzaghiauthor=H.+Reyes-Saldanaauthor=S.+Espitiaauthor=D.+Yuskinauthor=K.+Whelanauthor=M.+Martinauthor=M.+Morganauthor=W.+Chenauthor=H.+Al-Shammaauthor=B.+Smithauthor=D.+Chalmersauthor=D.+J.+Behan&title=Lorcaserin%2C+a+Novel+Selective+Human+5-hydroxytryptamine2C+Agonist%3A+In+Vitro+and+In+Vivo+Pharmacological+Characterization&doi=10.1124%2Fjpet.107.133348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization</span></div><div class="casAuthors">Thomsen, William J.; Grottick, Andrew J.; Menzaghi, Frederique; Reyes-Saldana, Hazel; Espitia, Stephen; Yuskin, Diane; Whelan, Kevin; Martin, Michael; Morgan, Michael; Chen, Weichao; Al-Shamma, Hussein; Smith, Brian; Chalmers, Derek; Behan, Dominic</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">325</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">577-587</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">5-Hydroxytryptamine (5-HT)2C receptor agonists hold promise for the treatment of obesity.  In this study, we describe the in vitro and in vivo characteristics of lorcaserin [(1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3 benzazepine], a selective, high affinity 5-HT2C full agonist.  Lorcaserin bound to human and rat 5-HT2C receptors with high affinity (Ki = 15±1 nM, 29±7 nM, resp.), and it was a full agonist for the human 5-HT2C receptor in a functional inositol phosphate accumulation assay, with 18- and 104-fold selectivity over 5-HT2A and 5-HT2B receptors, resp.  Lorcaserin was also highly selective for human 5-HT2C over other human 5-HT receptors (5-HT1A, 5-HT3, 5-HT4C, 5-HT55A, 5-HT6, and 5-HT7), in addn. to a panel of 67 other G protein-coupled receptors and ion channels.  Lorcaserin did not compete for binding of ligands to serotonin, dopamine, and norepinephrine transporters, and it did not alter their function in vitro.  Behavioral observations indicated that unlike the 5-HT2A agonist (±)-1-(2,5-dimethoxy-4-phenyl)-2-aminopropane, lorcaserin did not induce behavioral changes indicative of functional 5-HT2A agonist activity.  Acutely, lorcaserin reduced food intake in rats, an effect that was reversed by pretreatment with the 5-HT2C-selective antagonist 6-chloro-5-methyl-1-[6-(2-methylpyridin-3-yloxy)pyridin-3-yl-carbamoyl]indoline (SB242,084) but not the 5-HT2A antagonist (R)-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL 100,907), demonstrating mediation by the 5-HT2C receptor.  Chronic daily treatment with lorcaserin to rats maintained on a high fat diet produced dose-dependent redns. in food intake and body wt. gain that were maintained during the 4-wk study.  Upon discontinuation, body wt. returned to control levels.  These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT2C receptor, with potential for the treatment of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqDHE28aF3k7Vg90H21EOLACvtfcHk0lgY6PaC0ny-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVOjtrc%253D&md5=0626c3dabb7e89066e45ecd12cbc81f8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.133348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.133348%26sid%3Dliteratum%253Aachs%26aulast%3DThomsen%26aufirst%3DW.%2BJ.%26aulast%3DGrottick%26aufirst%3DA.%2BJ.%26aulast%3DMenzaghi%26aufirst%3DF.%26aulast%3DReyes-Saldana%26aufirst%3DH.%26aulast%3DEspitia%26aufirst%3DS.%26aulast%3DYuskin%26aufirst%3DD.%26aulast%3DWhelan%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DAl-Shamma%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DChalmers%26aufirst%3DD.%26aulast%3DBehan%26aufirst%3DD.%2BJ.%26atitle%3DLorcaserin%252C%2520a%2520Novel%2520Selective%2520Human%25205-hydroxytryptamine2C%2520Agonist%253A%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Pharmacological%2520Characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D325%26spage%3D577%26epage%3D587%26doi%3D10.1124%2Fjpet.107.133348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Aghajanian, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marek, G. J.</span><span> </span><span class="NLM_article-title">Serotonin and Hallucinogens</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">16S</span><span class="NLM_x">–</span> <span class="NLM_lpage">23S</span><span class="refDoi"> DOI: 10.1016/S0893-133X(98)00135-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2FS0893-133X%2898%2900135-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=16S-23S&author=G.+K.+Aghajanianauthor=G.+J.+Marek&title=Serotonin+and+Hallucinogens&doi=10.1016%2FS0893-133X%2898%2900135-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2898%2900135-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252898%252900135-3%26sid%3Dliteratum%253Aachs%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DMarek%26aufirst%3DG.%2BJ.%26atitle%3DSerotonin%2520and%2520Hallucinogens%26jtitle%3DNeuropsychopharmacology%26date%3D1999%26volume%3D21%26spage%3D16S%26epage%3D23S%26doi%3D10.1016%2FS0893-133X%2898%2900135-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Nichols, D. E.</span><span> </span><span class="NLM_article-title">Hallucinogens</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2003.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.pharmthera.2003.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=14761703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=131-181&author=D.+E.+Nichols&title=Hallucinogens&doi=10.1016%2Fj.pharmthera.2003.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Hallucinogens</span></div><div class="casAuthors">Nichols, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-181</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes.  They are considered physiol. safe and do not produce dependence or addiction.  Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts.  In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain.  These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT2A receptors, esp. those expressed on neocortical pyramidal cells.  Activation of 5-HT2A receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents.  These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC).  In vivo brain imaging in humans using [18F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metab., and correlations have been developed between activity in specific brain areas and psychol. elements of the ASC produced by hallucinogens.  The 5-HT2A receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research.  In addn., it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRl6lKmZ_4Y7Vg90H21EOLACvtfcHk0ljVnayRZKGjbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptFCmsg%253D%253D&md5=7b5246f6479d76736c5a7223c60a9e99</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DNichols%26aufirst%3DD.%2BE.%26atitle%3DHallucinogens%26jtitle%3DPharmacol.%2520Ther.%26date%3D2004%26volume%3D101%26spage%3D131%26epage%3D181%26doi%3D10.1016%2Fj.pharmthera.2003.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Rothman, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauser, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Evidence for Possible Involvement of 5-HT(2B) Receptors in the Cardiac Valvulopathy Associated with Fenfluramine and Other Serotonergic Medications</span> <span class="citation_source-journal">Circulation</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2836</span><span class="NLM_x">–</span> <span class="NLM_lpage">2841</span><span class="refDoi"> DOI: 10.1161/01.CIR.102.23.2836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1161%2F01.CIR.102.23.2836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=11104741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2000&pages=2836-2841&author=R.+B.+Rothmanauthor=M.+H.+Baumannauthor=J.+E.+Savageauthor=L.+Rauserauthor=A.+McBrideauthor=S.+J.+Hufeisenauthor=B.+L.+Roth&title=Evidence+for+Possible+Involvement+of+5-HT%282B%29+Receptors+in+the+Cardiac+Valvulopathy+Associated+with+Fenfluramine+and+Other+Serotonergic+Medications&doi=10.1161%2F01.CIR.102.23.2836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</span></div><div class="casAuthors">Rothman, Richard B.; Baumann, Michael H.; Savage, Jason E.; Rauser, Laura; McBride, Ace; Hufeisen, Sandra J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2836-2841</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are being investigated as treatments for drug dependence.  The occurrence of fenfluramine-assocd. valvular heart disease (VHD) has raised concerns that other serotonergic medications might also increase the risk of developing VHD.  We hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis.  Medications known or suspected to cause VHD (pos. controls) and medications not assocd. with VHD (neg. controls) were screened for activity at 11 cloned serotonin receptor subtypes by use of ligand-binding methods and functional assays.  The pos. control drugs were (±)-fenfluramine; (+)-fenfluramine; (-)-fenfluramine; its metabolites (±)-norfenfluramine, (+)-norfenfluramine, and (-)-norfenfluramine; ergotamine; and methysergide and its metabolite methylergonovine.  The neg. control drugs were phentermine, fluoxetine, its metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpiperazine.  (±)-, (+)-, And (-)-Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin 5-HT2B receptor and were partial to full agonists at the 5-HT2B receptor.  Our data imply that activation of 5-HT2B receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT2B receptors are unlikely to produce VHD.  We suggest that all clin. available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at 5-HT2B receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6spUXOCLtLrVg90H21EOLACvtfcHk0ljVnayRZKGjbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptVSjtrs%253D&md5=6b8c6059885dd9b058859089914c61b3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.102.23.2836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.102.23.2836%26sid%3Dliteratum%253Aachs%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DSavage%26aufirst%3DJ.%2BE.%26aulast%3DRauser%26aufirst%3DL.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DEvidence%2520for%2520Possible%2520Involvement%2520of%25205-HT%25282B%2529%2520Receptors%2520in%2520the%2520Cardiac%2520Valvulopathy%2520Associated%2520with%2520Fenfluramine%2520and%2520Other%2520Serotonergic%2520Medications%26jtitle%3DCirculation%26date%3D2000%26volume%3D102%26spage%3D2836%26epage%3D2841%26doi%3D10.1161%2F01.CIR.102.23.2836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corjay, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Link, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbaszade, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartig, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollis, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meunier, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robichaud, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D. W.</span><span> </span><span class="NLM_article-title">Possible Role of Valvular Serotonin 5-HT<sub>2B</sub> Receptors in the Cardiopathy Associated with Fenfluramine</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10617681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=75-81&author=L.+W.+Fitzgeraldauthor=T.+C.+Burnauthor=B.+S.+Brownauthor=J.+P.+Pattersonauthor=M.+H.+Corjayauthor=P.+A.+Valentineauthor=J.+H.+Sunauthor=J.+R.+Linkauthor=I.+Abbaszadeauthor=J.+M.+Hollisauthor=B.+L.+Largentauthor=P.+R.+Hartigauthor=G.+F.+Hollisauthor=P.+C.+Meunierauthor=A.+J.+Robichaudauthor=D.+W.+Robertson&title=Possible+Role+of+Valvular+Serotonin+5-HT2B+Receptors+in+the+Cardiopathy+Associated+with+Fenfluramine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Burn, Timothy C.; Brown, Barry S.; Patterson, John P.; Corjay, Martha H.; Valentine, Patricia A.; Sun, Jung-Hui; Link, John R.; Abbaszade, Ilgar; Hollis, Jeannine M.; Largent, Brian L.; Hartig, Paul R.; Hollis, Gregory F.; Meunier, Paul C.; Robichaud, Albert J.; Robertson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dexfenfluramine was approved in the United States for longterm use as an appetite suppressant until it was reported to be assocd. with valvular heart disease.  The valvular changes (myofibroblast proliferation) are histopathol. indistinguishable from those obsd. in carcinoid disease or after long-term exposure to 5-hydroxytryptamine (5-HT)2-preferring ergot drugs (ergotamine, methysergide).  5-HT2 receptor stimulation is known to cause fibroblast mitogenesis, which could contribute to this lesion.  To elucidate the mechanism of "fenphen"-assocd. valvular lesions, we examd. the interaction of fenfluramine and its metabolite norfenfluramine with 5-HT2 receptor subtypes and examd. the expression of these receptors in human and porcine heart valves.  Fenfluramine binds weakly to 5-HT2A, 5-HT2B, and 5-HT2C receptors.  In contrast, norfenfluramine exhibited high affinity for 5-HT2B and 5-HT2C receptors and more moderate affinity for 5-HT2A receptors.  In cells expressing recombinant 5-HT2B receptors, norfenfluramine potently stimulated the hydrolysis of inositol phosphates, increased intracellular Ca2+, and activated the mitogen-activated protein kinase cascade, the latter of which has been linked to mitogenic actions of the 5-HT2B receptor.  The level of 5-HT2B and 5-HT2A receptor transcripts in heart valves was at least 300-fold higher than the levels of 5-HT2C receptor transcript, which were barely detectable.  We propose that preferential stimulation of valvular 5-HT2B receptors by norfenfluramine, ergot drugs, or 5-HT released from carcinoid tumors (with or without accompanying 5-HT2A receptor activation) may contribute to valvular fibroplasia in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmkbFOXGVxcLVg90H21EOLACvtfcHk0ljVnayRZKGjbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslCltA%253D%253D&md5=b99b778d0de695d377aa4f0006b6dc47</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DBrown%26aufirst%3DB.%2BS.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DCorjay%26aufirst%3DM.%2BH.%26aulast%3DValentine%26aufirst%3DP.%2BA.%26aulast%3DSun%26aufirst%3DJ.%2BH.%26aulast%3DLink%26aufirst%3DJ.%2BR.%26aulast%3DAbbaszade%26aufirst%3DI.%26aulast%3DHollis%26aufirst%3DJ.%2BM.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26aulast%3DHollis%26aufirst%3DG.%2BF.%26aulast%3DMeunier%26aufirst%3DP.%2BC.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DRobertson%26aufirst%3DD.%2BW.%26atitle%3DPossible%2520Role%2520of%2520Valvular%2520Serotonin%25205-HT2B%2520Receptors%2520in%2520the%2520Cardiopathy%2520Associated%2520with%2520Fenfluramine%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D75%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Drugs and Valvular Heart Disease</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span><span class="refDoi"> DOI: 10.1056/NEJMp068265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1056%2FNEJMp068265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=17202450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=6-9&author=B.+L.+Roth&title=Drugs+and+Valvular+Heart+Disease&doi=10.1056%2FNEJMp068265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and valvular heart disease</span></div><div class="casAuthors">Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaFEwabTP8rVg90H21EOLACvtfcHk0ljl-S0mfP4KiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D&md5=e5161a25f1a2596cef68030f0f8a7b61</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMp068265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp068265%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDrugs%2520and%2520Valvular%2520Heart%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D6%26epage%3D9%26doi%3D10.1056%2FNEJMp068265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Cheng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT<sub>2C</sub>) Receptor Agonists for the Treatment of CNS Disorders</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1963</span><span class="NLM_x">–</span> <span class="NLM_lpage">1967</span><span class="refDoi"> DOI: 10.1002/cmdc.201500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1002%2Fcmdc.201500437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=26507582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1963-1967&author=J.+Chengauthor=A.+P.+Kozikowski&title=We+Need+2C+but+Not+2B%3A+Developing+Serotonin+2C+%285-HT2C%29+Receptor+Agonists+for+the+Treatment+of+CNS+Disorders&doi=10.1002%2Fcmdc.201500437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders</span></div><div class="casAuthors">Cheng, Jianjun; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The serotonin 2C (5-HT2C) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia.  In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group.  Challenges in this field and the possible future directions are described.  Homol. modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed.  Compared to known ligands, the improved pharmacol. profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr43VsLXn0mBLVg90H21EOLACvtfcHk0ljl-S0mfP4KiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslamsr3J&md5=4a7f2040f4c57da292c7ebac2de8d726</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWe%2520Need%25202C%2520but%2520Not%25202B%253A%2520Developing%2520Serotonin%25202C%2520%25285-HT2C%2529%2520Receptor%2520Agonists%2520for%2520the%2520Treatment%2520of%2520CNS%2520Disorders%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fcmdc.201500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bray, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goddard, W. A.</span><span> </span><span class="NLM_article-title">The Structure of Human Serotonin 2C G-Protein-Coupled Receptor Bound to Agonists and Antagonists</span> <span class="citation_source-journal">J. Mol. Graphics Modell.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">66</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.jmgm.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.jmgm.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18499489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVejsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=66-81&author=J.+K.+Brayauthor=W.+A.+Goddard&title=The+Structure+of+Human+Serotonin+2C+G-Protein-Coupled+Receptor+Bound+to+Agonists+and+Antagonists&doi=10.1016%2Fj.jmgm.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists</span></div><div class="casAuthors">Bray, Jenelle K.; Goddard, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Graphics & Modelling</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66-81</span>CODEN:
                <span class="NLM_cas:coden">JMGMFI</span>;
        ISSN:<span class="NLM_cas:issn">1093-3263</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The authors used the MembStruk computational procedure to predict the three-dimensional (3D) structure for the serotonin 5-HT2C G-protein-coupled receptor (GPCR).  Using this structure, the authors used the MSCDock computational procedure to predict the 3D structures for bound ligand-protein complexes for agonists such as serotonin and antagonists such as ritanserin, metergoline, and methiothepin.  In addn., the authors predicted the SAR data for a series of psilocybin analogs, both agonists and antagonists.  The authors performed mol. dynamics (MD) on serotonin bound to 5-HT2C and the authors find the protein and binding site to be stable after 5 ns.  The authors find good agreement with the currently known exptl. data and the authors predict a no. of new mutations which could be used to validate further the authors' predicted structures.  This agreement between theory and expt. suggests that the authors' 3D structure is sufficiently accurate for use in drug design.  The authors also compare a preliminary prediction for 5-HT2B with the authors' prediction for 5-HT2C and find a difference in TM5 that contributes to different serotonin binding modes in 5-HT2B and 5-HT2C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhAD9j85USf7Vg90H21EOLACvtfcHk0ljl-S0mfP4KiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVejsbzP&md5=a2d42e43b0e18604c0b81f1524cc9700</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.jmgm.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmgm.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DJ.%2BK.%26aulast%3DGoddard%26aufirst%3DW.%2BA.%26atitle%3DThe%2520Structure%2520of%2520Human%2520Serotonin%25202C%2520G-Protein-Coupled%2520Receptor%2520Bound%2520to%2520Agonists%2520and%2520Antagonists%26jtitle%3DJ.%2520Mol.%2520Graphics%2520Modell.%26date%3D2008%26volume%3D27%26spage%3D66%26epage%3D81%26doi%3D10.1016%2Fj.jmgm.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Dunlop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coupet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazandarani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawoschik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pangalos, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramamoorthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schechter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stack, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span> </span><span class="NLM_article-title">Characterization of Vabicaserin (SCA-136), a Selective 5-Hydroxytryptamine 2C Receptor Agonist</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">680</span><span class="refDoi"> DOI: 10.1124/jpet.111.179572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1124%2Fjpet.111.179572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=21402690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFeiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=673-680&author=J.+Dunlopauthor=S.+W.+Wattsauthor=J.+E.+Barrettauthor=J.+Coupetauthor=B.+Harrisonauthor=H.+Mazandaraniauthor=S.+Nawoschikauthor=M.+N.+Pangalosauthor=S.+Ramamoorthyauthor=L.+Schechterauthor=D.+Smithauthor=G.+Stackauthor=J.+Zhangauthor=G.+Zhangauthor=S.+Rosenzweig-Lipson&title=Characterization+of+Vabicaserin+%28SCA-136%29%2C+a+Selective+5-Hydroxytryptamine+2C+Receptor+Agonist&doi=10.1124%2Fjpet.111.179572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist</span></div><div class="casAuthors">Dunlop, John; Watts, Stephanie W.; Barrett, James E.; Coupet, Joseph; Harrison, Boyd; Mazandarani, Hossein; Nawoschik, Stanley; Pangalos, Menelas N.; Ramamoorthy, Siva; Schechter, Lee; Smith, Deborah; Stack, Gary; Zhang, Jean; Zhang, Guoming; Rosenzweig-Lipson, Sharon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">673-680</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The 5-hydroxytryptamine 2C (5-HT2C) receptor subtype has received considerable attention as a target for drug discovery, having been implicated in a wide variety of disorders.  Here, we describe the in vitro pharmacol. profile of the novel 5-HT2C receptor-selective agonist vabicaserin [(-)-4,5,6,7,9,9a,10,11,12,12a-decahydrocyclopenta[c] [1,4]diazepino[6,7,1-ij]quinoline hydrochloride] (SCA-136), including a comprehensive strategy to assess 5-HT2B receptor selectivity using diverse prepns. and assays of receptor activation.  Vabicaserin displaced 125I-(2,5-dimethoxy)phenylisopropylamine binding from human 5-HT2C receptor sites in Chinese hamster ovary cell membranes with a Ki value of 3 nM and was > 50-fold selective over a no. of serotonergic, noradrenergic, and dopaminergic receptors.  Binding affinity detd. for the human 5-HT2B receptor subtype using [3H]5HT was 14 nM.  Vabicaserin was a potent and full agonist (EC50, 8 nM; Emax, 100%) in stimulating 5-HT2C receptor-coupled calcium mobilization and exhibited 5-HT2A receptor antagonism and 5-HT2B antagonist or partial agonist activity in transfected cells, depending on the level of receptor expression.  In rat stomach fundus and human colonic longitudinal muscle endogenously expressing 5-HT2B receptors, vabicaserin failed to induce a 5-HT2B receptor-dependent contraction and produced a rightward shift of the 5-HT and α-methyl-5-HT concn.-response curves in these prepns., resp., consistent with 5-HT2B competitive antagonism.  Likewise, vabicaserin failed to induce a 5-HT2B receptor-mediated contraction in arteries from deoxycorticosterone acetate-salt-treated rats, a model of hypersensitized 5-HT2B receptor function, and produced a rightward shift in the 5-HT-induced response that was consistent with 5-HT2B receptor antagonism.  In summary, vabicaserin is a novel, potent, and selective 5-HT2C receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCYu5_bxpVxbVg90H21EOLACvtfcHk0ljFE-D9tD4rQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFeiur8%253D&md5=0426498cda326da150beedcebcb56aa5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.179572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.179572%26sid%3Dliteratum%253Aachs%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DWatts%26aufirst%3DS.%2BW.%26aulast%3DBarrett%26aufirst%3DJ.%2BE.%26aulast%3DCoupet%26aufirst%3DJ.%26aulast%3DHarrison%26aufirst%3DB.%26aulast%3DMazandarani%26aufirst%3DH.%26aulast%3DNawoschik%26aufirst%3DS.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26aulast%3DRamamoorthy%26aufirst%3DS.%26aulast%3DSchechter%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DStack%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520Vabicaserin%2520%2528SCA-136%2529%252C%2520a%2520Selective%25205-Hydroxytryptamine%25202C%2520Receptor%2520Agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D673%26epage%3D680%26doi%3D10.1124%2Fjpet.111.179572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rosenzweig-Lipson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunlop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, K. L.</span><span> </span><span class="NLM_article-title">5-HT<sub>2C</sub> Receptor Agonists as an Innovative Approach for Psychiatric Disorders</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">565</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span><span class="refDoi"> DOI: 10.1358/dnp.2007.20.9.1162244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1358%2Fdnp.2007.20.9.1162244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=18176661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitFKiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2007&pages=565-571&issue=9&author=S.+Rosenzweig-Lipsonauthor=J.+Dunlopauthor=K.+L.+Marquis&title=5-HT2C+Receptor+Agonists+as+an+Innovative+Approach+for+Psychiatric+Disorders&doi=10.1358%2Fdnp.2007.20.9.1162244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2C receptor agonists as an innovative approach for psychiatric disorders</span></div><div class="casAuthors">Rosenzweig-Lipson, Sharon; Dunlop, John; Marquis, Karen L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">565-571</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Modulating activity at the 5-HT2C receptor holds a tremendous amt. of therapeutic promise in multiple psychiatric indications.  However, the signaling and regulation of the 5-HT2C receptor is highly complex due to multiple signaling pathways and agonist-directed trafficking of this receptor.  Moreover, the 5-HT2C receptor is differentially regulated via RNA editing in multiple psychiatric disorders and following either pharmacol. or environmental manipulation.  Direct and indirect data suggest that both agonists and antagonists may provide benefits in several disorders.  The current review highlights the underlying complexities of this area and provides the rationale for using 5-HT2C agonists in the treatment of both schizophrenia and depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_al0DDqbYmrVg90H21EOLACvtfcHk0ljFE-D9tD4rQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitFKiurY%253D&md5=0b70b5f0ac66823e26b2f7a82651e7d3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2007.20.9.1162244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2007.20.9.1162244%26sid%3Dliteratum%253Aachs%26aulast%3DRosenzweig-Lipson%26aufirst%3DS.%26aulast%3DDunlop%26aufirst%3DJ.%26aulast%3DMarquis%26aufirst%3DK.%2BL.%26atitle%3D5-HT2C%2520Receptor%2520Agonists%2520as%2520an%2520Innovative%2520Approach%2520for%2520Psychiatric%2520Disorders%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2007%26volume%3D20%26issue%3D9%26spage%3D565%26epage%3D571%26doi%3D10.1358%2Fdnp.2007.20.9.1162244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wacker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varnes, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malmstrom, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ung, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuvich, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narayanan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janovitz, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehman-McKeeman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devenny, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robl, J. A.</span><span> </span><span class="NLM_article-title">Discovery of (R)-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a Selective, Orally Active Agonist of the 5-HT<sub>2C</sub> Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1379</span><span class="refDoi"> DOI: 10.1021/jm0612968</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0612968" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1365-1379&author=D.+A.+Wackerauthor=J.+G.+Varnesauthor=S.+E.+Malmstromauthor=X.+Caoauthor=C.+P.+Hungauthor=T.+Ungauthor=G.+Wuauthor=G.+Zhangauthor=E.+Zuvichauthor=M.+A.+Thomasauthor=W.+J.+Keimauthor=M.+J.+Cullenauthor=K.+W.+Rohrbachauthor=Q.+Quauthor=R.+Narayananauthor=K.+Rossiauthor=E.+Janovitzauthor=L.+Lehman-McKeemanauthor=M.+F.+Malleyauthor=J.+Devennyauthor=M.+A.+Pelleymounterauthor=K.+J.+Millerauthor=J.+A.+Robl&title=Discovery+of+%28R%29-9-Ethyl-1%2C3%2C4%2C10b-tetrahydro-7-trifluoromethylpyrazino%5B2%2C1-a%5Disoindol-+6%282H%29-one%2C+a+Selective%2C+Orally+Active+Agonist+of+the+5-HT2C+Receptor&doi=10.1021%2Fjm0612968"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm0612968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0612968%26sid%3Dliteratum%253Aachs%26aulast%3DWacker%26aufirst%3DD.%2BA.%26aulast%3DVarnes%26aufirst%3DJ.%2BG.%26aulast%3DMalmstrom%26aufirst%3DS.%2BE.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DHung%26aufirst%3DC.%2BP.%26aulast%3DUng%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DZuvich%26aufirst%3DE.%26aulast%3DThomas%26aufirst%3DM.%2BA.%26aulast%3DKeim%26aufirst%3DW.%2BJ.%26aulast%3DCullen%26aufirst%3DM.%2BJ.%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DQu%26aufirst%3DQ.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DRossi%26aufirst%3DK.%26aulast%3DJanovitz%26aufirst%3DE.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%26aulast%3DMalley%26aufirst%3DM.%2BF.%26aulast%3DDevenny%26aufirst%3DJ.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%2520%2528R%2529-9-Ethyl-1%252C3%252C4%252C10b-tetrahydro-7-trifluoromethylpyrazino%255B2%252C1-a%255Disoindol-%25206%25282H%2529-one%252C%2520a%2520Selective%252C%2520Orally%2520Active%2520Agonist%2520of%2520the%25205-HT2C%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1365%26epage%3D1379%26doi%3D10.1021%2Fjm0612968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Briner, K.; Burkholder, T. P.; Heiman, M. L.; Nelson, D. L. G.</span><span> </span><span class="NLM_article-title">Preparation of 1-(4-Trifluoromethylbenzofur-7-yl)piperazines Useful as Serotonin Agonists</span>. PCT Int. Appl. WO2001009123 A1,<span class="NLM_x"> </span><span class="NLM_year">2001</span><span class="NLM_x">, </span>(Eli Lilly and Co., U.S.).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=K.+Briner&author=T.+P.+Burkholder&author=M.+L.+Heiman&author=D.+L.+G.+Nelson&title=Preparation+of+1-%284-Trifluoromethylbenzofur-7-yl%29piperazines+Useful+as+Serotonin+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBriner%26aufirst%3DK.%26atitle%3DPreparation%2520of%25201-%25284-Trifluoromethylbenzofur-7-yl%2529piperazines%2520Useful%2520as%2520Serotonin%2520Agonists%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Jackson, M.; Hester, B.,  Jr.</span><span> </span><span class="NLM_article-title">6-Alkyl-1,2,3,4,5,6-hexahydrozepino[4,5-b]indoles</span>. U.S. Patent US3652588 A,<span class="NLM_x"> </span><span class="NLM_year">1972</span><span class="NLM_x">, </span>(The Upjohn Company).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1972&author=M.+Jackson&author=B.+Hester&title=6-Alkyl-1%2C2%2C3%2C4%2C5%2C6-hexahydrozepino%5B4%2C5-b%5Dindoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DM.%26atitle%3D6-Alkyl-1%252C2%252C3%252C4%252C5%252C6-hexahydrozepino%255B4%252C5-b%255Dindoles%26date%3D1972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Savage, D. S.; Sleigh, T.; Kellock, J.</span><span> </span><span class="NLM_article-title">Pharmaceutical 4-aminobenzo[b]biclyco[3.3.1]nonene Derivatives</span>. Ger. Offen. DE 2747987 A1,<span class="NLM_x"> </span><span class="NLM_year">1978</span><span class="NLM_x">, </span>(Organon).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1978&author=D.+S.+Savage&author=T.+Sleigh&author=J.+Kellock&title=Pharmaceutical+4-aminobenzo%5Bb%5Dbiclyco%5B3.3.1%5Dnonene+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSavage%26aufirst%3DD.%2BS.%26atitle%3DPharmaceutical%25204-aminobenzo%255Bb%255Dbiclyco%255B3.3.1%255Dnonene%2520Derivatives%26date%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Bentley, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebbington, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benwell, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bickerdike, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, J. E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dourish, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncton, M. A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamlyn, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennett, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malcolm, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansell, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monck, N. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quirk, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roffey, J. R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickers, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cliffe, I. A.</span><span> </span><span class="NLM_article-title">Indoline Derivatives as 5-HT<sub>2C</sub> Receptor Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2367</span><span class="NLM_x">–</span> <span class="NLM_lpage">2370</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.bmcl.2003.05.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=2367-2370&author=J.+M.+Bentleyauthor=D.+R.+Adamsauthor=D.+Bebbingtonauthor=K.+R.+Benwellauthor=M.+J.+Bickerdikeauthor=J.+E.+P.+Davidsonauthor=C.+E.+Dawsonauthor=C.+T.+Dourishauthor=M.+A.+J.+Dunctonauthor=S.+Gaurauthor=A.+R.+Georgeauthor=P.+R.+Gilesauthor=R.+J.+Hamlynauthor=G.+A.+Kennettauthor=A.+R.+Knightauthor=C.+S.+Malcolmauthor=H.+L.+Mansellauthor=A.+Misraauthor=N.+J.+T.+Monckauthor=R.+M.+Prattauthor=K.+Quirkauthor=J.+R.+A.+Roffeyauthor=S.+P.+Vickersauthor=I.+A.+Cliffe&title=Indoline+Derivatives+as+5-HT2C+Receptor+Agonists&doi=10.1016%2Fj.bmcl.2003.05.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DBentley%26aufirst%3DJ.%2BM.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DBebbington%26aufirst%3DD.%26aulast%3DBenwell%26aufirst%3DK.%2BR.%26aulast%3DBickerdike%26aufirst%3DM.%2BJ.%26aulast%3DDavidson%26aufirst%3DJ.%2BE.%2BP.%26aulast%3DDawson%26aufirst%3DC.%2BE.%26aulast%3DDourish%26aufirst%3DC.%2BT.%26aulast%3DDuncton%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DGaur%26aufirst%3DS.%26aulast%3DGeorge%26aufirst%3DA.%2BR.%26aulast%3DGiles%26aufirst%3DP.%2BR.%26aulast%3DHamlyn%26aufirst%3DR.%2BJ.%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DKnight%26aufirst%3DA.%2BR.%26aulast%3DMalcolm%26aufirst%3DC.%2BS.%26aulast%3DMansell%26aufirst%3DH.%2BL.%26aulast%3DMisra%26aufirst%3DA.%26aulast%3DMonck%26aufirst%3DN.%2BJ.%2BT.%26aulast%3DPratt%26aufirst%3DR.%2BM.%26aulast%3DQuirk%26aufirst%3DK.%26aulast%3DRoffey%26aufirst%3DJ.%2BR.%2BA.%26aulast%3DVickers%26aufirst%3DS.%2BP.%26aulast%3DCliffe%26aufirst%3DI.%2BA.%26atitle%3DIndoline%2520Derivatives%2520as%25205-HT2C%2520Receptor%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D2367%26epage%3D2370%26doi%3D10.1016%2Fj.bmcl.2003.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hruban, Z.</span><span> </span><span class="NLM_article-title">Pulmonary Changes Induced by Amphophilic Drugs</span> <span class="citation_source-journal">Environ. Health Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1289/ehp.7616111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1289%2Fehp.7616111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1976&pages=111-118&author=Z.+Hruban&title=Pulmonary+Changes+Induced+by+Amphophilic+Drugs&doi=10.1289%2Fehp.7616111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1289%2Fehp.7616111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.7616111%26sid%3Dliteratum%253Aachs%26aulast%3DHruban%26aufirst%3DZ.%26atitle%3DPulmonary%2520Changes%2520Induced%2520by%2520Amphophilic%2520Drugs%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D1976%26volume%3D16%26spage%3D111%26epage%3D118%26doi%3D10.1289%2Fehp.7616111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Robison, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visscher, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, F. H.</span><span> </span><span class="NLM_article-title">Generalized Phospholipidosis Induced by an Amphiphilic Cationic Psychotropic Drug</span> <span class="citation_source-journal">Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span><span class="refDoi"> DOI: 10.1177/019262338501300410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1177%2F019262338501300410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=3834585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADyaL28XktVSnurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1985&pages=335-348&author=R.+L.+Robisonauthor=G.+E.+Visscherauthor=S.+A.+Robertsauthor=R.+G.+Engstromauthor=H.+A.+Hartmanauthor=F.+H.+Ballard&title=Generalized+Phospholipidosis+Induced+by+an+Amphiphilic+Cationic+Psychotropic+Drug&doi=10.1177%2F019262338501300410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Generalized phospholipidosis induced by an amphiphilic cationic psychotropic drug</span></div><div class="casAuthors">Robison, Rodney L.; Visscher, George E.; Roberts, Stanley A.; Engstrom, Robert G.; Hartman, Howard A.; Ballard, Frances H.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-48</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    </div><div class="casAbstract">In rats, generalized phospholipidosis was induced by Sandoz 200-125 (I)  [102636-45-3] administered orally at 500 mg/kg/day for 4 wk; characteristic pulmonary lesions including extensive accumulations of large pale foamy macrophages and granular eosinophilic extracellular material were obsd.  Marked increases in phospholipids and cholesterol in the lungs were noted.  The phospholipidosis had nearly disappeared 4 wk after drug withdrawal.  The potential pulmonary toxicity in humans from amphiphilic drugs is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU4I-U6p1PtbVg90H21EOLACvtfcHk0lgDfyI7c7uwUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XktVSnurs%253D&md5=eb945ff71cf4b7567226966b8c22a5de</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F019262338501300410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F019262338501300410%26sid%3Dliteratum%253Aachs%26aulast%3DRobison%26aufirst%3DR.%2BL.%26aulast%3DVisscher%26aufirst%3DG.%2BE.%26aulast%3DRoberts%26aufirst%3DS.%2BA.%26aulast%3DEngstrom%26aufirst%3DR.%2BG.%26aulast%3DHartman%26aufirst%3DH.%2BA.%26aulast%3DBallard%26aufirst%3DF.%2BH.%26atitle%3DGeneralized%2520Phospholipidosis%2520Induced%2520by%2520an%2520Amphiphilic%2520Cationic%2520Psychotropic%2520Drug%26jtitle%3DToxicol.%2520Pathol.%26date%3D1985%26volume%3D13%26spage%3D335%26epage%3D348%26doi%3D10.1177%2F019262338501300410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Nonoyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, R. J.</span><span> </span><span class="NLM_article-title">Drug-Induced Phospholipidosis-Pathological Aspects and Its Prediction</span> <span class="citation_source-journal">J. Toxicol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1293/tox.21.9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1293%2Ftox.21.9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=9-24&author=T.+Nonoyamaauthor=R.+J.+Fukuda&title=Drug-Induced+Phospholipidosis-Pathological+Aspects+and+Its+Prediction&doi=10.1293%2Ftox.21.9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced phospholipidosis-pathological aspects and its prediction</span></div><div class="casAuthors">Nonoyama, Takashi; Fukuda, Ryo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-24</span>CODEN:
                <span class="NLM_cas:coden">JTPAE7</span>;
        ISSN:<span class="NLM_cas:issn">0914-9198</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Toxicologic Pathology</span>)
        </div><div class="casAbstract">A review.  Drug-induced phospholipidosis (PLDsis) is an excessive accumulation of polar phospholipids in cells or tissues/organs caused by xenobiotics.  Numerous drugs and chems. are capable of inducing the storage disorder in animals and humans; however, despite their diverse pharmacol. activities, each of these drugs shares common physicochem. properties: a hydrophobic arom. ring structure on the mol. and a hydrophilic side chain with a charged cationic amine group and therefore are in the group of cationic amphiphilic drugs.  In affected cells the appearance of membrane-bound inclusions, primarily lysosomal in origin, with a lamellar structure (lamellar bodies) is a definitive morphol. hallmark.  Massive accumulations can occur in animal tissues such as the lung with little effect on organ function.  The inducing drug also accumulates in assocn. with the excess phospholipid.  Although these alterations are generally reversible after cessation of drug treatment, PLDsis is of regulatory concern and an issue for drug safety for pharmaceutical companies.  Thus, the assessment of potential target organ dysfunction and the identification of clin. biomarkers are important objectives for new drug development.  Recent advances in biotechnol. such as metabonomics and toxicogenomics have been providing novel tools to elucidate the mechanisms of PLDsis and to establish biomarkers for screening tests in the preclin. stages and for monitoring in the clin. phases in addn. to conventional approaches such as morphol. (lamellar bodies) and biochem. methods including assays of specific metabolites and phospholipase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNnyTDVHV3bVg90H21EOLACvtfcHk0lgDfyI7c7uwUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbs%253D&md5=d91505b54cbf951cf30f8144f0c51ed9</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1293%2Ftox.21.9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1293%252Ftox.21.9%26sid%3Dliteratum%253Aachs%26aulast%3DNonoyama%26aufirst%3DT.%26aulast%3DFukuda%26aufirst%3DR.%2BJ.%26atitle%3DDrug-Induced%2520Phospholipidosis-Pathological%2520Aspects%2520and%2520Its%2520Prediction%26jtitle%3DJ.%2520Toxicol.%2520Pathol.%26date%3D2008%26volume%3D21%26spage%3D9%26epage%3D24%26doi%3D10.1293%2Ftox.21.9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Keiser, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irwin, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laggner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hufeisen, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuijer, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matos, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennon, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hert, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, K. L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoichet, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">Predicting New Molecular Targets for Known Drugs</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nature08506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1038%2Fnature08506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=19881490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=175-181&author=M.+J.+Keiserauthor=V.+Setolaauthor=J.+J.+Irwinauthor=C.+Laggnerauthor=A.+I.+Abbasauthor=S.+J.+Hufeisenauthor=N.+H.+Jensenauthor=M.+B.+Kuijerauthor=R.+C.+Matosauthor=T.+B.+Tranauthor=R.+Whaleyauthor=R.+A.+Glennonauthor=J.+Hertauthor=K.+L.+H.+Thomasauthor=D.+D.+Edwardsauthor=B.+K.+Shoichetauthor=B.+L.+Roth&title=Predicting+New+Molecular+Targets+for+Known+Drugs&doi=10.1038%2Fnature08506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting new molecular targets for known drugs</span></div><div class="casAuthors">Keiser, Michael J.; Setola, Vincent; Irwin, John J.; Laggner, Christian; Abbas, Atheir I.; Hufeisen, Sandra J.; Jensen, Niels H.; Kuijer, Michael B.; Matos, Roberto C.; Tran, Thuy B.; Whaley, Ryan; Glennon, Richard A.; Hert, Jerome; Thomas, Kelan L. H.; Edwards, Douglas D.; Shoichet, Brian K.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7270</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although drugs are intended to be selective, at least some bind to several physiol. targets, explaining side effects and efficacy.  Because many drug-target combinations exist, it would be useful to explore possible interactions computationally.  Here we compared 3665 US Food and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defining each target by its ligands.  Chem. similarities between drugs and ligand sets predicted thousands of unanticipated assocns.  Thirty were tested exptl., including the antagonism of the β1 receptor by the transporter inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel drug Vadilex, and antagonism of the histamine H4 receptor by the enzyme inhibitor Rescriptor.  Overall, 23 new drug-target assocns. were confirmed, five of which were potent (<100 nM).  The physiol. relevance of one, the drug N,N-dimethyltryptamine (DMT) on serotonergic receptors, was confirmed in a knockout mouse.  The chem. similarity approach is systematic and comprehensive, and may suggest side-effects and new indications for many drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozd-8cCXUskrVg90H21EOLACvtfcHk0liXQYNFTKueJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlers7vO&md5=974e65f5d5b4dabde1a463c429215546</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature08506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08506%26sid%3Dliteratum%253Aachs%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DLaggner%26aufirst%3DC.%26aulast%3DAbbas%26aufirst%3DA.%2BI.%26aulast%3DHufeisen%26aufirst%3DS.%2BJ.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DKuijer%26aufirst%3DM.%2BB.%26aulast%3DMatos%26aufirst%3DR.%2BC.%26aulast%3DTran%26aufirst%3DT.%2BB.%26aulast%3DWhaley%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DK.%2BL.%2BH.%26aulast%3DEdwards%26aufirst%3DD.%2BD.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPredicting%2520New%2520Molecular%2520Targets%2520for%2520Known%2520Drugs%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D175%26epage%3D181%26doi%3D10.1038%2Fnature08506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Nickols, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conn, P. J.</span><span> </span><span class="NLM_article-title">Development of Allosteric Modulators of GPCRs For Treatment of CNS Disorders</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1016/j.nbd.2013.09.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.nbd.2013.09.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=24076101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FitVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=55-71&author=H.+H.+Nickolsauthor=P.+J.+Conn&title=Development+of+Allosteric+Modulators+of+GPCRs+For+Treatment+of+CNS+Disorders&doi=10.1016%2Fj.nbd.2013.09.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Development of allosteric modulators of GPCRs for treatment of CNS disorders</span></div><div class="casAuthors">Nickols Hilary Highfield; Conn P Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a promising new strategy with potential for developing novel treatments for a variety of central nervous system (CNS) disorders.  Traditional drug discovery efforts targeting GPCRs have focused on developing ligands for orthosteric sites which bind endogenous ligands.  Allosteric modulators target a site separate from the orthosteric site to modulate receptor function.  These allosteric agents can either potentiate (positive allosteric modulator, PAM) or inhibit (negative allosteric modulator, NAM) the receptor response and often provide much greater subtype selectivity than orthosteric ligands for the same receptors.  Experimental evidence has revealed more nuanced pharmacological modes of action of allosteric modulators, with some PAMs showing allosteric agonism in combination with positive allosteric modulation in response to endogenous ligand (ago-potentiators) as well as "bitopic" ligands that interact with both the allosteric and orthosteric sites.  Drugs targeting the allosteric site allow for increased drug selectivity and potentially decreased adverse side effects.  Promising evidence has demonstrated potential utility of a number of allosteric modulators of GPCRs in multiple CNS disorders, including neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, as well as psychiatric or neurobehavioral diseases such as anxiety, schizophrenia, and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5AaOVGoQQ2DEC-75aqa5AfW6udTcc2eaw14mVoI0Xcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FitVejsA%253D%253D&md5=a1535b4448734bcae63e9797d2009737</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2013.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2013.09.013%26sid%3Dliteratum%253Aachs%26aulast%3DNickols%26aufirst%3DH.%2BH.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DDevelopment%2520of%2520Allosteric%2520Modulators%2520of%2520GPCRs%2520For%2520Treatment%2520of%2520CNS%2520Disorders%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2014%26volume%3D61%26spage%3D55%26epage%3D71%26doi%3D10.1016%2Fj.nbd.2013.09.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Im, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chio, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberts, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinh, D. M.</span><span> </span><span class="NLM_article-title">Positive Allosteric Modulator of the Human 5-HT<sub>2C</sub> Receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">78</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1124/mol.64.1.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1124%2Fmol.64.1.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=12815163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=78-84&author=W.+B.+Imauthor=C.+L.+Chioauthor=G.+L.+Albertsauthor=D.+M.+Dinh&title=Positive+Allosteric+Modulator+of+the+Human+5-HT2C+Receptor&doi=10.1124%2Fmol.64.1.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulator of the human 5-HT2C receptor</span></div><div class="casAuthors">Im, Wha Bin; Chio, Christopher L.; Alberts, Glen L.; Dinh, Dac M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-84</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The human 5-hydroxytryptamine-2C (5-HT2C) receptor has been the target of potential anxiolytics and antiobesity drugs, and its pos. allosteric modulator was discovered to be L-threo-α-D-galacto-octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(4-undecyl-2-piperidinyl)carbonyl]amino]-1-thiomonohydrochloride (2S-cis) (PNU-69176E).  The drug at low micromolar concns. (<25 μM) markedly enhanced [3H]5-HT binding (more than 300%) by increasing its affinity for low-affinity sites but with no appreciable effect on antagonist ([3H]mesulergine) binding.  Functionally, PNU-69176E alone rendered receptors constitutively active, producing the phenotypes of 5-HT-activated receptors, as measured with mesulergine-sensitive guanosine 5'-O-(3-[35S]thio)triphosphate binding, transient inositol 1,4,5-triphosphate release, and [3H]inositol phosphate accumulation.  These actions of PNU-69176E were obsd. with the human 5-HT2C receptor expressed in several mammalian cell lines (human embryonic kidney 293, NIH3T3, and SH-EP) at variable receptor densities (6 to 45 pmol/mg of protein), but not with analogous 5-HT and dopamine receptors (human 5-HT2A, 5-HT2B, 5-HT6, 5-HT7, and dopamine D2-long and D3 receptors).  Structurally, PNU-69176E consists of a long alkyl chain and a polar moiety, including the α-D-galactopyranoside.  Its analogs with shorter alkyl chains (Me to n-hexyl instead of n-undecyl group) failed to enhance [3H]5-HT binding, and also long alkyl amides are without allosteric modulation.  We propose that PNU-69176E may represent a new class of membrane receptor modulators, which probably need a long alkyl chain as a membrane anchor and target a selective polar head group to receptor modulatory sites near the membrane surface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMdPZHNbAJJbVg90H21EOLACvtfcHk0liXQYNFTKueJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvV2qtrs%253D&md5=26c9f18b3097e2a8921b7803bc836489</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fmol.64.1.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.64.1.78%26sid%3Dliteratum%253Aachs%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DChio%26aufirst%3DC.%2BL.%26aulast%3DAlberts%26aufirst%3DG.%2BL.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26atitle%3DPositive%2520Allosteric%2520Modulator%2520of%2520the%2520Human%25205-HT2C%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2003%26volume%3D64%26spage%3D78%26epage%3D84%26doi%3D10.1124%2Fmol.64.1.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="note"><p class="first last">It is worth noting that the apparent reduction in selectivity for compounds <b>67</b> and <b>69</b> vs 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> is possibly due to baseline drift in the functional assay, as the HEK293E cell lines that overexpress the respective receptor can appear to produce a functional response at high concentration. Indeed, each compound was tested several times in the 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> functional assay, and while some concentration response curves looked like a true concentration dependent response, others indicated little response with intrinsic activities of only ∼10% relative to serotonin. A more detailed evaluation of compounds appearing to be active toward either 5-HT<sub>2A</sub> or 5-HT<sub>2B</sub> is beyond the scope of this publication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Tanyi, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span> </span><span class="NLM_article-title">Disconnection Between the Early Onset Anorectic Effects by C75 and Hypothalamic Fatty Acid Synthase Inhibition in Rodents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1016/j.ejphar.2005.01.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2Fj.ejphar.2005.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=15777777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2005&pages=31-41&author=K.+W.+Rohrbachauthor=S.+Hanauthor=J.+Ganauthor=E.+J.+O%E2%80%99Tanyiauthor=H.+Zhangauthor=C.+L.+Chiauthor=R.+Taubauthor=B.+L.+Largentauthor=D.+Cheng&title=Disconnection+Between+the+Early+Onset+Anorectic+Effects+by+C75+and+Hypothalamic+Fatty+Acid+Synthase+Inhibition+in+Rodents&doi=10.1016%2Fj.ejphar.2005.01.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents</span></div><div class="casAuthors">Rohrbach, Kenneth W.; Han, Songping; Gan, Jinping; O'Tanyi, Eva J.; Zhang, Hongwei; Chi, Cecilia L.; Taub, Rebecca; Largent, Brian L.; Cheng, Dong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to explore the relationship between the anorectic effect of 3-carboxy-4-octyl-2-methylenebutyrolactone (C75) and its pharmacokinetic properties, studies of in vivo and in vitro pharmacol. characterization of C75 were performed in Fischer rats.  In a quant. measurement of food intake, we detd. that appetite suppression by C75 takes place within 4 h.  The C max for C75 of 2.6±1.5 μM was reached within 1-4 h after i.p. administration at 30 mg/kg, a drug level that causes complete blockade of food intake.  However, this concn. is substantially lower than the effective concn. used to inhibit rat fatty acid synthase enzyme activity in vitro (IC50: ∼200 μM) and hypothalamic enzyme activity was found not to be inhibited by i.p. administration of C75 at 30 mg/kg.  Instead, a dramatic induction of c-Fos expression was found in area postrema.  Collectively, these data indicate that the anorectic effect of C75 is independent of its inhibition of fatty acid synthase in the hypothalamus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphbCknlWT3JrVg90H21EOLACvtfcHk0liXQYNFTKueJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D&md5=bae875aacd7aa736cb95107bf170c6ab</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Tanyi%26aufirst%3DE.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DC.%2BL.%26aulast%3DTaub%26aufirst%3DR.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DCheng%26aufirst%3DD.%26atitle%3DDisconnection%2520Between%2520the%2520Early%2520Onset%2520Anorectic%2520Effects%2520by%2520C75%2520and%2520Hypothalamic%2520Fatty%2520Acid%2520Synthase%2520Inhibition%2520in%2520Rodents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D511%26spage%3D31%26epage%3D41%26doi%3D10.1016%2Fj.ejphar.2005.01.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duckworth, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaster, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulholland, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunders, D. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaney, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennett, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lightowler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. D.</span><span> </span><span class="NLM_article-title">Biarylcarbamoylindolines Are Novel and Selective 5-HT<sub>2C</sub> Receptor Inverse Agonists: Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1134</span><span class="refDoi"> DOI: 10.1021/jm990388c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990388c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1123-1134&author=S.+M.+Bromidgeauthor=S.+Dabbsauthor=D.+T.+Daviesauthor=S.+Daviesauthor=D.+M.+Duckworthauthor=I.+T.+Forbesauthor=L.+M.+Gasterauthor=P.+Hamauthor=G.+E.+Jonesauthor=F.+D.+Kingauthor=K.+R.+Mulhollandauthor=D.+V.+Saundersauthor=P.+A.+Wymanauthor=F.+E.+Blaneyauthor=S.+E.+Clarkeauthor=T.+P.+Blackburnauthor=V.+Hollandauthor=G.+A.+Kennettauthor=S.+Lightowlerauthor=D.+N.+Middlemissauthor=B.+Trailauthor=G.+J.+Rileyauthor=M.+D.+Wood&title=Biarylcarbamoylindolines+Are+Novel+and+Selective+5-HT2C+Receptor+Inverse+Agonists%3A+Identification+of+5-Methyl-1-%5B%5B2-%5B%282-methyl-3-pyridyl%29oxy%5D-5-pyridyl%5Dcarbamoyl%5D-6-trifluoromethylindoline+%28SB-243213%29+as+a+Potential+Antidepressant%2FAnxiolytic+Agent&doi=10.1021%2Fjm990388c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1021%2Fjm990388c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990388c%26sid%3Dliteratum%253Aachs%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DDabbs%26aufirst%3DS.%26aulast%3DDavies%26aufirst%3DD.%2BT.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDuckworth%26aufirst%3DD.%2BM.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DGaster%26aufirst%3DL.%2BM.%26aulast%3DHam%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DG.%2BE.%26aulast%3DKing%26aufirst%3DF.%2BD.%26aulast%3DMulholland%26aufirst%3DK.%2BR.%26aulast%3DSaunders%26aufirst%3DD.%2BV.%26aulast%3DWyman%26aufirst%3DP.%2BA.%26aulast%3DBlaney%26aufirst%3DF.%2BE.%26aulast%3DClarke%26aufirst%3DS.%2BE.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26aulast%3DHolland%26aufirst%3DV.%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DLightowler%26aufirst%3DS.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DTrail%26aufirst%3DB.%26aulast%3DRiley%26aufirst%3DG.%2BJ.%26aulast%3DWood%26aufirst%3DM.%2BD.%26atitle%3DBiarylcarbamoylindolines%2520Are%2520Novel%2520and%2520Selective%25205-HT2C%2520Receptor%2520Inverse%2520Agonists%253A%2520Identification%2520of%25205-Methyl-1-%255B%255B2-%255B%25282-methyl-3-pyridyl%2529oxy%255D-5-pyridyl%255Dcarbamoyl%255D-6-trifluoromethylindoline%2520%2528SB-243213%2529%2520as%2520a%2520Potential%2520Antidepressant%252FAnxiolytic%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1123%26epage%3D1134%26doi%3D10.1021%2Fjm990388c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wood, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reavill, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stean, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennett, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lightowler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackburn, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gager, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bromidge, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forbes, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middlemiss, D. N.</span><span> </span><span class="NLM_article-title">SB-243213; a Selective 5-HT<sub>2C</sub> Receptor Inverse Agonist with Improved Anxiolytic Profile: Lack of Tolerance and Withdrawal Anxiety</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">186</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span><span class="refDoi"> DOI: 10.1016/S0028-3908(01)00054-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1016%2FS0028-3908%2801%2900054-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=186-199&author=M.+D.+Woodauthor=C.+Reavillauthor=B.+Trailauthor=A.+Wilsonauthor=T.+Steanauthor=G.+A.+Kennettauthor=S.+Lightowlerauthor=T.+P.+Blackburnauthor=D.+Thomasauthor=T.+L.+Gagerauthor=G.+Rileyauthor=V.+Hollandauthor=S.+M.+Bromidgeauthor=I.+T.+Forbesauthor=D.+N.+Middlemiss&title=SB-243213%3B+a+Selective+5-HT2C+Receptor+Inverse+Agonist+with+Improved+Anxiolytic+Profile%3A+Lack+of+Tolerance+and+Withdrawal+Anxiety&doi=10.1016%2FS0028-3908%2801%2900054-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2801%2900054-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252801%252900054-5%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DReavill%26aufirst%3DC.%26aulast%3DTrail%26aufirst%3DB.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DStean%26aufirst%3DT.%26aulast%3DKennett%26aufirst%3DG.%2BA.%26aulast%3DLightowler%26aufirst%3DS.%26aulast%3DBlackburn%26aufirst%3DT.%2BP.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DGager%26aufirst%3DT.%2BL.%26aulast%3DRiley%26aufirst%3DG.%26aulast%3DHolland%26aufirst%3DV.%26aulast%3DBromidge%26aufirst%3DS.%2BM.%26aulast%3DForbes%26aufirst%3DI.%2BT.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26atitle%3DSB-243213%253B%2520a%2520Selective%25205-HT2C%2520Receptor%2520Inverse%2520Agonist%2520with%2520Improved%2520Anxiolytic%2520Profile%253A%2520Lack%2520of%2520Tolerance%2520and%2520Withdrawal%2520Anxiety%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D41%26spage%3D186%26epage%3D199%26doi%3D10.1016%2FS0028-3908%2801%2900054-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Fitzgerald, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostich, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartig, P. R.</span><span> </span><span class="NLM_article-title">High-Affinity Agonist Binding Correlates with Efficacy (Intrinsic Activity) at the Human Serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> Receptors: Evidence Favoring the Ternary Complex and Two-State Models of Agonist Action</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">2127</span><span class="NLM_x">–</span> <span class="NLM_lpage">2134</span><span class="refDoi"> DOI: 10.1046/j.1471-4159.1999.0722127.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10.1046%2Fj.1471-4159.1999.0722127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=10217294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;key=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1999&pages=2127-2134&author=L.+W.+Fitzgeraldauthor=D.+S.+Conklinauthor=C.+M.+Krauseauthor=A.+P.+Marshallauthor=J.+P.+Pattersonauthor=D.+P.+Tranauthor=G.+Iyerauthor=W.+A.+Kostichauthor=B.+L.+Largentauthor=P.+R.+Hartig&title=High-Affinity+Agonist+Binding+Correlates+with+Efficacy+%28Intrinsic+Activity%29+at+the+Human+Serotonin+5-HT2A+and+5-HT2C+Receptors%3A+Evidence+Favoring+the+Ternary+Complex+and+Two-State+Models+of+Agonist+Action&doi=10.1046%2Fj.1471-4159.1999.0722127.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action</span></div><div class="casAuthors">Fitzgerald, Lawrence W.; Conklin, Deborah S.; Krause, Carol M.; Marshall, Anne P.; Patterson, John P.; Tran, David P.; Iyer, Geeta; Kostich, Walter A.; Largent, Brian L.; Hartig, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2127-2134</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Many modern models of receptor-G protein function assume that there is a direct relationship between high-affinity agonist binding and efficacy.  The validity of this assumption has been recently questioned for the serotonin 5-HT2A receptor.  The authors examd. the intrinsic activities of various ligands in activating phosphoinositide hydrolysis and measured their resp. binding affinities to the high- and low-affinity states of the 5-HT2C (VNV isoform) and 5-HT2A receptors.  Ligand binding affinities for the high-affinity state of the receptors were detd. using 1-(4-[125I]iodo-2,5-dimethoxyphenyl)-2-aminopropane, whereas [3H]mesulergine and N-[3H]-methylspiperone were used, in the presence of excess guanine nucleotide [guanosine 5'-O-(3-thiotriphosphate)], to define binding to the low-affinity state of the 5-HT2C and 5-HT2A receptors, resp.  Antagonists labeled the high- and low-affinity states of each receptor with comparable affinities.  Previously identified inverse agonists of the 5-HT2C receptor behaved as silent antagonists in the authors' systems even when the receptor was over-expressed at a relatively high d.  In contrast, the ability of agonists to bind differentially to the high- and low-affinity states of the 5-HT2A and 5-HT2C receptors was highly correlated (R2 = 0.86 and 0.96, resp.) with their intrinsic activities.  These data suggest that high-affinity agonist states can account for agonist efficacy at human 5-HT2A or 5-HT2C receptors without the need for considering addnl. transition or active states of the receptor-ligand complex.  The procedure described herein may expedite drug discovery efforts by predicting intrinsic activities of ligands solely from ligand binding assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozA61mRFBtzbVg90H21EOLACvtfcHk0liGruAORMQqkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis12ltLg%253D&md5=76a7600ee51a0dff38298d091640ffd7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1999.0722127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1999.0722127.x%26sid%3Dliteratum%253Aachs%26aulast%3DFitzgerald%26aufirst%3DL.%2BW.%26aulast%3DConklin%26aufirst%3DD.%2BS.%26aulast%3DKrause%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DA.%2BP.%26aulast%3DPatterson%26aufirst%3DJ.%2BP.%26aulast%3DTran%26aufirst%3DD.%2BP.%26aulast%3DIyer%26aufirst%3DG.%26aulast%3DKostich%26aufirst%3DW.%2BA.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26atitle%3DHigh-Affinity%2520Agonist%2520Binding%2520Correlates%2520with%2520Efficacy%2520%2528Intrinsic%2520Activity%2529%2520at%2520the%2520Human%2520Serotonin%25205-HT2A%2520and%25205-HT2C%2520Receptors%253A%2520Evidence%2520Favoring%2520the%2520Ternary%2520Complex%2520and%2520Two-State%2520Models%2520of%2520Agonist%2520Action%26jtitle%3DJ.%2520Neurochem.%26date%3D1999%26volume%3D72%26spage%3D2127%26epage%3D2134%26doi%3D10.1046%2Fj.1471-4159.1999.0722127.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i91"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00385">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_81700"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00385">10.1021/acs.jmedchem.7b00385</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional data for compound <b>69</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_001.pdf">jm7b00385_si_001.pdf (553.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00385/suppl_file/jm7b00385_si_002.csv">jm7b00385_si_002.csv (4.22 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00385&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-14%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00385%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00385" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a2e6fe6b1234","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
